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i ABSTRACT 
 
Alexander M. Tothill  Cranfield University 
ABSTRACT 
A 3D-printed microfluidic lab-on-a-disc (LOAD) device was designed and 
manufactured using a low cost (~£1600) consumer grade fused deposition modelling 
(FDM) Ultimaker 2+ 3D printer with imbedded microfluidic channels 1 mm wide, 400 
µm depth and with a volumetric capacity of approximate 23 µl. FDM printers are not 
typically used, or are capable, of producing the fine detailed structures required for 
microfluidic fabrication; in addition 3D-printed objects can suffer from poor optical 
transparency. However, in this work, imbedded microfluidic channels were produced 
and the optical transparency of the device was improved though manufacture 
optimisation to such a point that optical colourimetric assays can be performed in a 
microfluidic cuvette device with sample path length of 500 µm and volumetric capacity 
of 190 µl. When acetone vapour treatment was used, it was possible to improve 
transparency of plastic samples by up to a further 30%. The LOAD device is capable of 
being spun using an unmodified optical disc drive (ODD), demonstrating the 
centrifugation based separation of plasma from whole blood in a low-cost FDM 
3D-printed microfluidic LOAD device. 
A cholesterol assay and glucose assay was developed and optimised using 
cholesterol oxidase (ChOx) or glucose oxidase (GlOx) respectively and horseradish 
peroxidase (HRP) for the oxidative coupling of chromotropic acid (CTA) and 
4-aminoantipyrine (AAP). This produced a blue quinoneimine dye with a broad 
absorbance peaking at 590 nm for the quantification of cholesterol/glucose in solution. 
The colourimetric enzymatic cascade assays were developed for use within low-cost 
FDM 3D-printed microfluidic devices to demonstrate the capabilities and functionality 
of the devices. For comparison, the assay was run in standard 96 well plates with a 
commercial plate reader. The results demonstrated that the quantification of 0-10 mM 
glucose solution using a 3D-printed microfluidic optical device had a performance 
comparable to a plate reader assay; glucose assay in whole blood samples R2 = 0.96. 
KEYWORDS: 3D-Printing; Microfluidics; Devices; Glucose; Enzymatic; Low cost; whole 
blood.  
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 Rationale for the Research 1.1
The increasing burden being placed on health care services by an aging 
population, obesity epidemic and diabetes epidemic (NICE, 2012) is creating the 
necessity for point-of-care (POC) testing for serious pathologies like cardiovascular 
disease and diabetes (Tang et al., 2007). However, the inaccuracy of presently 
available POC diagnostic devices relative to lab based assays, and their frequent 
limitation to a single analyte means that disease diagnosis continues to rely on the 
quantification of a panel of blood-based biomarkers utilising laboratory assays and 
equipment. Whilst lab-on-a-disc (LOAD) devices seek to solve this problem, the current 
commercial devices available are expensive, often in excess of £10,000, rendering 
them outside the budget of many institutions. 
The advance of solid freeform fabrication techniques, such as 3D-printing, has 
signiﬁcantly improved the ability to prepare solid structures with precise geometries 
(Hutmacher et al., 2004), including internal cavities, facilitating the rapid production of 
analytical platforms and the ability to alter or redesign any aspect without significantly 
inflating costs. While the use of 3D-printing to produce cost-effective tools for 
biomedical applications has significant potential (Cohen et al., 2006; Ballyns et al., 
2009), to-date its use in the optical and biosensors ﬁeld has been limited. The 
3D-printing instruments utilised in the manufacture of devices for biomedical 
applications can cost in excess of £150,000 and the materials are not readily available 
for public use, causing the technology to be inaccessible for the majority of 
establishments. In addition, the devices require post-print finishing including cleaning 
and polishing using sand paper and water to achieve the correct finish and acceptable 
levels of optical transparency for use (Chen et al., 2014). The necessity of post-print 
finishing techniques such as physical removal of material and polishing to improve 
3D-printed devices greatly limits the potential for use in optical microfluidic devices, 
especially those with inaccessible microfluidic channels, regardless of the 3D-printer 
quality. This emphasises the need for the development of accessible and affordable 
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prototyping technology and post-print finishing techniques suitable for biomedical 
microfluidics. 
Low-cost (< £2000) fused deposition modelling (FDM) 3D-printing technology is 
widely accessible, with a range of printing materials readily available from multiple 
sources. However, low-cost FDM 3D-printed optical assay platforms can suffer from 
the poor optical properties and performance of polymers available (Ho et al., 2015). 
Poor optical transparency is a fundamental obstacle that must be overcome for the 
technology to progress because of its impact on sensing performance. In addition, the 
low quality of objects manufactured by low-cost FDM 3D-printers render them 
unsuitable for use in a medical or diagnostic setting; POC devices rely heavily on 
microfluidic channels to control sample volume, reagent mixing and flow rate (Heller 
and Feldman, 2010; Gubala et al., 2012), and so far low-cost FDM 3D-printers have 
been incapable of constructing imbedded microfluidic channels suitable for use in a 
diagnostic setting (Au et al., 2014). 
The primary aim of this research is to investigate the feasibility of the use of 
low-cost FDM 3D-printing technology to develop a microfluidic LOAD device based on 
a digital versatile disc (DVD) for the rapid quantification of blood based analytes. The 
device should be capable of centrifuging whole blood to give clear plasma that can 
then be used for colourimetric quantitative assays and for the detection of biomarkers. 
The intention is that the device should be capable of using an unmodified optical disc 
drive (ODD) to operate as a low-cost reader. This would aid in the diagnosis and 
prognosis of disease states without the need for samples to be sent to a dedicated 
laboratory as well as being able to perform multiple assays on a single platform, 
something which few existing POC devices are capable of. Elevated cholesterol and 
glucose concentrations are linked to the progression of serious diseases such as 
cardiovascular disease (CVD) and diabetes mellitus (DM); consequently, they are 
widely screened for and quantified across the world. Cholesterol and glucose will be 
used as model markers to demonstrate the functionality of the LOAD device developed 
in this work. 
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 Aims and Objectives 1.2
The aim of this project is to design, develop and produce multiple imbedded 
microfluidic channels in a LOAD assay device with sufficient optical transparency that 
optical assays can be performed within. The device is intended to be capable of 
separating plasma from whole blood via centrifugation in ≤ 2 minutes to be 
competitive with existing centrifugal blood separation systems (Moen et al., 2016), and 
to be used with an unmodified ODD. It is hoped, that if successful, the combination of 
low-cost (< £2000) FDM 3D-printing technology with a microfluidic LOAD device could 
provide POC functionality, portability and affordability. In addition, quantitative 
colourimetric assays for glucose and cholesterol will be developed and optimised for 
use within the low-cost FDM 3D-printed microfluidic devices, to demonstrate the 
functionality and capability of such devices. In line with being able to use an 
unmodified ODD as a reader device, the assays should have absorbance (A) in the 650 
nm region, the wavelength of a DVD laser.  
Three fundamental principles must be demonstrated and proven to establish the 
feasibility of using low-cost FDM 3D-printing technology as a means of developing and 
manufacturing microfluidic LOAD assay devices for use with whole blood samples. 
1. Imbedded microfluidic channels can be formed. 
2. Quantitative whole blood optical assays can be performed in the 3D-printed 
microfluidic device. 
3. Separation of plasma from whole blood via centrifugation can be performed in 
the 3D-printed microfluidic device. 
If these three principles can be established, there is the potential for developing a 
LOAD device using low-cost FDM 3D-printing technology that is capable of performing 
centrifugation based whole blood separation and optical assays in microlitre blood 
volumes. The LOAD device will then be demonstrated for glucose detection. 
A systematic outline of the project and the thesis structure can be seen in Figure 1.1. 
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Figure 1.1: Schematic of the work carried out in this project and the layout of this 
thesis. (CTA: chromotropic acid; AAP: 4-aminoantipyrine; HRP: horseradish 
peroxidase; ChOx: cholesterol oxidase; GlOx: glucose oxidase). 
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 An Overview of Cardiovascular Disease and Diabetes Mellitus 2.1
Cardiovascular disease (CVD) is listed as the primary cause of death world-wide 
by The World Health Organisation (World Health Organisation, 2013). In 2008 an 
estimated 17.3 million deaths were related to CVDs equating to 30% of all deaths 
globally, with 7.3 million and 6.2 million deaths being due to coronary heart disease 
(CHD) and stroke respectively. It is estimated that deaths due to CHD and stroke alone 
will increase to 23.3 million by 2030 and that CVD will remain the leading cause of 
death in the world. Figure 2.1, shows the global distribution of reported CVD mortality 
rates in males and females. 
 
Figure 2.1: Global distribution of CVD mortality rates in (A) males and (B) females 
(age standardised, per 100,000) (Mendis et al. 2011). 
(B) 
(A) 
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The majority of CVDs are easily preventable with appropriate and early 
intervention by addressing the major risk factors such as type-2 diabetes mellitus (DM-
2), hypercholesterolemia, smoking and other tobacco use, poor diet and obesity, 
physical inactivity and hypertension (World Health Organisation, 2013). Although the 
number of deaths due to CVD has been declining steadily in England as shown by 
Figure 2.2, the prevalence of CVD related ailments is increasing (Scarborough et al., 
2011) with over three million people currently suffering from CVD and over 25% of 
deaths caused by some form of CVD as shown in Figure 2.3. This costs the UK over £30 
billion annually, however, 80%-90% of premature CVD is preventable and easily 
treatable if intervention is implemented early enough (Capewell et al., 2008). 
 
 
Figure 2.2: Proportion of all deaths caused by principal disease groups in England, 
2004-11 (Mellon et al., 2013). 
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Figure 2.3: Deaths by cause in the UK. Red= deaths due to CVD, Pink= other deaths 
(Figure taken from: Townsend et al., 2012). 
 
Diabetes mellitus (DM) is the most common endocrine disorder of 
carbohydrate metabolism. It is a lifelong condition where a person’s body is unable to 
regulate blood glucose levels due to either lack of insulin production (type-1 diabetes) 
or resistance to insulin (type-2 diabetes). Worldwide, it is a leading cause of morbidity 
and mortality and a major health problem for most developed societies. The 
prevalence of diabetes continues to increase; the World Health Organization (WHO) 
estimated that 71 million people worldwide were living with diabetes in 2000, and 
predicted the number to rise to 366 million by 2030 (Wild et al., 2004). A more recent 
WHO study states that the number of people with diabetes has already surpassed 
these predictions and that it had risen to 422 million in 2014. The study also shows 
that the global prevalence of diabetes in people over 18 years of age was 8.5% in 2014. 
A sedentary lifestyle combined with changes in eating habits and the increasing 
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frequency of obesity is thought to be the major causes of such increased rates (World 
Health Organisation, 2016).  
While treatment for diabetes varies according to type and severity, all patients 
are recommended to check regularly their blood glucose levels. Frequency of testing 
varies according to the patient but a type-1 diabetic would be expected to test at least 
4 times a day. The primary diagnostic tool for patients living with diabetes is the 
personal blood glucose monitor (Skeie et al., 2009; Tunis and Minshall, 2010). The aim 
of regular blood glucose testing is to provide real-time information for patients to 
modify medications, change dietary intake, and adjust physical activity in order to 
achieve glycaemic goals (Boutati and Raptis, 2009; American Diabetes Association, 
2010) and to help the patient maintain normal blood glucose levels. Failure to maintain 
normal blood glucose levels can lead to nephropathy, neuropathy, and retinopathy, 
and is a large risk factor for CVD (Matthews and Neil, 2008).  
Due to the increasing effectiveness of the pharmacological treatment that is 
used as an intervention for type-2 diabetes, the survival rate has improved. However 
this has led to increased prevalence of type-2 diabetes especially in developed 
countries (Støvring et al., 2003). Without proper implementation of dietary changes 
and increased physical activity to reduce obesity in type-2 diabetics this will inevitably 
result in increasing proportions of deaths from cardiovascular disease in these 
countries, as well as increased prevalence and associated consequences of other 
complications of diabetes (Wild et al., 2004).  
Cholesterol and glucose quantification have become routine in healthcare 
examinations (Plessis et al., 2000); they are well documented molecules with 
quantitative assays for both laboratory and POC use. Cholesterol and glucose are ideal 
example markers and therefore will be used to demonstrate the functionality of the 
LOAD test system that is to be developed in this project. 
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2.1.1 Cholesterol 
Cholesterol, cholest-5-en-3β-ol, is a steroid lipid, Figure 2.4, that is found 
naturally in blood and body tissues, especially liver, spinal cord, and brain. The majority 
of the cellular cholesterol is found in the cell membrane as an important structural 
molecule where it comprises approximately 45% of the total lipid (Girotti, 2002) and is 
involved in many biochemical processes (Hanukoglu, 1992). It is used in the synthesis 
of vitamin D, steroid hormones including cortisol, cortisone and aldosterone, and sex 
hormones including progesterone, oestrogen, and testosterone and used in the 
formation of nerve myelin (Pawlina and Ross, 2007). However due to increasingly 
unhealthy diet and passive lifestyle, sustained elevated levels have become 
synonymous with cardiovascular disease (Wilson, 2016).  
 
 
Figure 2.4: Chemical structure of cholesterol. 
 
Cholesterol is insoluble in water and blood, therefore, it circulates within the 
lipoproteins low-density lipoprotein (LDL) and high-density lipoprotein (HDL). 
Lipoprotein particles, known as chylomicrons, transport a mix of dietary lipids including 
triglycerides (85–92 %), phospholipids (6–12 %), cholesterol (1–3 %) and proteins (1–2 
%) from the gastrointestinal tract to the liver and other body sites (Hussain, 2000). 
Cholesterol is produced mainly in the liver from acetyl coenzyme A (CoA) via the HMG-
CoA reductase pathway (Mehta, 2013), at approximately 1 g a day (Freeman and 
Junge, 2005); other locations include adrenal glands, reductive organs and the 
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intestines. In the liver cholesterol is converted into LDL, which carries cholesterol to 
the body cells, HDL carries it back to the liver for excretion (American Heart 
Association, 2014). 
Animal fats are a mix of triglycerides, phospholipids and cholesterol (Berry, 
2004), and major dietary sources of cholesterol include cheese, egg yolk, and meat 
high in fat. Cholesterol is not found in plant sources in significant quantities as far as 
diet goes (Behrman and Gopalan, 2005). Fat intake via diet affects blood cholesterol 
levels. Diets high in unsaturated fat have been shown to have lower serum LDL and 
total cholesterol levels and higher HDL serum levels; diets high in saturated fat 
displayed higher LDL, HDL and total cholesterol levels (Mensink and Katan, 1992). Due 
to the link that has been established between low HDL and high LDL in cardiovascular 
disease prevalence, many public health bodies recommend reduction of LDL 
cholesterol via dietary and lifestyle changes (NHS UK, 2013). The production of 
cholesterol in the body is directly regulated by current cholesterol levels, increased 
cholesterol intake via food leads to decreased endogenous production. The primary 
mechanism for cholesterol regulation is detection of intracellular cholesterol in the 
endoplasmic reticulum by sterol regulatory element binding protein 1 and 2. In the 
1970s the work performed by Dr Michael S. Brown and Dr Joseph L. Goldstein shed 
light on large sections of the signalling pathway for which they won the 1985 Nobel 
Prize in Physiology or Medicine (Nobelprize.org, 2014). Cholesterol is removed from 
the body through oxidation in the liver into bile acids which are then excreted in bile 
(Javitt, 1994). As a monounsaturated lipid cholesterol is vulnerable to oxidation, one of 
the products is hydrogen peroxide which is usually the molecule being detected by 
existing cholesterol assays (Temani et al., 2014).  
Numerous methodologies exist for the quantification of cholesterol, often 
involving chemical and enzyme based assays (Brahim et al., 2001; Singh et al., 2004). It 
has been stated by Singh et al. (2004) that chemical reaction based cholesterol assays 
have commonly suffered interference from lack of specificity and selectivity and 
required the use of corrosive agents (Singh et al., 2006), in comparison, enzymatic 
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methods utilising cholesterol oxidase (ChOx) provide advantages to both selectivity 
and specificity.  
The following cholesterol blood levels are generally regarded as desirable (NHS UK, 
2013a): 
 Total cholesterol (TC):  ≤5.0 mM (2 mg/ml) for health adult.  
 Low-density lipoprotein (LDL) cholesterol after an overnight fast: ≤3.0 mM 
 High-density lipoprotein (HDL) cholesterol: ≥1.2 mM 
 TC/HDL ratio: ≤4.5.  
 
2.1.2 Glucose 
Glucose, also known as D-(+)-glucose, Figure 2.5, is an important carbohydrate 
in human metabolism (hyperphysics, 2016) and fuel source in biological systems; it is 
utilised through aerobic respiration, anaerobic respiration or fermentation. Glucose 
has 6 carbon atoms so is classed as a hexose monosaccharide.  
 
Figure 2.5: Chemical structure of glucose (Sigma-Aldrich, 2017). 
 
The human body utilizes glucose through aerobic respiration; glucose is 
metabolised and oxidised in the body via glycolysis, the Krebs cycle/citric acid cycle 
and oxidative phosphorylation to form CO2, water and energy primarily in the form of 
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adenosine triphosphate (ATP). Approximately 3.75 kilocalories (16 kilojoules) of food 
energy is produced per gram of glucose (Food and Agriculture Organization, 
2003). Glucose requires no digestion and therefore can be provided intravenously as a 
nutrient if required, for example in hospitals. Glucose is on the WHO list of essential 
medicines, the most important medications required in a basic health system (World 
Health Organisation, 2015). It is made during photosynthesis from water and carbon 
dioxide, using energy from sunlight.  
The majority of dietary carbohydrate often contains glucose, either as the only 
constituent (such as the polysaccharides starch and glycogen), or bonded with another 
monosaccharide (such as sucrose, which is a disaccharide of glucose with fructose, or 
lactose, which is a disaccharide of glucose with galactose) (Harvard School of Public 
Health, 2016). Glucose polysaccharides are broken down to monosaccharides in the 
duodenum and small intestine by pancreatic and intestinal glucosidases (Ferraris, 
2001); glucose is then transported into the blood stream. 
Following absorption, most glucose is absorbed and stored by the liver, adipose 
tissue and muscle cells under the influence of insulin. Insulin and glucagon are the 
most well-known of the glucoregulatory hormones (Aronoff et al., 2004). Insulin allows 
the body's cells to absorb and use glucose, decreasing blood glucose levels. Without it, 
glucose cannot enter the cell and therefore cannot be used as fuel for the body's 
functions (Hormone.org, 2017). Glucagon causes the liver cells to increase blood 
glucose levels by promoting the conversion of glycogen to glucose which is released 
into the blood stream. Typical blood glucose concentration is approximately 4-7 mM 
however it can become raised in people with diabetes (Diabetes.co.uk, 2017). As a 
result of its importance in human health, glucose is an analyte in common 
medical blood tests (Clarke and Foster, 2012).  
The following glucose blood levels are generally regarded as desirable for adults 
with type 1 diabetes (Diabetes UK, 2015): 
 On waking: 5-7 mM 
 Before meals: 4-7 mM 
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 90 minutes after meals: 5-9 mM 
The ever increasing population of diabetic patients in combination with the 
essential requirement to maintain normal blood glucose levels has resulted in glucose 
sensors leading the biosensor market (Yoo and Lee, 2010). The glucose biosensor 
market is  predicted to reach £24 billion by 2022 (Grand View Research, 2016). The 
glucose level meters are most commonly calibrated for blood-plasma, have a small 
sample requirement of 0.3-1.5 µl and have quick time to result, <10 seconds. Despite 
being the most accurate blood glucose assay methodology, laboratory analysis is 
unsuited for regular patient testing due to the time, cost and facility requirements. 
Therefore POC testing is usually used in both inpatient and outpatient environments. 
Enzyme based screen-printed electrodes are the most common form of disposable 
POC glucose biosensors (Yoo and Lee, 2010). They are cheap (£20-£30 per box of 50 
strips) and are used in conjunction with a digital meter, often no bigger than a mobile 
phone. 
 
 Point-of-Care (POC) Testing 2.2
With healthcare education improving and the public becoming more aware of 
their health and the long term effects of poor lifestyle and diet, the use of POC testing 
and home testing devices has become popular for risk monitoring and management 
(Ryan et al., 2010). The ability to give a patient an accurate measurement of their 
glucose or cholesterol in their homes or in a doctor’s surgery without the need for time 
consuming laboratory testing can help identify disease states such as 
hypercholesterolemia or diabetes earlier before permanent damage has occurred (Von 
Lode, 2005). 
The importance of early identification of elevated cholesterol or glucose levels 
can be the difference between life and death. CVD has no early warning signs, 
therefore minimising modifiable risk factors and tracking those which can be 
quantified, such as blood cholesterol levels, is vital for improving prognosis and 
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reducing disease prevalence. The difficulty in diagnosing CVD puts additional pressure 
on the ability to monitor early risk-factors, such as elevated blood cholesterol levels 
and monitoring the development of diabetic states through blood glucose levels. 
Diabetic patients have much more immediate requirements for disease monitoring. 
Hyperglycaemia if left untreated can lead to coma and death within days and 
hypoglycaemia if left untreated will lead to coma and death within hours 
(Diabetes.co.uk, 2017). 
When developing assays for the detection of biomarkers, sensitivity, specificity 
and short turn-around time is important, to allow results to be available within a 
clinically useful timeframe (Qureshi et al., 2012). These assays should be readily 
available on a wide range of analytical platforms and should be relatively inexpensive. 
Target turnaround times should be less than 1 hour from blood collection to the 
reporting of results (Weber et al., 2005). 
Point-of-care (POC) diagnostic tests are described as in-vitro tests at or near the 
site of patient care that do not require trained laboratory staﬀ or equipment to 
generate diagnostic data (Leedsth.nhs.uk, 2014). POC testing can be used for 
quantification or identification of proteins, nucleic acids, metabolites, drugs, dissolved 
ions and gases, human cells and microbes in samples of blood, saliva, urine, or other 
bodily ﬂuids or (semi)solids (Gubala et al., 2012). Capable of being used in a healthcare 
setting, patient home or in field conditions, POC tests are rapidly becoming the first 
choice for patient diagnostics as these tests are simple to use, sometimes capable of 
detecting multiple analytes (Birtwell and Morgan, 2009; Schudel et al., 2011), accept a 
sample with little or no pre-preparation and provide a result in seconds to hours 
(Meagher et al., 2008).  
Result interpretation is shifting away from simple colour change and towards 
quantitative read-outs from hand-held devices to benchtop instruments. These devices 
are often capable of providing a digital result and controlling the assay process if 
necessary (Gubala et al., 2012). Common requirements of POC devices include small 
sample size (<1 µl up to 1 ml depending on the biological media), low reagent 
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consumption (Wang et al., 2010), and utilisation of low-cost disposable consumables 
that control sample size, flowrate, preparation, reagent mixing and assay reaction time 
(Jonsson et al., 2008). These requirements are the key challenges that device 
developers must consider when designing a POC device. 
There are a number of detailed reviews of POC diagnostic devices in the 
academic literature, including micro-total-analysis-systems (Rivet et al., 2011), 
miniaturized isothermal nucleic acid ampliﬁcation (Asiello and Baeumner, 2011) and 
molecular biological techniques for gene assay (Lien and Lee, 2010), and current and 
anticipated technology for POC infection diagnosis (Bissonnette and Bergeron, 2010). 
These reviews articulate the growing trend towards the use of POC devices as 
replacements for laboratory based equipment. 
 
2.2.1 Advantages of Point-of-Care Diagnostics 
Methods used currently for disease diagnosis and chemical analysis are both 
time-consuming and labour-intensive, and many tests are restricted to biomedical 
laboratories as they require specialised instrumentation and trained staff (Gubala et 
al., 2012). Due to patients having to wait days or even weeks for test results, the delay 
initiating treatment has the potential for fatal consequences. To address these 
limitations, POC devices have been developed that offer rapid analytical testing and 
that allow medical diagnosis to be performed on-site by non-professionals, for 
example, as patients checking their own health conditions (Ryan et al., 2010). This 
allows treatment to be initiated promptly and subsequent monitoring can be 
implemented, resulting in improved patient outcome (Soper et al., 2006). 
POC devices are designed and intended specifically to provide quick 
test-to-result times in comparison to laboratory assay procedures and be performed 
by the patients themselves, or by a healthcare professional in a POC setting. While the 
samples do not require a dedicated laboratory and trained staff, resulting in reductions 
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in travel time and the provision of results, accuracy and reliability must not be 
sacrificed for speed (Gubala et al., 2012). 
In the past decade there has been a fundamental shift in healthcare, centred 
on patient self-care, whereby patients are actively encouraged to be directly involved 
in their personal health and treatment of chronic illness. This results in the patient 
taking an active interest in managing their condition and improves patient compliance 
(Price, 2001; Laurence et al., 2010) resulting in better clinical outcomes (Douketis, 
2001). The development of POC devices enables and encourages patients to self-test. 
This has a large impact on reducing doctor and healthcare professional work load, 
reduces hospital admissions and increases public awareness and education of 
healthcare and disease. 
POC readers can cost significantly less than laboratory instruments as they are 
smaller, less complex and often specialised in performing a single diagnostic test. For 
example, a Varioskan Flash spectral scanning multimode reader (ThermoScientific Ltd., 
UK) can cost approximately £38,500 (VWR.com, 2017) whereas a POC glucose meter 
often costs <£30. As POC readers are often intended for use with disposable sample 
devices, there is no need for cleaning or calibration of the reader. However, the 
relative complexity of the consumables compared to a blood-tube, results in greater 
consumable costs which are often passed onto patients (Gubala et al., 2012). The fact 
that patients are able to perform the testing themselves also reduces staff costs for 
the healthcare institution. 
 
2.2.2 Disadvantages of Point-of-Care Diagnostics 
Some of the advantages of POC diagnostics can also be viewed as 
disadvantages. As mentioned in section 2.2.1, the reduced complexity of low-cost POC 
readers results in increased complexity of the consumables required for operation. 
Whereas a dedicated pathology laboratory has a reduced cost per test, when spread 
over the thousands of samples processed, the POC consumables are often the financial 
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responsibility of the patient, which can become expensive.  Readers and devices are 
often capable of performing only a single type of assay and only one assay per run. 
Therefore, multiple readers and different consumable devices are necessary for the 
detection and quantification of multiple analytes, which further increases cost.  
The POC setting is often heavily reliant on the person performing the test to be 
able to understand and perform the correct protocol, which is not always possible, and 
which can lead to incorrect interpretation of results and may lead to patient harm if, 
for example, incorrect dosing of medication is given as a consequence. In addition 
there is less chance of a healthcare professional being able to identify warning signs 
should a patient misinterpret diagnostic data. 
Issues have been raised about the accuracy of results obtained from POC 
devices, specifically those with single-use test cartridges, and about how errors in POC 
device design can contribute to possible inaccuracy (Gubala et al., 2012). A report was 
published by Venge et al. comparing POC results for the cardiac biomarker cardiac 
troponin I with those from laboratory analysers and the subsequent effect on patient 
diagnosis (Venge et al., 2010). Venge et al. discuss how laboratory based assays 
identified elevated cardiac troponin I levels in more patients than did the POC assays. 
The consequence was that laboratory testing was able to identify a higher proportion 
of people in the study (80.9%) who died of CVD than were identified by the POC assays 
(50.6%). The conclusion was that “the clinical judgment of the patient with suspected 
myocardial ischemia should not solely rely on results from POC assays.” (Venge et al., 
2010). 
This demonstrates the challenges of quantification in POC devices, as diagnostic 
and therapeutic information is gathered from a single test and calibration is performed 
across batch sampling. In addition, vital processes such as mixing, incubation timing, 
sample normalization, and rinsing may not be performed or controlled as well as in 
laboratory tests (Gubala et al., 2012). For example, where reagents are contained 
within the POC device, the key process of reagent-sample mixing is dependent on and 
affected by the efficacy with which the reagent distribution occurs within the sample, 
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which is beyond the control of the user. Should variances in reagent uniformity within 
the sample occur, variances in the result will also occur. Gubala et al. specifies that 
“critical issues arise in the dispersion of dried reagents into the sample, in the mixing 
of reagents and sample, and in the control of incubation time” (Gubala et al., 2012). In 
addition, the use of whole blood samples in POC devices often requires filtration 
features, which increases the risk of unforeseen reactivity between filter materials and 
blood components that may influence results. 
 
2.2.3 Point-of-Care Glucose Monitor 
A biosensor can be defined as a “compact analytical device or unit 
incorporating a biological or biologically derived sensitive recognition element 
integrated or associated with a physio-chemical transducer” (Turner, 2000). As 
mentioned in section 2.1.2, glucose quantification biosensors are the leader in 
commercial POC testing, and the technology is expansively described (Wang, 2008; 
Heller and Feldman, 2010).  
The majority of the current commercial self-test glucose quantification systems 
are enzymatic electrochemical biosensors, and the development of the technology has 
led to a reduction in the time-to-result to < 5 seconds and to a reduction in the 
required blood sample volume to as little as 0.06 µl. Examples of electrochemical POC 
devices can be seen in Figure 2.6. 
The three main components of a biosensor are: 
1. A biological detection part, usually enzymes or antibodies, which identifies the 
target analyte from other chemicals (Chambers et al., 2008; Goode et al., 
2016). 
2. A transducer, for example an electrochemical or optical device, that converts 
the biorecognition event into a quantifiable signal (Newman and Setford, 
2006). 
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3. A signal processing system that converts the signal into a readable form 
(Hiratsuka et al., 2008).  
The glucose biosensor operates by the oxidisation of glucose into gluconic acid and 
hydrogen peroxide by immobilised glucose oxidase (GlOx) (Weibel and Brights, 1971). 
GlOx is the standard enzyme for glucose biosensors due to its specificity and 
selectivity. It is also cheap, readily available and resistant to a wide range of pH and 
temperature (Heller and Feldman, 2008; Bankar et al., 2009). The hydrogen peroxide 
undergoes oxidisation at a catalytic anode that measures the number of electron 
transfers, which is proportional to the concentration of glucose in the sample 
(Guilbault and Lubrano, 1973). As blood oxygenation levels can vary, modern glucose 
assays bypass oxygen and instead rely on the use of mediators such as 
ferrocene-derivatives which undergo redox reactions and are quantified (Heller and 
Feldman, 2008). Electrochemical transducers are used because of their better 
sensitivity, reproducibility, easy maintenance and low cost  compared to other 
transducers such as optical, thermometric, piezoelectric, and magnetic (Yoo and Lee, 
2010). 
 
  
Figure 2.6: (A) personal glucose monitor (Abbott Laboratories, USA); (B) personal 
cholesterol monitor (Bioptik Technology Inc., Taiwan). 
 
(A) (B) 
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The personal glucose meter is a compact system (smaller than a mobile phone), 
cheap (<£30) and is simple to use as results are displayed digitally and are able to 
determine the blood sugar level within seconds (<10 seconds). Glucose meters use 
cheap (<£30 for a pack of 50) disposable microfluidic electrochemical sensor chips that 
require small sample size (<10ul) using whole blood. The personal glucose meter 
device embodies the ideal parameters of a POC testing system (Chin et al., 2012). 
Other such devices include electrochemical cholesterol meters and lateral flow 
pregnancy tests (Koczula and Gallotta, 2016). 
 
2.2.4 Lateral Flow Assays 
The lateral-flow assay (LFA), presented in 1988 by Unipath, is widely used for 
pregnancy confirmation (Figure 2.7) and ovulation tracking and is the most commonly 
available commercial POC diagnostic method (Lee, 2008). Other uses include screening 
for infectious disease, drugs and blood based protein markers (Gubala et al., 2012). 
LFA devices utilise fluid flow to operate and incorporate porous membranes, 
antibodies and an optical transducer system (Lee, 2008). 
 
Figure 2.7: Lateral flow pregnancy test. 
In an LFA, sample fluid containing the analyte disperses particulate labels with 
adsorbed antibodies or nucleic acids, which bind specifically to the analyte during an 
incubation phase; labels are often colloidal gold, latex spheres or dyed polystyrene 
(Lee, 2008; Assadollahi et al., 2009). The labelled analyte is then immobilised and 
detected optically in the read-out zone. The concentration of label in the read-out 
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zone is influenced by sample flow rate and by the quantity of analyte in the sample 
(Gubala et al., 2011). An illustration of the principle of an LFA can be seen in Figure 2.8. 
 
Figure 2.8: (A) Typical lateral ﬂow immunoassay format. (B) Sample is applied to the 
sample pad. Analyte present in the sample binds to the antibody-conjugated label, 
and then binds to the control line and test line to return a positive result. If the 
analyte is absent, the label binds only to the control line, generating a negative 
control result (Gubala et al., 2012).  
Gubala et al. discuss the primary limitations of LFA, specifically accuracy. This is 
due to lack of control of the sample volume into which the label is dispersed, 
uniformity of dispersion and flow rate, which is the main determinant of contact and 
incubation times (Gubala et al., 2012). Materials used in LFA development are another 
area of concern, as standard LFA materials—nitrocellulose, polyester, rayon—suﬀer 
from varying degrees of nonspeciﬁc binding, brittleness, and sensitivity to humidity 
(Assadollahi et al., 2009).  
As with the majority of POC devices, LFA and hand-held electrochemical 
devices can generally perform quantification of only one specific analyte and perform 
one assay run at a time per device. This limits their application in performing a bank of 
diagnostic tests on one device at the same time. As discussed in section 2.2.2, a key 
(A) 
(B) 
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criticism of POC devices is their lack of accuracy when compared to laboratory based 
tests. The ability to provide a suite of diagnostic data from a single operation on one 
device would not only mitigate the inaccuracy as multiple analytes can be compared, 
but would also provide far greater quantitative diagnostic data for the user to utilize 
when considering therapeutic and prognostic outcomes for the patient. 
Multi-marker POC devices would also provide healthcare professionals with the 
ability to look for other indicators or markers of disease states. If ambulance staff were 
able to quantify multiple biomarkers associated with a heart attack, then they could 
start lifesaving procedures on route to the hospital rather than delaying treatment, 
therefore greatly increasing heart attack survival rates. Multi-marker devices such as 
the Abbott i-STAT (Abbott Laboratories, USA) have been produced, however, these 
devices are still prohibitively expensive for most POC settings (> £6000 for a 
refurbished model (Blockscientificstore.com, 2017)). The use of inexpensive readily 
available multi-marker testing devices for home or POC use may reduce workload on 
hospital pathology labs and doctor’s surgeries, and may reduce hospital admissions 
through the screening and testing of common biomarker molecules and early 
identification of disease states.  
 
 Lab-On-A-Disc (LOAD) 2.3
The requirement for new developments of economical analytical screening 
tools has prompted miniaturisation as a potential method to improve performance, 
speed, and portability (Arnandis-Chover et al., 2014). Lab-on-a-chip, LOAD and 
microfluidic analysis systems are some of the most recent developments in 
miniaturisation of chemical and biological analysis (Mirasoli et al., 2014). Ideally these 
analytical tools should be designed to be capable of performing all the steps of the 
analysis (sample pre-treatment, reagents delivery, mixing, separation and detection) 
with the advantages of low sample and reagent consumption, fast analysis, reduced 
costs (Mirasoli et al., 2014). Miniaturisation has practical advantages when it comes to 
application. The ability to scale down traditional bench-top analytical processes and to 
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transfer them to a portable self-operating system is leading the way for extra-
laboratory analyses in clinical chemistry, food analysis, environmental monitoring and 
bio-warfare protection (Mark et al., 2010). There is also the potential to automate 
standard time-consuming laboratory practices (Chen et al., 2012). 
A range of detection technologies have been employed in miniaturised 
analytical systems, with most applications relying on fluorescence and electrochemical 
detection (Nwankire et al., 2013; Mirasoli et al., 2014). However, the lack of simple and 
portable analytical sensing systems combining high resolution detection and 
quantification at competitive costs restricts the spread of molecular detection and 
quantification in POC settings outside the lab (Arnandis-Chover et al., 2014).  
LOAD platforms, particularly microfluidic centrifugal systems, are a source of 
interest in both academia and industry, as they have a potential to integrate labour 
intensive biochemical assay procedures onto a single, portable automated device with 
low cost (Nwankire et al., 2013). LOAD systems integrate a number of microﬂuidic 
components for liquid operations on a platform similar to a compact disc (CD) through 
the use of the capillary-effect and centrifugal and Coriolis force on a rotating reference 
frame, with no requirement for connection to external pumps or power supplies (Chen 
et al., 2012). A LOAD system requires only a single motor to control complex ﬂuid 
transportation and sample loading at different rotation speeds, which simplifies 
complex assay procedures (Bruchet et al., 2013). Furthermore, the materials 
themselves and the methods used for the fabrication of LOAD systems are relatively 
inexpensive and facilitate large volume and low cost manufacture. Due to the low cost, 
these platforms could be considered disposable, which helps eliminate 
cross-contamination of biological samples (Rivet et al., 2011). In addition, because they 
are single-use, they do not require recalibration or maintenance. Plastics are 
lightweight and easy to transport and store, offering the potential for the use of the 
devices to improve health care in developing countries, where expensive equipment is 
not available (Mark et al., 2010). 
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The LOAD has been considered an ideal solution for POC applications not only 
because of the reduced amount of reagents and analysis time but also because it 
reduces errors related to human intervention (Kim et al., 2013). Furthermore, it can 
handle relatively large numbers of blood samples which could be an additional 
advantage for large scale screening for pathology. Having a rapid, accurate, and 
easy-to-use test available in a POC setting would provide great beneﬁts to the health 
care system and the patients. Thus, the development of an ‘at-line’, 
‘sample-to-answer’ microﬂuidic-based assay system for biomarker monitoring is an 
important development for the diagnostic industry (Nwankire et al., 2013). 
Blood is the most commonly tested biological sample; plasma separation from 
whole blood is a key step for sample preparation in POC diagnostics (Toner and Irimia, 
2005) and is often the ﬁrst step in biomedical diagnostics (Kinahan et al., 2014). 
Various methods of plasma separation from whole blood have been investigated in 
order to reduce the volume of whole blood required and to develop diagnostic devices 
for use in a POC setting. Systems utilizing hydrodynamic focusing (Di Carlo et al., 2008), 
filtration (VanDelinder and Groisman, 2006), acoustic standing waves (Petersson et al., 
2005), electrophoresis (Nakashima et al., 2010) and magnetic forces (Takayasu et al., 
2000) have been investigated for use in microfluidic devices. However, density based 
cell separation by centrifugation remains the gold standard method for plasma 
separation in whole blood in both microfluidic devices and conventional clinical 
settings (Kim et al., 2013). Centrifuge based blood separation can be implemented and 
performed in LOAD platforms with relative ease (Burger et al., 2012) compared to the 
previously stated separation methods. LOAD platforms are also able to perform 
biochemical analysis on the samples, in addition to plasma separation within the same 
platform. Therefore, LOAD has been considered as an ideal solution for POC 
applications. 
Centrifugation is simple and efﬁcient but requires a relatively large volume of 
the sample (typically larger than 1 mL), which requires staff with medical training to 
obtain the sample which can be painful or uncomfortable for the patient. Efforts to 
incorporate LOAD platforms for biomedical applications include blood-based 
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processing (Lee et al., 2009; Schaff and Sommer, 2011) shown in Figure 2.9, nucleic 
acid analysis (Focke et al., 2010; Lutz et al., 2010) and immunoassays (Chen et al., 
2011). 
 
 
Figure 2.9: (A) LOAD blood analyser; (B) Dual layer LOAD platform (Lee et al., 2009). 
 
Centrifugal microfluidic LOAD platforms are particularly suited to POC blood 
separation as they can perform not only plasma separation using reduced sample 
volume, Figure 2.10 (Kim et al., 2013), but also allow a variety of follow-up biochemical 
analysis to be undertaken on the same platform. For example, fully integrated 
colourimetric analysis of clinical chemistry (Lee et al., 2011) and pathogenic virus DNA 
extraction have been demonstrated using plasma samples separated from whole blood 
on spinning discs in an automated and parallel fashion (Cho et al., 2007; Madou et al., 
2006).  
(A) (B) 
28 Chapter 2: Literature Review 
 
Alexander M. Tothill  Cranfield University 
 
Figure 2.10: Separation of plasma from whole blood on centrifugal microfluidic LOAD 
platform after 30 seconds (d: depth). (Kim et al., 2013) 
Research into microfluidics has been increasing during the past decade (Mark 
et al., 2012). However, despite several devices going to market successfully and the 
market expected to reach £6 Billion by 2020 from £2.4 Billion in 2015 (Markets and 
Markets, 2015), the availability of microfluidic products is limited and they are not sold 
in large numbers in mass markets (Mark et al., 2012).  
Market penetration is restricted by several factors. The development of 
microfluidic POC devices is often time consuming and expensive, not only for the 
microfluidic devices but also for the processing instrument. The primary and 
fundamental hurdle is the technical development of an acceptable device; aspects 
such as accuracy, reproducibility, long-term stability, acceptable sample size, 
portability and ease of use must be overcome and then an instrument capable of 
reading the device/interpreting the results with the same standards must be 
developed (Gubala et al., 2012). These factors result in extremely high development 
costs, which limits the potential applications to those which will provide a return on 
such high investments (Whitesides, 2006). Once the technical aspects have been 
overcome, the customer is then presented with a substantial upfront investment for a 
processing instrument, commonly in the range of £10,000–£100,000 or more, which is 
severely limiting, especially in resource deprived areas (Mark et al., 2012). Devices 
such as the glucose meter have had success because these hurdles have been 
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overcome, such that the costs to the customer make it readily available to the general 
public and not just highly funded laboratories. 
With the development of LOAD platforms progressing, the main obstacle faced 
is the analysis and interpretation of the results produced within the platform. The 
readers produced are designed from the ground up for a specific LOAD platform with 
specialised custom components (Lee et al., 2011) resulting in expensive units such as 
the Abaxis Piccolo Xpress, with the reader unit costing in excess of £14,000 and the 
LOAD panels costing £104 for 10 (Figure 2.11). Units such as these are only suitable for 
clinical settings and not for general POC testing.  
 
 
 Figure 2.11: Abaxis Piccolo Xpress LOAD instrument (Abaxis.com, 2014). 
 
An approach being adopted by device developers to mitigate the high 
development costs, and the subsequently inflated retail costs, is to produce disposable 
devices for use with existing off-the-shelf instruments (Li et al., 2008). This removes 
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the requirement for the development of expensive custom instrumentation that 
inflates development and purchase costs. This approach has several advantages for 
both developers and customers and the combination of microfluidic liquid handling 
and off-the-shelf processing instruments could open new potential markets and 
facilitate commercial distribution of useful microfluidic products (Mark et al., 2012). 
Device companies would not have to invest time and resources developing 
instrumentation from the ground up and instead inexpensive, disposable microfluidic 
devices can be designed to be operated on existing, mass-produced instruments that 
are already common in labs or at home. The instruments could be utilised either as 
they are or with modification. However, the instruments would likely require a 
minimum of a firmware update to be used with the devices. As the level of 
modification required increases, so does cost, but the use of mass-produced 
components from instruments greatly mitigates these costs and the required 
resources are substantially less than developing an instrument from concept (Li et al., 
2008). Reduced development costs for device companies would decrease investment 
costs and render more research applications financially viable. In addition, the 
customer would not be discouraged by high investments for an instrument and 
benefits from miniaturization, integration and automation of liquid handling 
operations (Mark et al., 2012). 
There has been progress towards this goal, with Nie et al. developing a paper 
based device for the quantification of glucose, cholesterol and L-lactate in human 
plasma that can be used with a standard electrochemical glucose meter, Figure 2.12 
(Nie et al., 2010). This device highlights the cost advantages; a low-cost disposable chip 
using an off-the-shelf electrochemical glucose reader available for less than £20 (Nie et 
al., 2010). One must be aware that developing devices for use with unmodified 
instruments would require collaboration between instrument developers and device 
developers to define and share approval procedures, responsibilities and warranties, 
especially for significantly controlled markets such as diagnostics, however both 
parties would benefit since instrument applications and therefore its customer base 
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are expanded, while the device developers market the consumables (Mark et al., 
2012). 
 
Figure 2.12: Paper based glucose sensor for use in a standard off-the-shelf glucose 
meter (Nie et al., 2010). 
A cheaper approach to develop LOAD players is to utilize and modify existing 
mass produced technology to achieve the same goal. Arnandis-Chover et al. used 
adapted Blu-Ray optical drive components to develop a screening device and platform 
using high density arrays (Arnandis-Chover et al., 2014).  
 
2.3.1 Optical Disc Drives (ODD) and Discs. 
Mass produced electronic optical disc drives (ODD), as seen in Figure 2.13, are 
resources with high potential for inexpensive molecular screening developments.  
ODDs contain all the components necessary to act as both a centrifuge and a fixed 
wavelength spectrophotometer (depending on the wavelength of the laser diode) in a 
single small, compact unit whilst offering good sensitivity and accuracy with minimal 
technical expertise and maintenance (Arnandis-Chover et al., 2014). As a result, optical 
drives and CDs have been used in chemical and biochemical assays by adapting 
standard drives as quantitative detectors (Morais et al., 2008; Yu et al., 2013). 
ODDs are an integral part of many consumer appliances such as compact disc 
(CD) players, digital versatile disc (DVD) players and computers. They use lasers to read 
and write data to or from optical discs. Some drives can only read from discs, but most 
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are commonly both readers and writers. CDs, DVDs, and Blu-ray discs are common 
types of optical media which can be read and recorded by such drives.  
 
 
Figure 2.13: A common mass produced optical disc drive (Newegg.com, 2014).  
Optical drives and CDs have been used for chemical and biochemical assays by 
adapting standard drives as quantitative detectors (Morais et al., 2008; Yu et al., 2012). 
An audio–video optical storage system consists of an optical drive and corresponding 
optical media.  
The main elements of an optical drive are:  
 An optical path consisting of a semiconductor laser and a set of optical lenses 
to shape, focus and guide the laser beam,  
 A motor mechanism to drive the disc,  
 A signal detection system, usually using photodiodes, for the light reflected 
from the disc. 
(Arnandis-Chover et al., 2014) 
ODDs are attractive instruments for microfluidic POC systems since they are 
inexpensive (£10–£50) and readily available, however, they have limited capabilities in 
terms of liquid processing, thermal control and optical readout (Mark et al., 2012). By 
combining a microfluidic LOAD platform with an ODD, it is possible to circumvent ODD 
limitations and create a low-cost, easy to use, portable POC system for the 
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identification and accurate quantification of biomarkers. Figure 2.14 shows the 
internal components as seen inside an ODD. 
 
Figure 2.14: Optical disc drive without top casing showing internal components. (A) 
Disc rotation array; (B) Laser array (Ebay.com, 2014). 
 
Different types of discs require different wavelengths. CDs use a wavelength of 
780 nm, DVDs use a wavelength of 650 nm and Blu-ray discs use a wavelength of 405 
nm. Due to the similarities between CD and DVD requirements, one laser set-up can be 
used for both. However, Blu-ray discs require a different laser set-up, such that optical 
drives that can accept both CD/DVD and Blu-ray discs will contain multiple lasers, as 
seen in Figure 2.15. 
Optical drives intended for computer use are internal, connected via an ATA or 
SATA interface, or external which usually have USB or FireWire interfaces.  
 
(A) 
(B) 
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Figure 2.15: Blu-Ray drive containing two laser systems, one for Blu-Ray discs and 
one for CD/DVD discs (Study.com, 2014).  
 
The data on optical discs is encoded in binary in the form of a single continuous 
spiral track of microscopic bumps (known as pits) or dye of differing reflectivity. Pits 
represent a zero, and flat surface/lack of pit (known as lands) represent a one. An 
optical drive reads data from a disc by shining the laser at the disc; pits scatter the light 
whereas lands reflect the light back which is detected by photodiodes that output 
electrical signals (Woodford, 2016).  
In addition to the laser set-up, an optical drive has a rotational mechanism to 
spin the disc. Originally designed to work at only constant linear velocity where the 
disc speed varies between 200 – 500 revolutions per minute (RPM) depending on 
where the laser is reading, modern optical drives are capable of spinning much faster 
with more variability, as the needs of data discs evolved away from pure audio which 
require a constant read speed. Recent optical drives are easily capable of exceeding 
speeds of 12,000 RPM. However, there are safety concerns regarding the disc integrity 
when spun at extremely high speeds for prolonged periods. The extremely high speed 
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drives, such as 52x CD/DVD-RW which can spin at 30,000 RPM,  have been known to 
exceed the physical limitations and structural capability of the discs, shattering them 
inside the drives with a risk of causing serious injury (Cochrane, 2002). While discs 
have also been shown to shatter at 20,000 RPM, the discs in these cases most likely 
had prior damage and contain structural weaknesses. At 25,000 RPM, structurally 
sound discs with no prior damage have been shown to fail and shatter whilst being 
spun for prolonged periods. Despite cases being reported of discs exploding at high 
speeds, it is extremely rare when the total number of discs and optical drives being 
used each day are taken into account (Rees, 2003). 
The surface material used for the manufacture of optical discs is polycarbonate. 
CD and DVD discs are up to 120 mm in diameter, 1.2 mm thick with a 15 mm diameter 
spindle hole at the centre. CDs are a single clear polycarbonate substrate disc 
containing the data covered by a reflective aluminium surface to reflect the laser light 
and allow the data to be read, which is protected by a lacquer on which a label is 
usually printed. DVDs comprise of two polycarbonate substrate discs each of which is 
covered by a metallic layer (not always aluminium) and bonded together (Sharpless, 
2003). 
Bosco et al. performed statistical detection of PDGF proteins through aptamer-
based surface functionalization of micro-cantilever arrays using a plug-and-play CD-like 
platform and laser system components from a DVD optical drive (Bosco et al., 2013). 
They used a DVD-ROM based optical readout system to scan the micro-cantilever 
surfaces. The deflection profiles were measured using the astigmatic detection method 
embedded in commercial optical drives (Hnilička et al., 2005). This platform used a 
custom built pulley belt system in order to rotate the disc rather than the drive system 
used within optical drives. Bosco et al. noted that utilising a DVD based optical reading 
system offered numerous advantages compared to traditional optical readout systems, 
for example the large amount of data provided for implementation of statistical data 
analysis and sensing reliability evaluation. The DVD laser optical unit provided 
nanometre resolution readout for multiple measurements of individual cantilevers 
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profiles, enhancing the amount of statistical data acquired on each assay (Bosco et al., 
2013). 
As discussed in section 2.3, a cheaper approach to developing POC instruments 
is to utilize and modify existing mass produced technology to achieve the same goal. 
While a number of microfluidic devices for use with optical disk drives have been 
developed, they often require extensive manual preparation steps, significant 
modification to the disc drive and are not plug-and play solutions. Examples include 
automated haematocrit measurements (Riegger et al., 2007), Ca2+ concentration 
measurements (Potyrailo et al., 2006), biotin/streptavidin binding, DNA hybridization 
and IgG/anti-IgG interactions (Li et al., 2008) and an immunoassay for C-reactive 
protein (Lange et al., 2006). Arnandis-Chover et al. used adapted Blu-Ray optical drive 
components to develop a screening device and platform using high density arrays 
(Arnandis-Chover et al., 2014) and Yu et al. have developed a digital readout 
methodology for screening biomolecular binding reactions on a disc using a standard 
unmodified computer drive (Yu et al., 2013). 
 
2.3.2 Particle Separation on a Centrifugal Microfluidic Platform 
Microfluidics in rotating systems uses centrifugal, Coriolis and Euler forces to 
transport and manipulate liquids through their interaction with microstructures. Figure 
2.16 shows the forces experienced by a liquid plug on a rotating disc. 
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Figure 2.16: Forces experienced by a fluid plug on a rotating disc. 
 
Centrifugal force (FC), as illustrated in Figure 2.17, is given by: 
Equation 1: 𝐹𝑐 = 𝑟𝜔
2𝑚 (1) 
Where r is the radial position, ω is angular velocity (or linear velocity/r) and m is mass. 
 
 
Figure 2.17: Illustration of centrifugal force (Calctool.org, 2008). 
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Sedimentation of particles in a centrifugal ﬁeld is due to the density difference 
of the suspended particles and the media. The sedimentation of the particles can be 
accelerated by exposing them to a centrifugal force (FC) given by: 
Equation 2: 𝐹𝐶 = 𝑟ω
2𝑉𝑃(𝑃𝑃 − 𝑃𝑙) (2) 
Where VP is the volume of the particle, PP and Pl are the mass density of the particle 
and the liquid, respectively.  
When the particle with radius rP sediments in liquid with viscosity ƞl at velocity µ, the 
friction force (Fr) caused by the Stokes drag is: 
Equation 3: 𝐹𝑟 = −6𝜋ƞ𝑙𝑟𝑃𝜇 (3) 
Neglecting the interaction between the particles, the interplay of the centrifugal force 
and the friction force leads to the sedimentation velocity (u) given by: 
Equation 4: 𝑢 = 𝑠𝑃𝑟𝜔
2 (4) 
With the sedimentation coefﬁcient (SP): 
Equation 5: 𝑆𝑃 =
𝑚𝑃
6𝜋ƞ𝑙𝑟𝑃
(1 −
𝑝𝑙
𝑝𝑃
) (5) 
Where mP is the mass of the particle. The empirical sedimentation coefﬁcient of 
erythrocyte is 0.27 × 10−7 s (Van Wie and Hustvedt, 1988). 
In 1920 it was seen that erythrocytes in whole blood would sediment at a faster 
rate when the container was inclined at an angle as opposed to being vertical, which is 
known as the Boycott effect. The proposed explanation for the enhanced 
sedimentation rate is that there is an increased surface area available for particle 
sedimentation. In a vertical container, particles can settle only on the bottom, whereas 
in an inclined container they can also settle on the upward facing wall. During the 
particle sedimentation process, the particles ﬁrst approach the inclined wall and form 
concentrated slurry that is signiﬁcantly heavier than the clear liquid, which rapidly 
slides down toward the bottom of the tube (Kim et al., 2013). 
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Ponder and Nakamura and Kuroda proposed a kinematic model, PNK theory, to 
explain the Boycott effect and the increased settling rate observed in an inclined 
container (Kim et al., 2013). According to PNK theory:   
Equation 6: 𝑣 = −𝑣0 (1 +
ℎ
𝑤
sin 𝜃)   (6) 
Where v is the sedimentation velocity in the slanted vessel, v0 is the sedimentation 
velocity in the same vessel un-tilted, h is the height of blood cell suspension, w is the 
width of the vessel, 𝜃 and is the tilt angle from vertical. This equation suggests that the 
settling rate is increased by a factor of (1 + h/w sinθ) over the non-tilted case. Thus, 
the sedimentation rate in a slanted container is equal to the vertical settling rate of 
particles multiplied by the horizontal projection of the channel area available for 
settling (Davis and Acrivos, 1985).  
Kim et al. described the effects of sedimentation chamber geometry on blood 
separation times in rotating discs, particularly focusing on inducing the Boycott effect 
by inclining sedimentation chambers relative to the direction of centrifugal force (Kim 
et al., 2013). Whole blood samples were spun at 2400 and 3600 RPM for three minutes 
and both speeds were able to separate plasma. These speeds are well within optical 
drive spin capabilities and the physical tolerance limit for polymer discs. As shown in 
Figure 2.18, the distance for particle sedimentation is shorter in a slanted channel than 
a straight channel. 
Kim et al. showed that greater channel tilt angle, smaller channel width, lower 
sample cell fraction, and higher spin speed could enhance the blood separation rate 
and the channel depth or rotating direction did not. Signiﬁcant enhancement of the 
blood separation rate, as high as 8 times for whole blood, was observed in the 
narrower separation channels on a spinning disc with larger tilt angles with respect to 
the radial direction (Kim et al., 2013). These factors will need to be considered when 
optimisation of the assay platform design used in this project takes place. 
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Figure 2.18: Blood separation in a tilted channel and a straight channel. The blue 
arrows show how the particle sedimentation distance is shorter in a slanted than a 
straight channel (Kim et al., 2013). 
 
 3D-Printing Technology 2.4
The advance of solid freeform fabrication techniques, such as 3D-printing, has 
improved signiﬁcantly the ability to prepare solid structures with precise geometries 
(Hutmacher et al., 2004), including internal cavities, facilitating the rapid production of 
analytical platforms. The use of computer-aided designs (CAD) and data from imaging 
provides the ability to alter or redesign any aspect without significantly inflating costs. 
The rapid advancement of low-cost (<£2000 for the printer) 3D printing technology is 
partly due to the free and open source software and hardware development (Zhang et 
al., 2013). In addition, there is a large library of CAD models available freely 
(Thingiverse.com, 2016) which provide shortcuts to product development. 
The ability to manufacture detailed and complex prototypes in a fast and 
efficient way has caused rapid prototyping technology to become a useful tool for 
many areas of research and development. Fused deposition modelling (FDM) based 3D 
printers are readily available for purchase, either as self-assembly kits (Velleman.eu, 
2016) or as pre-assembled units (MakerBot.com, 2016). While the use of 3D-printing 
to produce cost-effective tools for biomedical applications has significant potential 
(Ballyns et al., 2009; Cohen et al., 2006), its use in the optical and biosensors ﬁeld is 
limited to-date. By developing a cheap, simple sensing platform capable of quantifying 
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a variety of different molecules in whole blood and other bodily fluids, the prevalence 
of disease states and the strain exerted on healthcare facilities may be lessened. 
When investigating manufacturing procedures, the following core principles for all 
production processes must be considered: 
 Performance requirements (i.e. tolerances, strength, weight, etc.)  
 Production cost requirements  
 Quality reproducible during mass production  
 Uniform material properties throughout component. 
(Thelibraryofmanufacturing.com, 2014) 
A large variety of methods have been used for the fabrication of microﬂuidic 
platforms, both standard chips and LOAD. Most techniques used for LOAD device 
channel formation (Moschou et al., 2006; Nunes et al., 2010) , such as thermoforming, 
injection moulding, lamination (Miserere et al., 2012), laser ablation, soft lithography, 
computer numerical control micro-milling (Kazarine et al., 2012), xurography 
(Bartholomeusz et al., 2005) and hot embossing, leave open faces that have to be 
closed by an additional layer. The device enclosing may be performed by adhesive, 
thermal and mechanical-based bonding techniques. This however introduces the 
potential for weakness and flaws in structural integrity which increases the risk of 
leaks, especially in centrifugal microfluidic platforms. It also adds additional design and 
manufacturing steps to the process, increasing production costs and time. 
Most solid freeform fabrication techniques are an additive fabrication process that 
can rapidly recreate 3D CAD models with high accuracy by slicing them into layers and 
building the layers up progressively from a wide range of materials using deposition 
tools. These fabrication techniques include selective laser sintering, fused deposition 
modelling, and stereolithography. The designed external and internal (pore) geometry 
of the structure that is to be built can either be devised using 3D drawing computer 
software, be described using mathematical equations (Gabbrielli et al., 2008), or be 
derived from scanning data of imaging technologies such as MRI or CT techniques 
42 Chapter 2: Literature Review 
 
Alexander M. Tothill  Cranfield University 
(Mankovich et al., 1994). The possibility of using data from scans makes these 
manufacturing technologies particularly useful for applications in biomedical 
engineering, since it enables the fabrication of patient speciﬁc models or implants. The 
CAD-ﬁle describes the geometry and size of the parts to be built.  
Solid freeform fabrication technology has the potential to fabricate LOAD platforms 
more rapidly with higher precision. Stereolithography techniques have been used to 
fabricate a silicone aortic valve replica based on X-ray computed tomography scans 
(Schaefermeier et al., 2009; Sodian et al., 2002). FDM has been employed to engineer 
hard tissue scaffolds such as knee menisci and intervertebral discs (Ballyns et al., 2009) 
and encapsulated cells (Cohen et al., 2006). These applications illustrate the beneﬁts in 
the manufacturing of tailored parts on-site for use in clinical practice. 
Originally, solid freeform fabrication techniques were developed to create 
prototypes when designing new products. Traditional prototyping methods involve 
laborious mould making and casting steps (Pham and Gault, 1998), whereas the ability 
to create an object within hours from a computer design by rapid prototyping 
signiﬁcantly speeds up the development of products. Where traditional methods 
require the production of new moulds every time alterations are made to the design, 
which is time consuming and expensive, solid freeform fabrication requires only 
alteration of the CAD file, which affords the rapid production of analytical platforms, as 
well as the ability to alter or redesign any and all aspects without significantly inflating 
costs. 
As solid freeform fabrication technologies are continuously evolving, fabrication 
costs are decreasing and the properties of the manufactured parts are improving. 
Therefore, these techniques are being used increasingly for the rapid manufacture of 
products in small batches. The time gain in product development, freedom of design 
and tool-free fabrication can outweigh the increased fabrication costs per item 
(Wendel et al., 2008). The possibilities for using solid freeform fabrication methods for 
biomedical applications are numerous. But, despite the commercial availability of the 
technique for more than 20 years, it is still not extensively used in the medical and 
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diagnostic ﬁelds. Figure 2.19 shows an overview of solid freeform fabrication 
techniques. 
 
Figure 2.19: Overview of solid freeform fabrication technologies used for biomedical 
applications. For each technique, the symbols indicate whether polymers and/ or 
ceramics, hydrogels and living cells have been employed (Melchels et al., 2010). 
 
FDM is an extrusion based 3D printing method in which a pre-formed filament 
of a suitable material is fed and melted inside a heated liquefier before being extruded 
through a nozzle. The system operates in a temperature-controlled environment to 
maintain sufficient fusion energy between each layer.  
Drawbacks of the FDM technique include the need for the input material to be 
of a specific diameter and to have material properties suitable to allow it to be fed 
through the rollers and nozzle. Any changes in the properties of the material require 
effort to recalibrate the setting of the feeding parameters. As a result, FDM has a 
narrow processing window. The resolution of FDM is relatively low, at 250 µm feature 
size.  
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As the process liquefies the materials used, the range of materials that can be 
used are limited to those with thermoplastic properties and the high temperatures 
used almost completely exclude natural polymers and prevent the incorporation of 
biomolecules into the platform structure, which can limit its versatility. Modifications 
of FDM to circumvent these limitations have encouraged the emergence of several 
new techniques. These include techniques that eliminate the requirement for 
precursor filaments or a system with reduced operating temperatures. A basic FDM 
setup is illustrated in Figure 2.20. 
 
Figure 2.20: Basic Fused Deposition Modelling (FDM) setup (RepRap.org, 2014). 
 
Stereolithography uses photo-polymerisation to solidify liquid resin under 
spatially controlled conditions; an illustration of the equipment set up is shown in 
Figure 2.21. A pattern is illuminated on the surface of the resin using a 
computer-controlled laser beam or a digital light projector with a computer-driven 
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building stage. The resin is solidified to a defined depth in the shape of the pattern, 
causing it to adhere to a support platform. After photo-polymerisation of the ﬁrst 
layer, the platform is moved away from the surface and the built layer is recoated with 
liquid resin. A pattern is then cured in this second layer. As the depth of curing is 
slightly larger than the platform step height, good adherence to the ﬁrst layer is 
ensured (unreacted functional groups on the solidiﬁed structure in the ﬁrst layer 
polymerise with the illuminated resin in the second layer). This is repeated to form a 
solid 3D object. After draining and washing-off excess resin the structure requires post-
curing with ultraviolet light to ensure that the conversion of reactive groups is 
complete and to improve the mechanical properties of the structure. 
Stereolithography is particularly versatile with respect to the freedom of 
designing structures and the scales at which these can be built: submicron-sized 
structures as well as decimetre-sized objects have been fabricated. Regarding accuracy 
and resolution, stereolithography is superior to all other solid freeform fabrication 
techniques. While in most fabrication techniques the smallest details are 50-200 µm in 
size, many commercially available stereolithography setups can build objects that 
measure several cubic centimetres at a claimed accuracy of 20 µm. 
 
Figure 2.21: Stereolithography principle set up (Custompart.net, 2008). 
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While stereolithography has been in use for many years due to its high 
accuracy and quick turnaround time, it is used more for producing a physical 
representation of the final product rather than the final product itself, since the 
models produced are generally not as strong or durable as the final product needs to 
be. In addition, the increased cost (printer, supplies and materials) relative to other 
3D-printing techniques, have resulted in stereolithography not being used as a product 
manufacturing technique. FDM printing is flexible in its applications and purposes due 
to the different materials available for use and it produces printed products that are 
sufficiently strong and durable to be considered final products. Overall it is less 
expensive than stereolithography, whilst maintaining many of the same characteristics. 
Therefore, this project will use FDM based 3D printing to produce the LOAD devices.  
 Chen et al. used polyjet based 3D-printing technology of a proprietary acrylate-
based polymer material, Vero Clear, to produce plates for use with a standard plate 
reader for the quantitative analysis of red blood cells for transfusion medicine. Whilst 
capable of printing the plates, the Objet Connex 350 Multi-material 3D printer that was 
used to print the devices costs over £150,000 and the devices required post-print 
finishing including cleaning and polishing using sand paper and water to achieve 
acceptable physical properties and the levels of optical transparency required for use 
with a standard plate reader (Chen et al., 2014); these finishing techniques would be 
unsuitable for use in sealed microfluidic channels. In addition, the material used is not 
readily available for public use.  
Erkal et al. also used an Objet Connex 350 Multi-material 3D printer to produce 
0.5 mm2 microfluidic channels for use with electrodes for the detection of dopamine. 
Post-print techniques including sonication and scraping were required to properly form 
the channels of desired specification (Erkal et al., 2014).  
The recent introduction of the Fluidic Factory in March 2016 by Dolomite 
(Dolomite, Royston, UK) seeks to use FDM 3D-printing technology for the production 
of fluidically sealed microfluidic chips. However, the starting price of £14,000 for the 
printer and the £350 cost of each reel of cyclic olefin copolymer (Dolomite, 2016), 
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restricts access of affordable FDM 3D-printing technology for the production of 
microfluidic devices to consumers with relatively large financial resources.  
Following the 3D-printing of objects, there are several post-print finishing 
methods that can be utilised to improve the quality/properties. These methods 
include: 
 Cutting/trimming/grinding- the physical removal of polymer material to 
improve the form/structure of the object. As the process involves 
removing material from the structure, direct access to the area is 
required and errors can compromise the integrity of the object. 
 Sanding/ polishing- the physical removal of polymer material to 
decrease the surface roughness and improve the surface finish. As the 
process involves removing material from the structure, direct access to 
the area is required and errors can compromise the integrity of the 
object. 
 Chemical treatment- applying a chemical agent such as acetone to the 
object to decrease the surface roughness and improve the surface 
finish. Direct application requires direct access to the surface being 
treated; indirect application such as vapour treatment does not 
necessarily require direct access to the surface, however, control of the 
application process can be more difficult (Ultimaker.com, 2016a).  
 Annealing/heat treatment- baking the object to increase the heat 
deflection temperature so parts retain more stiffness and form at higher 
temperatures. It can also improve object strength by improving strand 
and layer merging. Does not require direct access to all object surfaces, 
however, some shrinkage/warping may occur and object colour will 
change to opaque due to crystallisation of the polymer occurring (Proto-
Pasta.com, 2017).  
The requirement for post-print finishing techniques, such as physical removal 
of material and polishing, to improve 3D-printed objects greatly limits the potential for 
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3D printing of optical microfluidic devices, especially for the fabrication of inaccessible 
microfluidic channels. This emphasises the need for developing accessible and 
affordable prototyping technology. 
 
2.4.1 Manufacturing Materials 
Traditionally, glass and silicon have been used in the fabrication of microfluidic 
devices due to their well-established properties and compatibility with manufacturing 
techniques such as photolithography and micromachining (Ansari et al., 2016). More 
recently, the use of relatively inexpensive large scale techniques such as injection 
moulding and hot embossing has led to an increase in the use of polymers for 
economical microfluidic device manufacture (Becker and Locascio, 2002). As well as 
being low-cost and disposable, polymers are highly adaptable for diagnostic purposes 
(Siegrist et al., 2010). This has resulted in materials such as polymethylmethacrylate 
(PMMA) and polydimethylsiloxane (PDMS) becoming highly desirable for microfluidic 
device prototyping and manufacture (Ansari et al., 2016) and for disposable lab 
equipment such as PMMA cuvettes (Sigma-Aldrich, 2016a). 3D-printed optical assay 
platforms can suffer from the poor optical characteristics (Willis et al., 2012) of the 
available polymers,  such as polylactic acid (PLA) and acrylonitrile butadiene styrene 
(ABS), particularly their poor optical transparency, which is a fundamental obstacle 
that must be overcome for the technology to progress. 
Currently, the two most commonly used materials in low-cost FDM 3D printing 
are PLA and ABS. PLA is made from plants rich in starch like potato, corn and wheat. It 
is both commercially 100% compostable and 100% biodegradable. ABS is petroleum 
based plastic and is not safe to use for products which may come into contact with 
food. PLA and ABS are known as thermoplastics; they become soft and pliable with 
more liquid properties when heated and return to a solid state when cooled; this is a 
repeatable process.  
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While many thermoplastics exist, few are used in 3D printing due to the 
requirements imposed by the process; there are 3 different stages the material has to 
pass to be considered for use. The first stage is processing base plastic resin into a 
filament that the printer can accept for use. The plastic needs to form a consistent 
filament that is uniform in size, shape, density and be bubble free. The second stage is 
extrusion and trace-binding during the 3D printing process, which gives aesthetically 
pleasing and physically accurate parts. The final stage comprises the physical 
properties of the part; the material properties should match the proposed function, 
strength, durability, finish, transparency etc. (Chilson, 2013). 
While ABS and PLA are both able to make physically accurate parts, there are 
differences between them that can influence the choice of the use of one over the 
other. With ABS, the major factor is its tendency to warp during printing, especially 
during the initial printing stages when the molten filament encounters a cold printing 
build table (MakerGeeks.com, 2014). This can render the parts unusable within the 
first few minutes of printing. The simplest method for reducing warping is the use of a 
heated build table (English, 2012). However, not all 3D printers have a heated build 
table and the ones that do tend be significantly more expensive; the Ultimaker Original 
(Ultimaking Ltd., Netherlands) does not have a heated build table and starts at €995, 
whereas the Ultimaker 2 (Ultimaking Ltd., Netherlands) does have a heated build table 
included and starts at €1895. PLA does not suffer from warping to the same degree as 
ABS and therefore is often the material of choice when a heated build table is not 
available. For fine, sharp features, ABS is inferior to PLA as there commonly will be 
rounding of the points/corners (Chilson, 2013). A small amount of cooling at the nozzle 
can improve the points, but this runs the risk of reducing interlayer adhesion, which 
can lead to cracks in the part. The properties of PLA offer several advantages over ABS. 
At operating/printing temperature, PLA has increased fluidity than ABS and, if actively 
cooled, allows the production of sharper details without the risk of cracks. The greater 
flow can also result in better interlayer adhesion and increased strength (Chilson, 
2013). 
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In general, ABS is strong, with a degree of flexibility that is greater than PLA, 
which makes it easier to work with and finish (Grieser, 2016). Its higher extrusion 
temperature, 235°C to 256°C, gives it higher resistance to heat (MakerGeeks.com, 
2014). Also acetone can be used as a plasticiser which allows it to be welded, 
smoothed and finished using acetone. These properties make it a favoured material for 
mechanical/practical uses. PLA is as strong as ABS, but is far more brittle, which can 
make it harder to work with or finish. Its tendency to crack and shatter before bending 
limits practical applications and the lower extrusion temperature, approximately 
210°C, makes it unsuitable for many conditions that involve raised temperatures due 
to it deforming and losing structural integrity and strength (MakerGeeks.com, 2014). 
However, due to its lower extrusion temperatures and increased fluidity when molten, 
this material has potential for great structural integrity and interlayer strength, higher 
maximum print speeds, increased printing resolution and finer details on prints, as well 
as far less tendency to warp. It also generally has a better finish after printing, reducing 
or removing entirely the need for finishing depending on personal preference. This 
makes it popular for display, hobby or household use (Chilson, 2013). 
Due to its tendency to crack and splinter rather than bend, PLA is considered 
weaker than ABS; however similar force is required for them to fail (English, 2012). 
More commonly it is the calibration of the printer and the settings being used that 
result in a weaker or stronger object rather than the material used. Fill density, print 
speed, extrusion temperature, layer resolution and shell/wall thickness will all 
contribute to the structural strength of the item (English, 2012). 
 
 This Project 2.5
This project will investigate low-cost FDM 3D-printing as a potential 
development and production method for microfluidic LOAD devices. A LOAD device 
will be designed and optimised using 3D-printing for use with a mass-produced ODD. 
Mark et al. describes how most presented examples of microfluidic POC devices for 
use with ODDs still require extensive manual preparation steps and are not plug-and-
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play solutions yet (Mark et al., 2012). This project attempts to demonstrate the 
capability of 3D-printed LOAD devices as a one-step analytical platform that does not 
require such preparatory steps and has the potential for use in an ODD. Chin et al. lists 
central challenges to the commercialisation of microfluidic POC diagnostic devices, this 
includes methods of sample collection and working with complex sample specimens 
such as whole blood (Chin et al., 2012). In this project, device development was aimed 
to progress towards the use of microfluidic quantities (<50 µl) of whole blood such that 
samples ultimately can be taken using a finger prick device. This will ensure the device 
can use existing POC sample collection methods and is viable with complex sample 
specimens. 
In order to be used as an assay platform, e.g. for the quantitative detection of 
cholesterol or glucose markers, the LOAD will be designed to integrate optical assays. 
Reagents will react with the target analytes in the sample solution and induce a colour 
change (Rivet et al., 2011). For readout of the results of the assay, the intensities of the 
colours can be compared with those of calibration curves to quantify the 
concentration of analytes. With the use of this approach, colourimetric-assay-based 
paper-on-chip devices have been used to successfully quantify glucose, pH, and 
protein levels thus, colourimetric detection methods are ideal for simple POC diagnosis 
because of their visual readouts, low cost, and stability (Rivet et al., 2011). Optical 
detection and quantification are widely employed in microfluidics and provide high 
sensitivity, rapidity and easy implementation for quantitative purposes (Rivet et al., 
2011). 
As discussed in section 2.4, the equipment and running costs of 3D-printers 
primarily used for developing medicinal devices are prohibitively expensive 
(>£150,000), which, when combined with equally costly and commercially restricted 
consumables (which can be in excess of £750 per container of polymer) and monthly 
licensing fees to simply operate the machinery, is beyond the financial capabilities of 
many development and research laboratories.  
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This project will also explore the benefits of affordable and readily available 
FDM 3D-printing technology as a device development tool for POC devices whilst 
overcoming the limitations of FDM 3D-printing; firstly the poor product finish 
compared to traditional manufacturing methods and the poor optical transparency of 
FDM 3D-printed devices (Gross et al., 2014) achievable when using readily available 
filament and affordable FDM 3D-printers. Secondly, the formation of imbedded 
microfluidic channels, which are a fundamental requirement for any POC diagnostic 
device. PLA will be the material used for device development and optimisation. 
The LOAD device should be of the same dimensions of a CD (120 mm diameter 
and 1.2 mm thick), contain imbedded microfluidic channels (volume < 50 µ) and have 
optical transparency sufficient that colour can be visually observed within the 
channels.  
The combination of microfluidic LOAD devices with low-cost FDM 3D-printing 
and mass-produced off-the-shelf optoelectric drives offers the potential for developing 
POC analytical tools at a fraction of the cost and time; the notion being that existing 
optical-disc drives could one day be repurposed with minimal modification as 
affordable diagnostic readers for use with the LOAD platform being developed in the 
project. The LOAD device would be a cheap, disposable platform, capable of testing 
multiple samples for multiple analytes simultaneously depending on platform design 
and colourimetric chemistries and suitable for both lab and POC due to relatively low 
upfront costs to the consumer. 
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 Introduction  3.1
The quantification of metabolites such as cholesterol, glucose, urea and lactate 
in whole blood is highly important in clinical diagnostics. Cholesterol is abundant in 
humans and animals, being a structural component of cell membranes. Nerve, brain, 
skin and liver tissues contain particularly high volumes of cholesterol and it is the 
central component of nerve myelin (Saher et al., 2005). Its role in the progression of 
disease states such as hypertension, arteriosclerosis, cerebral thrombosis, and 
coronary heart diseases makes its assay important for diagnosis and prevention of 
such conditions.  
With the number of people living with diabetes increasing every day and 
expected to rise to 366 million by 2030, the quantification of glucose in solution 
remains of great importance. Diabetic patients are expected to self-monitor personal 
blood glucose levels through the use of home testing kits and healthcare professionals 
regularly perform blood glucose testing at health check-ups to screen for pre-diabetes 
or diabetes. For that reason, there is always a requirement for the development and 
progression of glucose assay methods. Hence, cholesterol and glucose were selected 
as the analytes of interest in this work. 
Numerous analytical procedures involving chemical and enzymatic techniques 
have been used within cholesterol and glucose assays, (Brahim et al., 2001; Singh et 
al., 2006; Tsierkezos and Ritter, 2014; Yoo and Lee, 2010). However, enzymatic 
methods have been most popular due to their increased specificity and selectivity. 
Enzymatic methods use cholesterol oxidase (ChOx) or glucose oxidase (GlOx) to oxidize 
cholesterol or glucose respectively to produce hydrogen peroxide (H2O2); the H2O2 is 
then quantified. 
Wong et al. discovered that horseradish peroxidase (HRP) catalyses the oxidative 
coupling of chromotropic acid (CTA) and aminoantipyrine (AAP) with hydrogen 
peroxide to produce a blue quinoneimine dye with high absorbance (A) at 650 nm 
region (Wong et al., 1981). This reaction coincides with the output wavelength of the 
laser diodes used in DVD players (650 nm). The absorbance can then be measured and 
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compared against a calibration curve giving a concentration of cholesterol or glucose in 
blood samples. The method involves a single aqueous reagent, requires no sample pre-
treatment, is reproducible, simple, specific, and uses no corrosive reagents. The 
enzyme catalysis reaction is shown below: 
 
Equation 7: 𝑐ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙 + 𝑂2
𝐶ℎ𝑂𝑥
→   𝑐ℎ𝑜𝑙𝑒𝑠𝑡 − 4 − 𝑒𝑛 − 3 − 𝑜𝑛𝑒 + 𝐻2𝑂2 
(7) 
 
Equation 8: 𝐶𝑇𝐴 + 𝐴𝐴𝑃 +  2𝐻2𝑂2
𝐻𝑅𝑃
→   𝑞𝑢𝑖𝑛𝑜𝑛𝑒𝑖𝑚𝑖𝑛𝑒 𝑑𝑦𝑒 + 4𝐻2𝑂 
(8) 
 
Equation 9: 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 + 𝐻2𝑂 + 𝑂2
𝐺𝑙𝑂𝑥
→   𝑔𝑙𝑢𝑐𝑜𝑛𝑖𝑐 𝑎𝑐𝑖𝑑 + 𝐻2𝑂2 
(9) 
 
It is theoretically possible to quantify any chemical reaction that produces H2O2 
using the enzymatic coupling of CTA and AAP via HRP. While this reaction has been 
used in the past to quantify glucose, it has not been used to quantify cholesterol. The 
quantification of cholesterol using this method will be investigated in this chapter. 
The National Institute for Health and Care Excellence (NICE) recommends 
intervention, either lifestyle or pharmaceutical, by a healthcare professional if a person 
has total cholesterol levels >5.0 mM, (NICE, 2014). Therefore, the cholesterol range of 
the optical assay to be developed in this work needs to cover a cholesterol 
concentration range of 0-10 mM, as this is the region where the majority of patients’ 
levels will lie. The reagents applied in the assay to be developed will be used at a 
concentration suitable for 0-12 mM cholesterol to ensure excess.  
 
The following cholesterol blood levels are generally regarded as desirable (NHS UK, 
2013a): 
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 Total cholesterol (TC):  ≤5.0 mM (2 mg/ml) for health adult.  
 Low-density lipoprotein (LDL) cholesterol after an overnight fast: ≤3.0 mM 
 High-density lipoprotein (HDL) cholesterol: ≥1.2 mM 
 TC/HDL ratio: ≤4.5.  
The following glucose blood levels are generally regarded as desirable for adults with 
type 1 diabetes (Diabetes UK, 2015): 
 On waking: 5-7 mM 
 Before meals: 4-7 mM 
 90 minutes after meals: 5-9 mM 
The clinically relevant quantification range for glucose is generally 2-10 mM. This 
chapter discusses the enzymatic cascade and details the methods and procedures used 
to develop and evaluate the colourimetric reagent and the optical assay used for the 
quantification of cholesterol and glucose in whole blood. 
 
 Materials and Methods 3.2
Phosphate buffered saline (PBS) (10 mM phosphate buffer, 2.7 mM potassium 
chloride and 137 mM sodium chloride, pH 7.4) tablets, chromotropic acid disodium salt 
dihydrate (CTA), 4-aminoantipyrine (AAP), Horseradish peroxidase Type II essentially 
salt-free, lyophilized powder, 150-250 units/mg solid (using pyrogallol) (HRP), glucose, 
cholesterol, Triton X-100, cholesterol oxidase from Streptomyces sp. lyophilized 
powder, ≥20 units/mg protein (ChOx), glucose oxidase from Aspergillus Niger 
lyophilised powder ~200 units/mg protein (GlOx), hydrogen peroxide solution 30 wt. % 
in H2O (H2O2) were all purchased from Sigma-Aldrich (Poole, UK). Defibrinated whole 
horse blood was purchased from TCS Biosciences (Buckingham, UK). Ultrapure water 
(18 MΩcm) was obtained using a Milli-Q water system (Millipore Corp., Tokyo, Japan). 
A Varioskan Flash spectral scanning multimode reader (ThermoScientific Ltd., 
UK) was used in conjunction with the PC software package SkanIt, to determine the 
absorbance values of the well plate assays performed in this project; all readings were 
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carried out at wavelengths of 590 nm or 650 nm, unless otherwise stated. Sample 
readings were carried out in 96-well Nunc-Immuno MaxiSorp flat bottom plates 
(Sigma-Aldrich, UK). Heraeus Fresco 17 Centrifuge (ThermoScientific, UK), Heraeus 
Megafuge 16R Centrifuge (ThermoScientific, UK) and Mini Star silverline 
microcentrifuge (VWR, USA) were used for sample preparation when necessary. 
The concentration of cholesterol in samples was tested and quantified 
independently using an EasyTouch GC Blood Glucose/Cholesterol Dual-Function 
Monitoring System (Bioptik Technology, Taiwan). The concentration of glucose in 
samples was tested and quantified independently using an Optium Exceed Blood 
Glucose Monitoring System (Abbott, UK).  
 
3.2.1 Buffers and Solutions 
All solutions were prepared daily, protected from light, kept at the stated 
temperatures and allowed to return to room temperature until use. 
 CTA stock solution (100 mM) was prepared by dissolving 400.3 mg CTA in 10 ml 
PBS pH 7.4 and kept at 4°C until use. 
 AAP stock solution (100 mM) was prepared by dissolving 203.24 mg AAP in 10 
ml PBS pH 7.4 and kept at 4°C until use.  
 H2O2 solution concentrations 0-12 mM were prepared by diluting H2O2 30%wt 
using PBS pH 7.4 and stored at 4°C until use. 
 ChOx 100 units / ml was prepared by adding 1 ml PBS, pH 7.4 to 4.3 mg ChOx 
solid and stored at -20°C until use.  
 GlOx 1000 units / ml was prepared by adding 1 ml PBS, pH 7.4 to 5.88 mg GlOx 
solid and stored at -20°C until use. 
 HRP 1000 units / ml was prepared by adding 1 ml PBS, pH 7.4 to 6 mg HRP and 
stored at 4°C until use. 
 Cholesterol was used as a substrate for ChOx and prepared according to the 
Sigma-Aldrich protocol (Sigma-Aldrich, 2013). A 100 mg of cholesterol solid was 
58 Chapter 3: Development of a Quantitative Optical Assay for Cholesterol and 
Glucose 
 
Alexander M. Tothill  Cranfield University 
dissolved in 1.0 ml of Triton X-100 by heating to 70-80°C and stirring, until the 
solution was clear. A 9.0 ml aliquot PBS pH 7.4 heated to 70-80 °C was added to 
get a ﬁnal concentration of 100 mg / 10 ml (25.86 mM). Solutions of diﬀerent 
concentration ranging from 1-10 mM were prepared similarly and stored at 
4 °C until use. Cholesterol solution was allowed to return to room temperature 
before use. 
 
3.2.2 Enzyme Specifications 
Horseradish Peroxidase (HRP) 
The properties of the enzyme HRP used in this work as listed (Sigma-Aldrich, 
2014a) were as follows: 
 Optimal pH range: 6.0–6.5 (activity at pH 7.5 is 84% of the maximum).  
 PH stability: most stable in the pH range of 5.0–9.0. 
 Storage/Stability: Store the product at 2–8 °C. The enzyme remains active for at 
least 2 years. Solutions show a loss of <2% of activity per week if stored 
at -20 °C. 
 Specific Activity: 150–250 units mg solid (pyrogallol as substrate) 
 Unit (U) definition (purpurogallin): 1 U will form 1.0 mg of purpurogallin from 
pyrogallol in 20 seconds at pH 6.0 at 20 °C. This unit is equivalent to ~18 mM 
units per minute at 25 °C. 
 Unit definition (ABTS): 1 U corresponds to the amount of enzyme which 
oxidizes 1 μmol ABTS (Fluka No. 11557) per minute at pH 6.0 and 25°C. 
 Molecular weight: ~44 kDa. Consists of at least 5 isoenzymes. 
 Inhibitors: sodium azide, cyanide, L-cystine, dichromate, ethylenethiourea, 
hydroxylamine, sulphide,  vanadate, p-aminobenzoic acid, and Cd2+, Co2+, Cu2+, 
Fe3+, Mn2+, Ni2+, and Pb2+ ions. 
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Cholesterol Oxidase (ChOx) 
The properties of the enzyme ChOx used in this work as listed (Sigma-Aldrich, 
2014b) were as follows: 
 Optimal pH: 6.0 
 pH Range: 6.0-8.0 
 Optimum temperature : 60°C 
 pH Stability : pH 5.0 – 10.0 (25°C, 20 hr)  
 Thermal stability : Below 45°C (pH 7.0, 15 min) 
 Specific activity: 20 units/mg protein 
 Unit Definition: 1U will convert 1.0 μmol of cholesterol to 4-cholesten-3-one 
per min at pH 7.5 at 25 °C.  
 Molecular weight: 50 kDa 
 Inhibitors : Ionic detergents, Hg2+, Ag+ 
 
Glucose Oxidase (GlOx) 
The properties of the enzyme GlOx used in this work as listed (Sigma-Aldrich, 2015) 
were as follows: 
 Optimal pH: 5.5 
 pH Range: 4.0-7.0 
 Optimum temperature : 60°C 
 pH Stability : pH 5.0 – 10.0 (25°C, 20 hr)  
 Thermal stability : Below 45°C (pH 7.0, 15 min) 
 Specific activity: 200 units/mg protein 
 Unit Definition: 1U will convert 1.0 μmol of β-D-glucose to D-gluconolactone 
and H2O2 per min at pH 5.1 at 35 °C.  
 Molecular weight: 186 kDa 
 Inhibitors: Ag+, Hg2+, and Cu2+ ions, phenyl mercuric acetate and 
p-chloromercuribenzoate. 
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3.2.3 Preliminary Investigation into Chromotropic Acid (CTA) and 
4-Aminoantipyrine (AAP) Concentration. 
1 ml samples containing HRP (5 U/ml), CTA (0-10 mM) and AAP (0-10 mM) were 
prepared from stock solutions. The reaction was started by adding H2O2 (12 mM). The 
sample was incubated for 10 minutes then the absorbance at 650 nm was measured in 
100 µl. The sample was allowed to incubate for a further 10 minutes (20 minute total 
incubation time) and the absorbance was measured again.  
A preliminary absorbance spectrum was produced from a 1 ml sample 
containing HRP (5 U/ml), CTA (2 mM), AAP (2 mM) and H2O2 (4 mM). The absorbance 
was measured in 100 µl after 10 minute incubation. 
 
3.2.4 Investigation of CTA:AAP molar ratio. 
Samples containing HRP (6 U/ml), CTA and AAP were prepared in PBS. The 
reaction was started by adding H2O2 (5 mM). Total sample volume was 1 ml. The 
sample was incubated for 2 minutes then the absorbance at 650 nm was measured. 
The sample was allowed to incubate for a further 8 minutes (10 minute total 
incubation time) and the absorbance was measured again. The molar ratios tested 
were 0-80 mM CTA with 10 mM AAP and 10 mM CTA with 0-80 mM AAP. The 
absorbance was measured in 100 μl of each sample. 
An experiment was performed to induce AAP radical dimerization. H2O2 (5mM) 
was added to sample containing AAP (40 mM) and HRP (6 U/ml). Total sample volume 
was 1 ml. 
Experiments were performed to determine which ratio of CTA:AAP should be 
used. Samples containing HRP (6 U/ml), CTA (0-40 mM) and AAP (10 mM) were 
prepared in PBS. The reaction was started by adding H2O2 (0-10 mM). Total sample 
volume was 1 ml. The assay was read after 2 minute incubation at a wavelength of 650 
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nm (n=3). The absorbance was measured in 100 μl of each sample. The absorbance 
was measured in a 1 in 10 dilution.  
 
3.2.5 Optimisation of Horseradish Peroxidase (HRP) Concentration. 
Samples containing HRP (1 U/ml), CTA (6 mM) and AAP (6 mM) were prepared 
in PBS. The reaction was started by adding H2O2 (4 mM). Total sample volume was 1 
ml. The sample was incubated for 5 minutes then the absorbance at 650 nm was 
measured in 100 µl every 5 minutes up to 20 minute total incubation time. This 
process was repeated with HRP concentration 0-6 U/ml and H2O2 concentration 4 mM 
and 8 mM. 
 
3.2.6 Optimisation of Cholesterol Oxidase (ChOx) Concentration. 
Samples containing ChOx (0.25 U/ml), HRP (6 U/ml), CTA (6 mM) and AAP (6 
mM) were prepared in PBS. The reaction was started by adding cholesterol (2.75 mM). 
Total sample volume was 1 ml. The sample was incubated for 5 minutes then the 
absorbance at 650 nm was measured in 100 µl every 5 minutes up to 20 minute total 
incubation time. This process was repeated with ChOx concentration 0-1 U/ml per 
sample and cholesterol concentration 2.75 and 8.9 mM. 
 
3.2.7 Development of the Cholesterol Assay in Buffer. 
Sample solutions containing ChOx (1 U/ml), HRP (6 U/ml), CTA (6 mM) and AAP 
(6 mM) were prepared in PBS. The reaction was started by adding cholesterol (2.75 
mM). Total sample volume was 1 ml. The sample was incubated for 5 minutes and the 
absorbance at 650 nm was measured in 100 µl every 5 minutes up to 20 minute total 
incubation time. This process was repeated with cholesterol concentrations in the 
range 2.75 - 9.3 mM. 
62 Chapter 3: Development of a Quantitative Optical Assay for Cholesterol and 
Glucose 
 
Alexander M. Tothill  Cranfield University 
3.2.8 Development of the Cholesterol Assay in Plasma. 
Defibrinated horse plasma was prepared by centrifuging defibrinated whole 
horse blood at 5000 RPM for 15 minutes and extracting the liquid fraction. Sample 
containing HRP (6 U/ml), CTA (6 mM), AAP (6 mM) and cholesterol (2.6 mM) in 
defibrinated horse plasma were prepared. The reaction was started by adding ChOx (1 
U/ml). Total sample volume was 1 ml. The sample was incubated for 5 minutes.  The 
absorbance at 650 nm was measured in 100 µl every 5 minutes up to 20 minute total 
incubation time. This process was repeated with horse plasma with cholesterol 
concentrations in the range 2.6-9.8 mM. 
 
3.2.9 Development of the Cholesterol Assay in Whole Blood. 
Sample solutions containing HRP (12 U/ml), CTA (12 mM), AAP (12 mM) and 
cholesterol (0-12 mM) in defibrinated whole horse blood were prepared. The reaction 
was started by adding ChOx (2 U/ml). Total sample volume was 1 ml. The samples 
were then mixed thoroughly and left to incubate at room temperature for 5 minutes 
for the enzyme reaction to take place and for the colour to develop. The samples were 
then centrifuged for 5 minutes at 8000 RPM and the liquid fraction extracted. The 
absorbance at 650 nm was measured in 100 µl after a total of 10 and 20 minutes 
incubation. 
 
3.2.10 Optimisation of Glucose Oxidase (GlOx) Concentration. 
Samples containing GlOx (0-50 U/ml), HRP (6 U/ml), CTA (20 mM) and AAP (10 
mM) were prepared in PBS. The reaction was started by adding glucose (10 mM). Total 
sample volume was 1 ml. The sample was incubated for 2 minutes then the 
absorbance at 590 nm was measured in 100 µl. 
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3.2.11 Development of the Glucose Assay in Buffer. 
Sample solutions containing GlOx (20 U/ml), HRP (6 U/ml), CTA (20 mM) and 
AAP (10 mM) in PBS were prepared. The reaction was started by adding glucose (0-10 
mM). Total sample volume was 1 ml. The sample was incubated for 2 minutes and the 
absorbance at 590 nm was measured in 100 µl. 
An experiment was performed to investigate the glucose assay reaction in 
buffer over time. Samples containing GlOx (20 U/ml), HRP (6 U/ml), CTA (20 mM) and 
AAP (10 mM) were prepared in PBS. The reaction was started by adding glucose (0-10 
mM). Total sample volume was 1 ml. The sample was incubated for 5 minutes then the 
absorbance at 590 nm was measured in 100 µl. Absorbance was measured again after 
7, 10 and 30 minutes total incubation time. 
 
 Results and Discussion 3.3
The results from each stage of assay development are presented and discussed 
in detail in this section. Results are not necessarily presented chronologically. All plots 
utilise mean values of at least 3 absorbance readings taken at 590 nm or 650 nm and 
error bars are shown on all graphs representing ± 1 standard deviation. 590 nm is the 
theoretical peak of the absorbance curve produced by the blue quinoneimine dye of 
CTA and AAP (Wong et al., 1981); 650 nm is the wavelength of a DVD optical drive 
laser. HRP concentration can be determined by either a kinetic or a fixed time method. 
As the fixed time method is more applicable in most clinical assays (Wong et al., 1981), 
and this particular assay, it was chosen for this investigation. All absorbance values 
displayed on graphs have been standardised against the blank absorbance of the well 
plate containing samples with CTA, AAP, HRP, ChOx/GlOx and 0 mM substrate; blank 
solutions displayed < 5 % absorbance in all cases. All incubations were performed at 
room temperature. 
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3.3.1 Preliminary Investigation into Chromotropic Acid (CTA) and 
4-Aminoantipyrine (AAP) Concentration. 
The glucose and cholesterol assays involve the use of an enzymatic cascade to 
produce a blue dye with an absorbance correlating to substrate concentration. The 
reagents that combine to produce the dye are CTA and AAP. According to the reaction 
proposed by Wong et al., Figure 3.1, 2M H2O2 reacts with 1M of CTA and 1M AAP in 
the presence of HRP with a molar ratio of CTA:AAP for maximum colour produced 
being 4:1 (Wong et al., 1981).  
1M cholesterol or glucose is oxidized, producing 1M H2O2. Cholesterol has a 
clinically relevant concentration range of 0-5 mM. A broad quantification range of 0-10 
mM is important to provide emergence intervention if cholesterol concentration is 
significantly elevated. A solution consisting of CTA (6 mM) and AAP (6 mM) will give a 
broad cholesterol quantification range of 0-10 mM with a 2 mM excess. Glucose has a 
clinically relevant range of 0-10 mM; concentrations above 7 mM are seen as elevated, 
which is common after eating, and should be reduced (Diabetes UK, 2015). A broad 
quantification range of 0-20 mM is important to provide emergence intervention if 
glucose concentration is significantly elevated. A solution consisting of CTA (10 mM) 
and AAP (10 mM) will give a broad glucose quantification range of 0-20 mM. 
It is necessary that the concentrations of CTA and AAP are sufficient to quantify 
substrate within the required detection range (0-10 mM). Experiments were 
performed to determine what concentration values and ratio of CTA:AAP are 
applicable to practice and produce a blue quinoneimine dye of required concentration. 
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Figure 3.1: Proposed mechanism for peroxidase-catalysed formation of a 
quinoneimine dye (Wong et al., 1981). 
 
H2O2 solution was used as a substitute for the substrate in the optimisation of 
CTA+AAP solution concentration since the cholesterol+ChOx or glucose+GlOx reaction 
are unnecessary for this reaction. Removal of the cholesterol/glucose reaction would 
ensure that the concentration of CTA+AAP reagent solution could be determined 
quickly whilst preserving enzyme quantities. H2O2 is thermodynamically unstable and 
therefore is constantly decomposing over time to water and oxygen. As a result, the 
molar concentration of H2O2 provides an estimate for the concentration rather than 
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accurate concentration, and therefore its use may provide inaccurate recordings. 
However, since the concentration of H2O2 solution being used is across the clinically 
relevant range expected of an assay for cholesterol or glucose (0-10 mM) it will be 
sufficient for initial assay development and optimisation. If the assay reagents at the 
chosen concentrations and ratios give distinct absorbance for the H2O2 solutions then 
it will be suitable for the required quantification range of 0-10 mM. However, further 
testing over the entire substrate concentration range will be performed using 
substrate samples (cholesterol and glucose) to confirm this.  
As these were the first attempts at working with the assay reagents and 
generating quinoneimine dye, assay/incubation times were greater than the objective 
(≤ 2 minutes).  Previous studies conducted by Wong et al., which aspects of this work 
was attempting to recreate, have used 5 - 60 minute incubation intervals (Wong et al., 
1981). Incubation times of 5 or 10 minute intervals were used initially, and then as 
optimisation progressed, incubation times of 2 minutes were used. The absorbance (A) 
of the samples was calculated automatically by the plate reader using the following 
metric: 
Equation 10: 𝐴 = 𝑙𝑜𝑔 
𝐼𝑜
𝐼
 (10) 
Where Io = the intensity of incident light; I = intensity of transmitted light. 
Samples containing HRP (5 U/ml), CTA (1 mM) and AAP (1 mM) were prepared 
in PBS. The reaction was started by adding H2O2 (12 mM). Total sample volume was 1 
ml. The sample was incubated for 10 minutes then the absorbance at 650 nm was 
measured in 100 µl. 100 µl volume was chosen due to the size of the 96 well plates 
that were used to measure absorbance and the need for sufficient sample to fill the 
bottom of the well. The sample was allowed to incubate for a further 10 minutes (20 
minute total incubation time) and the absorbance was measured again. This process 
was repeated with CTA (0-10 mM) + AAP (0-10 mM) solution. The increasing 
concentration of quinoneimine dye can be seen in Figure 3.2.  
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Figure 3.2: The image shows the increasing quinoneimine dye concentration 
observed as CTA+AAP concentration increases. Each well contains 100 μl taken from 
each 1 ml sample. Each sample contains HRP (5 U/ml), H2O2 (12 mM) and varying 
concentrations of CTA and AAP as follows: Line (A) CTA (0 mM), AAP (0 mM); (B) CTA 
(1 mM), AAP (1 mM); (C) CTA (3 mM), AAP (3 mM); (D) CTA (5 mM), AAP (5 mM); (E) 
CTA (6 mM), AAP (6 mM); (F) CTA (8 mM), AAP (8 mM).  
 
The absorbance readings observed in the experiments were high (above 1 AU). 
It is well known in spectrophotometry, due to the Beer-Lambert Law, that when 
absorbance values exceed a value of 1, the accuracy of the results begins to decease, 
and once a value of 2 AU is reached then the results are regarded as inaccurate and 
samples should be diluted or the sample path length reduced before analysis (Higson, 
2004). Due to the potential inaccuracy of the data, one must be cautious when 
drawing conclusions from absorbance data in excess of 2 AU. However, the Varioscan 
plate reader has a linear measurement range of 0-4 AU when using a 96-well plate, as 
stated by the manufacturer, so the absorbance recorded is within the limits of 
accuracy for this specific piece of equipment. 
(E) 
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In the presence of H2O2 and HRP, AAP and CTA combined to form a deep blue 
compound with a broad absorbance band between 550-650 nm with a peak at 590 nm, 
as shown in the preliminary spectrum in Figure 3.3. The broad absorbance peak 
introduces the flexibility for measuring absorbance across a wide range of 
wavelengths, with the absorbance and trend line shifting accordingly; this is 
demonstrated in section 5.3.1. 
 
 
Figure 3.3: Preliminary absorbance spectrum produced from a 1 ml sample 
containing HRP (5 U/ml), CTA (2 mM), AAP (2 mM) and H2O2 (4 mM). The absorbance 
was measured in 100 µl after 10 minute incubation. 
 
In the absence of either H2O2 or HRP, no absorbance within the 550-650 nm 
range was detected. The absorbance detected at 650 nm in 10 control/blank samples 
containing HRP (5 U/ml), CTA (6m M) and AAP (6 mM) can be seen in Figure 3.4. In all 
cases the observed absorbance of the control/blank samples was < 5 % of the 
observed absorbance at the lowest substrate concentration. 
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Figure 3.4: Absorbance detected in 10 control/blank solutions containing HRP (5 
U/ml), CTA (6m M) and AAP (6 mM). 
 
The preliminary results (data not shown) showed that as the CTA+AAP 
concentration increased the absorbance increased. The absorbance readings taken 
after 20 minutes incubation showed no further increase. Therefore, it was concluded 
that the reaction was complete after 10 minutes incubation. It was also seen from the 
data that the dye was stable for up to 20 minutes after the reaction, but the dye does 
appear to be unstable and break down over time. When samples were observed after 
extended periods of time (after an hour or more) the colour seen is more brown/black 
and cloudy. The stability of the dye produced over time needs further investigation. 
However, if absorbance is recorded within 5 minutes this should not be problematic 
for this assay, especially as the dye has been seen to be stable for up to 20 minutes. 
Using the equations (Equation 7-9) originally proposed by Wong et al., and 
subsequent testing based on these formulae, it was seen that a substrate 
concentration range of 0-10 mM can be measured colourimetrically using CTA (6 mM) 
and AAP (6 mM). A benefit of the blue dye absorbing in the 650 nm range is that it is a 
visible colour change with the potential for eye based analysis if there is a clearly 
distinguishable colour difference between substrate concentrations. Although this 
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qualitative approach is not acceptable for the quantification of substrates such as 
glucose or cholesterol, where accurate quantification is required for clinical and 
therapeutic purposes, it is acceptable for tests such as proteinuria which uses a 
‘dip-stick’ colour change to determine the presence of protein in urine (bpac.org, 
2013).  
Preliminary testing of the CTA+AAP solution, using serial dilutions, showed that 
a large excess of AAP compared to CTA caused reduced blue quinoneimine dye 
production and instead resulted in a brown colouration. Having the CTA in excess 
compared to the AAP however, did not decrease the blue quinoneimine dye 
production. The effect of CTA:AAP molar ratio was investigated further in section 3.3.2. 
 
3.3.2 Investigation of CTA:AAP molar ratio. 
It was observed during the preliminary testing performed in section 3.3.1, that 
the molar ratio of CTA:AAP has an effect on the concentration of quinoneimine dye 
produced. Experimentation was performed to investigate this effect.  
The absorbance difference with increasing concentration of CTA (0-80 mM) and 
fixed AAP (10 mM) can be seen in Figure 3.5 and is illustrated by Figure 3.6. A fixed 10 
mM reagent concentration is employed rather than the 6 mM previously used (for a 
broad cholesterol range of 0-10 mM), as 10 mM is necessary for substrate 
quantification required in the broad glucose assay range (0-20 mM).  
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Figure 3.5: Change in absorbance recorded at a range (0-80 mM) of CTA 
concentrations with H2O2 (5 mM), HRP (6 U/ml) and AAP (10 mM) in PBS (n=3). 
 
 
Figure 3.6: The image shows the quinoneimine dye concentration observed as CTA 
concentration increases. Group 1 is undiluted sample; group 2 is a 1 in 10 dilution. 
Each well contains 100 μl taken from each 1 ml sample. Each sample contains HRP (6 
U/ml), H2O2 (5 mM), AAP (10 mM) and varying concentrations of CTA as follows: Line 
(A) 0 mM; (B) 10 mM; (C) 20 mM; (D) 30 mM; (E) 40 mM; (F) 50 mM; (G) 60 mM; (H) 
70 mM; (I) 80 mM. 
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As can be seen in Figure 3.5 and is illustrated by Figure 3.6, as the 
concentration of CTA increased, the absorbance detected increased; there was a 165% 
absorbance increase when the molar ratio of CTA:AAP was increased from 1:1 to 8:1. 
However, the strong absorbance detected (1.4-2 AU) at the lower CTA concentrations 
(10-40 mM) indicated that a low concentration ratio of CTA to AAP should be used to 
maintain accuracy. If the absorbance needed to be increased, then a higher 
concentration of CTA could be used. This demonstrated flexibility in the assay 
absorbance which could be adjusted to user requirements, however, this also 
introduced the potential for inaccuracy in the absorbance data, as imprecise 
quantification of assay reagents between stock solutions would result in different 
absorbance values generated in the assay reaction. The stability of the quinoneimine 
dye was also apparent, with <2% decrease in absorbance after 10 minutes incubation 
(Figure 3.5). The absorbance difference with fixed concentration of CTA (10 mM) and 
increasing AAP (0-80 mM) can be seen in Figure 3.7. 
 
 
Figure 3.7: Change in absorbance recorded at a range (0-80 mM) of AAP 
concentrations with H2O2 (5 mM), HRP (6 U/ml) and CTA (10 mM) in PBS (n=3).  
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Figure 3.7 shows that, as the AAP concentration increased relative to that of 
CTA, absorbance decreased; there was a 65% absorbance decrease when the molar 
ratio of CTA:AAP was increased from 1:1 to 1:8. It could be seen that a high 
concentration of AAP compared to CTA decreased the quinoneimine dye intensity, and 
instead a murky brown colouration was formed, as can be seen in Figure 3.8.    
 
 
Figure 3.8: The image shows the quinoneimine dye concentration observed as AAP 
concentration increases. Group 1 is undiluted sample; group 2 is a 1 in 10 dilution. 
Each well contains 100 μl taken from each 1 ml sample. Each sample contains HRP (6 
U/ml), H2O2 (5 mM), CTA (10 mM) and varying concentrations of AAP as follows: Line 
(A) 0 mM; (B) 10 mM; (C) 20 mM; (D) 30 mM; (E) 40 mM; (F) 50 mM; (G) 60 mM; (H) 
70 mM; (I) 80 mM. 
 
Nicell and Wright explain how increased concentration of AAP with respect to 
phenol in an oxidised HRP colourimetric reaction results in dimerization of AAP radicals 
and decreased dye production  (Nicell and Wright, 1997). An experiment was 
performed to induce AAP radical dimerization to confirm if this is occurring in the 
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CTA+AAP reaction. H2O2 (5mM) was added to sample containing AAP (40 mM) and HRP 
(6 U/ml). Total sample volume was 1 ml. The results can be seen in Figure 3.9.  
 
Figure 3.9: 1 ml samples containing HRP (6 U/ml) and AAP (40 mM) in PBS after 5 
minutes incubation. (A) Contains no H2O2; (B) contains H2O2 (5 mM). 
As can be seen in Figure 3.9, the sample becomes visually much darker when 
H2O2 is added. In the CTA+AAP reaction, CTA is oxidised by HRP producing CTA radicals. 
The CTA radicals then react with AAP to produce AAP radicals and CTA. AAP radicals 
then react with CTA radicals in solution and H2O2 to produce the blue quinoneimine 
dye. Increasing the AAP in the reagent mixture increases the probability of direct 
oxidation of AAP by oxidised HRP, which then increases the concentration of aminyl 
radicals and subsequently the probability of their dimerization (Nicell and Wright, 
1997). The result of this is a decreased concentration of blue quinoneimine dye and an 
increased concentration of AAP dimers, the source of the brown colouration seen. By 
maintaining a high concentration of CTA with respect to AAP, the blue dye reaction 
pathway should be enhanced. 
From these experiments assay optimisation has progressed and it is important 
that CTA is always in excess to AAP to prevent the direct competition between CTA and 
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AAP for oxidised HRP and increase the blue quinoneimine dye production reactional 
pathway. 
As it was observed that increasing molar ratio of CTA:AAP increases 
absorbance, it was concluded that a low (1:1-4:1) concentration ratio of CTA:AAP 
would be appropriate. Experiments were performed to determine which ratio of 
CTA:AAP should be used, ensuring that the chosen CTA and AAP concentrations are 
capable of quantifying a 0-10 mM substrate range. The results are shown in Figure 
3.10. 
 
Figure 3.10: Change in absorbance recorded at a range (0-40 mM) of CTA 
concentrations with H2O2 (0-10 mM), HRP (6 U/ml) and AAP (10 mM) in PBS (n=3). 
As can be seen in Figure 3.10, there is a (<10%) observable difference between 
the investigated concentrations of CTA at 10 mM H2O2 and all are capable of producing 
an absorbance curve for H2O2 (0-10 mM). The absorbance detected for 30 mM CTA 
shows a slightly greater absorbance (5%) than the other concentrations. However, the 
error observed puts the absorbance within range of the other data. The results show 
that a 1:1 ratio of CTA:AAP could be used to measure a substrate range of 0-10 mM, 
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but, due to the reduction in absorbance observed when AAP is greater, it was 
determined that a ratio of 2:1 CTA:AAP would be used in the assay to ensure that the 
concentration of CTA is always greater than that of AAP and that the quinoneimine dye 
remains stable. In addition, a concentration of CTA (20 mM) and AAP (10 mM) should 
be capable of quantifying broad ranges of both cholesterol (0-10 mM) and glucose (0-
20 mM), therefore, a concentration of CTA (20 mM) and AAP (10 mM) will be used in 
the assay in subsequent testing. 
It should be noted that the work performed in this section occurred after the 
HRP (section 3.3.3), ChOx (section 3.3.4) and cholesterol assay optimisation (section 
3.3.5-3.3.7) which is why a higher concentration of HRP is utilised (6 U/ml) and neither 
the CTA (20 mM) and AAP (10 mM) concentrations or molar ratio of CTA:AAP of 2:1 
were applied to those stages of assay development. 
 
3.3.3 Optimisation of Horseradish Peroxidase (HRP) Concentration 
Experiments were performed to determine the necessary concentration of HRP 
for an acceptable (<5 minutes) reaction rate. PBS pH 7.4 is used as the solution 
medium in order to mimic physiological conditions. Its use would also provide easy 
identification of lower reaction rate at specific enzyme concentrations, allowing 
increased enzyme concentration to be used to compensate without needing sample 
pre-treatment, which is undesirable for a POC assay. While the optimum pH for HRP 
activity is 6-6.5, at pH 7.5 the activity is 84% (section 3.2.2), which is an acceptable 
activity without needing increases in enzyme concentration to compensate.  
4 mM and 8 mM H2O2 concentrations were used as 4 mM substrate lies within 
the clinically relevant range for cholesterol (0-5 mM) and 8 mM lies above this range. 
H2O2 was used as a substitute for cholesterol/ChOx in this reaction to reduce the 
potential for interference and to conserve ChOx.  In all cases, blue quinoneimine dye in 
the 650 nm region was produced, with the colour intensity increasing as the sample 
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H2O2 concentration increased. In the absence of either H2O2 or HRP no blue dye was 
produced and no absorbance at 650 nm was detected. 
At 4 mM substrate there was no observable absorbance difference between 
the different HRP concentrations across all incubation periods ranging from 5-20 
minutes with the reaction reaching completion within 5 minutes. This suggested that a 
HRP concentration of 0.5 U/ml would be sufficient for this assay. However, Figure 3.11 
showed that as the substrate concentration is increased to 8 mM (above the clinically 
relevant cholesterol and glucose detection range of 0-5 mM and 4-7 mM respectively 
but within the broad detection ranges of cholesterol 0-10 mM and glucose 0-20 mM), 
the difference in reaction rate becomes apparent. It can be seen in Figure 3.11 that 
after 20 minutes incubation all HRP concentrations had reached reaction completion. 
HRP concentrations less than 2 U/ml were insufficient to ensure completion of the 
reaction within 5 minutes and a HRP concentration of 1 U/ml displayed incomplete 
reaction after 15 minutes incubation.  
 
Figure 3.11: Change in absorbance recorded at a range (0-6 U/ml) of HRP 
concentrations with H2O2 (8 mM), CTA (6 mM) and APP (6 mM) in PBS (n=3). 
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The data shows that an enzyme concentration of 3 U/ml was sufficient to 
complete the reaction containing 8 mM substrate within 5 minutes. However, due to 
the increased clinically relevant quantification range of glucose (0-20 mM) and the 
additional enzyme reaction step yet to be implemented (ChOx/GlOx) it was decided 
that a HRP concentration of 6 U/ml would be used to maintain a reaction time ≤5 
minutes. In addition, a concentration of 6 U/ml would reduce any impact that resulting 
from decreased HRP enzyme activity (84% at pH 7.5) due to the assays’ environmental 
conditions (blood has approx. pH 7.4). It should also be noted that the results display 
no absorbance interference due to the HRP concentration. High absorbance was 
detected (above 2 AU) therefore samples may need to be diluted as the assay 
optimisation continues, to increase accuracy of readings. 
 
3.3.4 Optimisation of Cholesterol Oxidase (ChOx) Concentration 
Investigations were performed to try to determine the necessary concentration 
of ChOx for a reaction rate <5 minutes. PBS pH 7.4 is used as the solution medium in 
order to mimic blood conditions; it would also provide easy identification of lower 
reaction rates at specific enzyme concentrations allowing increased enzyme 
concentration to be used to compensate, without a requirement for sample pre-
treatment. It should be noted that at this stage in the project quantities of ChOx 
available for assay optimisation was severely limited. As a result, the use of ChOx was 
restricted in an attempt to conserve enzyme. 
The primary issue encountered with the ChOx assay, and subsequent testing 
involving cholesterol, was concerned with preparing the cholesterol solution. Due to its 
strongly hydrophobic properties, a high concentration of surfactant and high 
temperatures are needed to encourage cholesterol solids to dissolve in the water 
based solution. When preparing the cholesterol solution, the cholesterol would 
dissolve in Triton X-100 when heated to 70-80°C. Upon addition of PBS pH 7.4 and 
when heated to 70-80°C, the solution becomes cloudy due to the cholesterol forming 
an emulsion. When cooled the solution clarifies again and forms 2 distinct phases. 
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When the phases are mixed thoroughly, a precipitation of cholesterol can be seen in 
the form of white crystals. Despite numerous efforts these crystals could not be 
dissolved. In addition, the high concentration of surfactant would cause bubbles to 
form in the sample that could not be removed and that interfered with the absorbance 
detected. As a result, testing was difficult whenever cholesterol solution was used and 
the tests had to be repeated many times. 
Independent quantification of cholesterol concentration was sought to 
establish the concentrations in solution. It would have been preferential to use a 
commercial cholesterol quantification assay kit for use with the plate reader, such as 
those offered by Sigma-Aldrich (Poole, UK) (Sigma-Aldrich, 2014c), for greater 
accuracy, however, due to cost this was not possible. Therefore, an Easy Touch GC 
monitor (Bioptik Technology, Taiwan), was used to determine the cholesterol 
concentrations of the samples; this is a low-cost (£30) POC electrochemical sensor. As 
discussed in section 2.2.2, POC tests are inherently inaccurate and this particular 
device and associated company websites are currently unavailable at the time of 
writing. As a consequence the displayed cholesterol concentration values varied 
significantly from the prepared concentration by up to ± 1.8 mM as seen in Table 3.1. 
Despite the lack of accuracy in independently quantifying the cholesterol 
concentration, a trend line was still investigated, however, a quantification method 
with greater accuracy will be utilised for any future cholesterol assay optimisation that 
takes place after this project.  
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Table 3.1: Cholesterol solution concentration as prepared and the concentration 
stated using an Easy Touch GC monitor (Bioptik Technology, Taiwan) approx. 10 
minutes after preparation (n=6). 
Prepared 
Concentration 
Tested 
Concentration 
3 mM 2.75 mM ± 1.3 
5 mM 5.5 mM ± 1.6 
7 mM 7.6 mM ± 1.5 
8 mM 8.9 mM ± 1.8 
10 mM 9.3 mM ± 1.4 
 
 
After 30 minutes from preparation, further cholesterol precipitation was 
observed and the solution became cloudy and heterogeneous. This solution gave 
varying concentrations, rendering it unusable. While it is possible to purchase 
cholesterol solution, the cholesterol is dissolved in chloroform. Chloroform causes 
denaturation and precipitation of proteins in solution and does not mix with water. 
Thus it was decided that it would not be used, to prevent enzymatic damage in the 
assay.  
ChOx has been used in cholesterol assays for many years, however, there are 
several different sources of ChOx isolated from Nocardia, Streptomyces, Mycobacteria, 
Brevibacterium, Schizophyllum, Pseudomonas, fluorescens, Cellulomonas, and 
Brevibacterium. ChOx from Streptomyces was chosen for use, as Lolekha et al. 
suggested it is superior in terms of increased stability and lower cost compared with 
ChOx from other sources (Lolekha and Jantaveesirirat, 1992). The Clinical Chemistry 
Standardization Section of Centers for Disease Control uses the Streptomyces enzyme 
for cholesterol determination (Warnick, 1986). Experiments performed by Lolekha et 
al. also came to the conclusion that ChOx from Streptomyces is recommended for the 
determination of serum cholesterol by enzymatic methods (Lolekha et al., 2004). 
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In all cases, blue quinoneimine dye with an absorbance peak in the 650 nm 
region was produced, with the colour intensity increasing as the cholesterol 
concentration increased and over time as the reaction continued. In the absence of 
either cholesterol or ChOx, no blue dye was produced and no absorbance in the 650 
nm wavelength range was detected. Figure 3.12 shows that, at 2.75 mM of cholesterol, 
0.5 U/ml ChOx is sufficient to complete the reaction within 5 minutes. This, however, is 
towards the lower end of the detection range.  
 
 
Figure 3.12: Change in absorbance recorded at a range (0-1 U/ml) of ChOx 
concentrations with cholesterol (2.75 mM), HRP (6 U/ml), CTA (6 mM) and AAP (6 
mM) in PBS (n=3). 
 
Figure 3.13 shows that as cholesterol concentration increased to 5.5 mM, 1 
U/ml ChOx required over 10 minutes to complete the reaction and 0.5 U/ml required 
up to 20 minutes. 
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Figure 3.13: Change in absorbance recorded at a range (0-1 U/ml) of ChOx 
concentrations with cholesterol (5.5 mM), HRP (6 U/ml), CTA (6 mM) and AAP (6 
mM) in PBS (n=3). 
 
Figure 3.14, shows that at a cholesterol concentration of 7.6 mM, a ChOx 
concentration of <1 U/ml was unable to complete the reaction within 20 minutes.  
 
Figure 3.14: Change in absorbance recorded at a range (0-1 U/ml) of ChOx 
concentrations with cholesterol (7.6 mM), HRP (6 U/ml), CTA (6 mM) and AAP (6 
mM) in PBS (n=3).  
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The slow reaction rate at high cholesterol concentrations is confirmed by Figure 
3.15 for 8.9 mM cholesterol. The reaction was incomplete within 20 minutes at ChOx 
concentrations <1 U/ml. 
 
 
Figure 3.15: Change in absorbance recorded at a range (0-1 U/ml) of ChOx 
concentrations with cholesterol (8.9 mM), HRP (6 U/ml), CTA (6 mM) and AAP (6 
mM) in PBS (n=3).  
 
As the HRP concentration is capable of completing a reaction of 8 mM H2O2 
within 5 minutes, it can be assumed that the rate limiting factor is the ChOx 
concentration. The enzyme concentrations employed in these reactions are lower than 
ideal, resulting in slower reaction rates; it would be preferential to investigate a ChOx 
concentration range of 0-10 U/ml and observe the reactions. However, if incubation 
time and temperature is controlled, it is still possible to take a measurement of 
cholesterol concentration without requiring reaction completion. For example, when 
the 1 U/ml ChOx absorbances are plotted after 5 minutes incubation, Figure 3.16, the 
general trend in increasing absorbance can be seen.  
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Figure 3.16: Change in absorbance recorded at a range (0-8.9 mM) of cholesterol 
concentrations with ChOx (1 U/ml), HRP (6 U/ml), CTA (6 mM) and AAP (6 mM) in 
PBS (n=3). 
 
A ChOx concentration of 1 U/ml will be used for future work. It should also be 
noted that the results displayed no absorbance interference due to the ChOx 
concentration. 
 
3.3.5 Development of the Cholesterol Assay in Buffer 
The first stage of the combined assay testing involved the use of buffer solution 
spiked with cholesterol solution, as shown in Figure 3.17.  
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Figure 3.17: The image shows the quinoneimine dye concentration observed as 
cholesterol concentration increases after 5 minutes incubation. The assay contains 
cholesterol (0-9.3 mM), ChOx (1 U/ml), HRP (6 U/ml), CTA (6 mM) and AAP (6 mM). 
 
In all cases, blue quinoneimine dye in the 650 nm region was produced, as can 
be seen in Figure 3.17, with the colour intensity increasing as the cholesterol 
concentration increased and over time as the reaction continued. In the absence of 
cholesterol no blue dye was produced and no absorbance at 650 nm was detected. 
After 5 minutes of incubation, a clear correlation between concentration and 
absorbance can be seen, as shown in Figure 3.18. The absorbance increases as the 
incubation time increases and the reaction continues. The long reaction time observed 
highlights the low ChOx concentration of 1 U/ml and reiterates the need for increased 
ChOx enzyme in the final assay. The distinct absorbance produced at each cholesterol 
concentration shows that the combined assay can quantify cholesterol in solution.  
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Figure 3.18: Change in absorbance recorded at a range (0-9.3 mM) of cholesterol 
concentrations with ChOx (1 U/ml), HRP (6 U/ml), CTA (6 mM) and AAP (6 mM) in 
PBS (n=7).  
 
3.3.6 Development of the Cholesterol Assay in Plasma 
The second stage of the combined assay testing used horse plasma spiked with 
cholesterol solution as the sample. The unspiked horse plasma was tested for the 
baseline cholesterol already present in the sample; it was then spiked with cholesterol 
solutions to produce the necessary sample concentrations. The concentration of the 
cholesterol solution used to spike the plasma was increased so that the sample would 
be diluted as little as possible.  
Defibrinated horse blood was used as it contains no anticoagulant, reducing the 
risk of interference with assay reagents. Risk of infection by blood samples is null, so 
vaccinations are not required, but safe handling must be adhered to, as with any 
laboratory based reagents. It is also low-cost (approximately £10 per 100 ml) and 
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readily available. For this project, the blood samples are used to demonstrate the 
assay functionality, specifically colour generation, in whole blood and, as the project 
progresses, blood separation within 3D-printed devices. Thus horse blood samples 
fulfil this role adequately. 
 The horse plasma was prepared by centrifuging defibrinated whole horse 
blood at 5000 RPM for 15 minutes and extracting the liquid fraction. Ideally, 
transparent, pale yellow plasma would be extracted after centrifugation. However this 
was not possible, regardless of centrifugation time and speed. Several different 
preparations of horse blood were tested for their plasma properties, including 
defibrinated horse blood and oxalated horse blood. Cell solids would separate in 
defibrinated horse blood and horse blood in oxalate, but the resulting liquid fraction 
was still red, rather than the pale yellow colour that is expected when human blood is 
separated. It was suspected that the red colouration present in the plasma was due to 
cell lysis releasing cell protein, which became dissolved in the plasma. The reason for 
the cell lysis is suspected to be due to the blood not being freshly harvested before 
each use; there was always a minimum of 24 hours between the blood being 
harvested and the earliest possible testing. 
As the absorbance of the blue quinoneimine dye is in the 550-650 nm 
wavelength range, the impact on absorbance measurements of the red plasma should 
be minimal. However, it would complicate readings being performed by eye without a 
spectrophotometer.  As can be seen in Figure 3.19, the plasma obtained had a strong 
red colour. Defibrinated whole horse blood was used in all assay testing due to the lack 
of anticoagulant (such as oxalic acid in oxalated blood) which may introduce 
cross-reactivity in the assay. 
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Figure 3.19: Transparent red plasma after defibrinated whole horse blood was 
centrifuged at 5,000 RPM for 15 minutes. 
 
The solution to this was to ‘wash’ the blood. 1 ml of defibrinated whole horse 
blood was centrifuged for 2 minutes in 1.5 ml Eppendorf tubes using a benchtop 
microcentrifuge at 6000 RPM to separate the solid blood cells from the liquid plasma. 
The 500 µl of liquid component was then extracted, ensuring no solid was removed, 
and replaced with the same volume of PBS pH 7.4 solution. The blood solution was 
then mixed thoroughly and the red blood cells resuspended. This process was 
repeated once more until the red colouration was not visible in the liquid component 
produced after centrifugation. There is a slight colour difference observed between 
the raw blood and the ‘washed’ blood, however, this should not influence blood 
separation results. Images can be seen in Figure 3.20. In addition, there would likely be 
a change in viscosity between the raw and ‘washed’ blood, with the raw blood being 
more viscous and therefore requiring more force to separate the blood cells. However, 
this should not significantly impact experimentation at this stage of preliminary 
development. 
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Figure 3.20: Defibrinated whole horse blood after centrifugation, (A) wash 0; (B) 
wash 1; (C) wash 2; (D) suspended whole horse blood before (left) and after (right) 
washing. 
As the experimentation using whole blood in this project was to demonstrate 
that blood cells can be separated within a 3D-printed device using a standard DVD 
optical drive and that a DVD optical drive is capable of applying sufficient centrifugal 
force necessary to separate blood cells within the desired time period (≤ 2 minutes), it 
was concluded that this protocol of ‘washing’ the blood to produce a colourless/pale 
yellow liquid component from whole blood was sufficient for this project, and this 
stage of assay/device development, to demonstrate the blood separation capabilities 
of the platform/device. It should be noted that the blood washing protocol was not 
investigated before the cholesterol assay development and only implemented when 
assay development progressed to the stage of whole blood separation and glucose 
assay performance in 3D-printed devices (section 5.3.1).  
Experimentation of the cholesterol assay in horse plasma was performed. Two control 
sample tests were performed. The first contained horse plasma with no assay reagents 
added, with the aim of testing for interference introduced by the red plasma. The 
second control contained HRP (6 U/ml), CTA (6 mM) and AAP (6 mM) in horse plasma 
with no ChOx, in order to test for possible interactions between the plasma and the 
reagents, which may introduce interference. In all cases, blue quinoneimine dye in the 
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650 nm region was produced with the colour intensity increasing as the cholesterol 
concentration increased and over time as the reaction continued, as seen in Figure 
3.21. 
 
Figure 3.21: The image shows the quinoneimine dye concentration observed as 
cholesterol concentration increases. (A) Colour immediately after sample application 
(0 minutes incubation); (B) colour after 5 minutes incubation.  
Figure 3.22 shows that the combined assay produces clearly distinguished 
absorbance values quantifying cholesterol in plasma. As the cholesterol concentration 
increased so did the absorbance. No absorbance was detected in control 1, so it can be 
concluded there was no interference introduced through the use of red plasma. In the 
absence of ChOx in control 2, no blue dye was produced and no absorbance at 650 nm 
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was detected and so it is concluded that there were no observable reactions/matrix 
effects between the plasma and reagents. 
 
Figure 3.22: Change in absorbance recorded at a range (0-9.3 mM) of cholesterol 
concentrations with ChOx (1 U/ml), HRP (6 U/ml), CTA (6 mM) and AAP (6 mM) in 
horse plasma (n=9).  
 
3.3.7 Development of the Cholesterol Assay in Whole Blood 
The final stage of the combined assay testing was undertaken using whole 
horse blood spiked with cholesterol solution as the sample. The untreated whole horse 
blood was tested for the cholesterol already present in the sample. It was then spiked 
with cholesterol solution to produce the necessary sample concentrations. The 
concentration of the cholesterol solution used to spike the plasma was increased so 
the sample would be diluted as little as possible. According to the supplier, 
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approximately 50 μl plasma is obtained from 100 μl whole blood. This results in an 
increased reagent concentration of approximately 100% when whole blood is used 
rather than PBS/plasma. It was decided that reagent quantities (ChOx, HRP, CTA, and 
AAP) would not be adjusted accordingly so the established quantities would remain 
acceptable in both plasma and whole blood samples of the same volume. However, it 
is expected that the reaction rate in whole blood will increase due to the increased 
concentration of reagents relative to PBS/plasma. 
Sample solutions containing HRP (12 U/ml), CTA (12 mM), AAP (12 mM) and 
cholesterol (0-12 mM) in defibrinated whole horse blood were prepared. The reaction 
was started by adding ChOx (2 U/ml). Total sample volume was 1 ml. The samples 
were then mixed thoroughly and left to incubate at room temperature for 5 minutes 
for the enzyme reaction to take place and for the colour to develop. The results are 
shown in Figure 3.23. 
 
Figure 3.23: The image shows the quinoneimine dye concentration observed in 
whole horse blood as cholesterol concentration increases. (A) Before addition of 
ChOx; (B) after addition of ChOx (2 U/ml) and 5 minutes incubation. 
The samples were then centrifuged for 5 minutes at 8000 RPM and the liquid fraction 
extracted, as shown in Figure 3.24.   
Increasing cholesterol concentration. 
(A) 
(B) 
0 mM 12 mM 
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Figure 3.24: The image shows the quinoneimine dye concentration observed as 
cholesterol concentration increases in plasma extracted from whole horse blood.  
The absorbance at 650 nm was measured in 100 µl after a total of 10 minutes, 
after the initiation of the reaction (5 minutes incubation and 5 minutes centrifugation) 
and then again after a further 10 minutes (20 minutes total), to monitor any 
absorbance changes. A control was run containing HRP (12 U/ml), CTA (12 mM) and 
AAP (12 mM) in whole horse blood but no ChOx enzyme. Figure 3.25 shows that the 
combined assay can be used to quantify cholesterol in whole blood with absorbance 
increasing as cholesterol concentration increases.  
 
Figure 3.25: Change in absorbance recorded at a range (0-12 mM) of cholesterol 
concentrations with ChOx (2 U/ml), HRP (12 U/ml), CTA (12 mM) and AAP (12 mM) in 
whole horse blood (n=6).  
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There was a minor increase in absorbance (<2%) across all concentrations after 20 
minutes total incubation time indicating that the reaction was largely complete after 
10 minutes; this is due to the 100% increased enzyme concentration in whole blood 
relative to plasma. The experiments performed showed that ChOx, HRP, CTA and AAP 
when mixed together produce an enzymatic cascade and optical reaction that can 
distinguish between a range of cholesterol concentrations in various solution mediums 
including whole blood. There was clear correlation between the different cholesterol 
concentrations and absorbance produced; as cholesterol concentration increases, 
absorbance increases. The current study was quantifying free cholesterol in whole 
blood. The reaction could be expanded to quantify total cholesterol in blood through 
the addition of cholesterol esterase into the enzyme mixture. However this has yet to 
be implemented at this stage. The application of this assay for the detection of 
cholesterol in whole blood has previously not been published. 
The work presented so far has demonstrated the capability of the assay for the 
quantification of cholesterol in plasma and whole blood samples. The assay can be 
altered for the detection and quantification of other compounds that can be reacted to 
produce H2O2. Compounds such as lactate and glucose could be assayed by simply 
replacing ChOx with lactate oxidase or GlOx respectively. Assay development for the 
quantification of glucose is now detailed. 
 
3.3.8 Optimisation of Glucose Oxidase (GlOx) Concentration 
GlOx from Aspergillus Niger was used in this assay as it is the most commonly 
used source of GlOx in glucose assays and is widely available (Bankar et al., 2009). 
Experiments were performed to try to determine the necessary concentration of GlOx 
for an acceptable reaction time (≤2 minutes). PBS pH 7.4 is used as the solution 
medium in order to mimic blood conditions, and to provide easy identification of 
reaction rates at specific enzyme concentrations, allowing increased or decreased 
enzyme concentration to be used where required compensating for device limitations 
without needing sample pre-treatment, which is undesirable for this assay. The 
95 Chapter 3: Development of a Quantitative Optical Assay for Cholesterol and 
Glucose 
 
Alexander M. Tothill  Cranfield University 
optimum pH range for GlOx is 4-7, so at pH 7.4 the reaction rate should not be 
impacted. However, should the reaction rate be too slow, a higher quantity of enzyme 
can be used to help negate this. It was decided to observe the reaction rate at a single 
substrate concentration at the high end of the clinically relevant glucose range of the 
substrate detection scale (10 mM) and at a single incubation time reasonable for a 
point-of-care device (POC) (2 minutes). This would be sufficient to determine what 
concentration of GlOx would be necessary for an acceptable assay rate without 
requiring excessive consumption of enzyme and reagents.  
In all cases, blue quinoneimine dye was produced and visible with the colour 
intensity increasing as GlOx concentration increased. In the absence of GlOx no blue 
dye was produced. Figure 3.26 shows the absorbance produced using 10 mM glucose 
solution with varying GlOx concentration after 2 minutes incubation. There was an 
approximate 34% increase in absorbance between 5 U/ml and 50 U/ml; the greater the 
GlOx concentration the greater the absorbance detected due to the greater reaction 
rate. The data showed that the reaction time can be controlled by adjusting enzyme 
concentrations. 
 
Figure 3.26: Change in absorbance recorded at a range (0-50 U/ml) of GlOx 
concentrations with glucose (10 mM), HRP (6 U/ml), CTA (20 mM) and AAP (10 mM) 
in PBS (n=3). 
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A GlOx concentration of 20 U/ml of sample will be used for future work as this 
will provide an acceptable reaction time (≤2 minutes). By increasing or decreasing GlOx 
concentration, the reaction rate can be changed and therefore shift the absorbance 
curve up or down according to requirements. While higher concentrations would 
decrease the reaction time, this would put more emphasis on precise incubation time 
and potentially introduce discrepancies/errors should absorbance readings be taken 
too early or late. When moving towards on-device testing, smaller enzyme quantities 
could be used whilst maintaining the relative concentration and reaction rates due to 
smaller sample volumes and therefore, smaller glucose quantities being used. It should 
also be noted that the results display no absorption interference due to the GlOx 
concentration. 
 
3.3.9 Development of the Glucose Assay in Buffer 
The first stage of glucose assay testing uses PBS buffer pH 7.4 spiked with 
glucose solution as the sample, as shown in Figure 3.27. The assay combines 
concentration data obtained from the previous experiments on CTA and AAP (section 
3.3.2), HRP (section 3.3.3) and GlOx (section 3.3.8).  In all cases blue quinoneimine dye 
in the 590 nm region was produced, as can be seen in Figure 3.27, with the colour 
intensity increasing as glucose concentration increased as can be seen in Figure 3.28. 
In the absence of glucose, no blue dye was produced and no absorbance at a 
wavelength of 590 nm was detected. 
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Figure 3.27: Glucose assay in buffer. The image shows the quinoneimine dye 
concentration observed as glucose concentration increases. Group 1 is undiluted 
sample; group 2 is a 1 in 10 dilution. Each well contains 100 μl taken from each 1 ml 
sample. Each sample contains GlOx (20 U/ml), HRP (6 U/ml), CTA (20 mM), AAP (10 
mM) and varying concentrations of glucose as follows: Line (A) 0 mM; (B) 1 mM; (C) 2 
mM; (D) 3 mM; (E) 4 mM; (F) 5 mM; (G) 6 mM; (H) 7 mM; (I) 8 mM; (J) 9 mM; (K) 10 
mM. 
 
 
Figure 3.28: Change in absorbance recorded at a range (0-10 mM) of glucose 
concentrations with GlOx (20 U/ml), HRP (6 U/ml), CTA (20 mM) and AAP (10 mM) in 
PBS (n=3). 
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An experiment was performed to investigate the glucose assay reaction in 
buffer over time. The intention was to monitor reaction progression with longer 
incubation periods and to identify a time range in which the quinoneimine dye remains 
stable and can be used to quantify glucose concentration. The sample was incubated 
for 5 minutes then the absorbance at 590 nm was measured in 100 µl. Absorbance was 
measured again after 7, 10 and 30 minutes total incubation time. In all cases blue 
quinoneimine dye in the 590 nm region was produced with the colour intensity 
increasing as glucose concentration increased and over time up to 10 minutes as the 
reaction continued, as seen in Figure 3.29. 
 
 
Figure 3.29: Change in absorbance recorded at a range (0-10 mM) of glucose 
concentrations with GlOx (20 U/ml), HRP (6 U/ml), CTA (20 mM) and AAP (10 mM) in 
PBS (n=3). 
 
As can be seen in Figure 3.29, the absorbance measured after each period of 
incubation increases as the glucose concentration increases. The absorbance curve 
0
0.5
1
1.5
2
2.5
0 2 4 6 8 10
A
b
so
rb
an
ce
 (
5
9
0
 n
m
) 
Glucose (mM) 
5 Minutes
7 Minutes
10 Minutes
30 Minutes
99 Chapter 3: Development of a Quantitative Optical Assay for Cholesterol and 
Glucose 
 
Alexander M. Tothill  Cranfield University 
shifts up as the incubation time increases and as the reaction continues. Between 
10-30 minutes incubation the absorbance begins to decrease. This illustrates the 
stability of quinoneimine dye over 10 minutes, after which decomposition begins and 
absorbance drops. However, as the assay is intended to generate results within 2 
minutes in a POC setting, this is not problematic. The reaction can be completed within 
this time period simply by increasing enzyme concentration if necessary. The distinct 
absorbance produced at each glucose concentration shows that the assay can quantify 
glucose in solution and the absorbance curve can be shifted by changing incubation 
time: shorter incubation time results in lower absorbance, longer incubation results in 
higher absorbance up to 10 minutes. Assay optimisation will continue, however, this 
shows that it is possible to quantify glucose concentration in buffer with a range of 
0-10 mM as required for the project aims and objectives. 
 
 Conclusions 3.4
It was shown that HRP, CTA and AAP when mixed together with either ChOx or 
GlOx, produce an enzymatic cascade and blue quinoneimine dye with a correlation 
between absorbance and substrate (cholesterol/glucose) concentration. A substrate 
range of 0-10 mM was quantified in various solution mediums including whole blood. 
The experiments presented demonstrate a quantification method for cholesterol in 
whole blood that has not been published previously. The final assay reagent 
concentrations were CTA (20 mM), AAP (10 mM), HRP (6 U/ml), ChOx (1 U/ml) and 
GlOx (20 U/ml).  
The ChOx concentration was found to be the primary rate limiting factor 
encountered in the cholesterol assay, however, as demonstrated in section 3.3.7, this 
did not prevent the quantification of cholesterol in whole blood or the generation of a 
trend line within a 5 minute incubation period; as cholesterol concentration increased 
the absorbance increased. The low reaction rate seen could be corrected through the 
use of an increased concentration of ChOx in the assay. However, in an attempt to 
conserve ChOx quantities, the increased concentration was not implemented. Despite 
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long/incomplete reaction times seen in the combined assay, with optimisation and a 
fixed time assay, cholesterol quantification could still be performed by generating a 
calibration curve using lower absorbance values. 
Difficulties were encountered during testing regarding the making of 
cholesterol solution, the independent quantification of cholesterol and the red 
coloured plasma obtained from the whole horse blood. The results showed that the 
red plasma had a minimal effect on absorbance and the ‘blood washing’ protocol that 
was developed would aid in observing blood cell separation performed in a LOAD 
device. The use of a low cost POC electrochemical assay for the independent 
quantification of cholesterol in solution was not ideal due to the inaccuracy displayed, 
however, absorbance trend lines were obtained regardless; a cholesterol 
quantification method with improved accuracy will be used in future work.  
An enzymatic assay capable of quantifying 0-10 mM glucose concentration in 
buffer has been developed and optimisation has progressed. The experiments 
performed showed that GlOx, HRP, CTA and AAP, when mixed together, produce an 
enzymatic cascade and optical reaction that can distinguish between a range of 
glucose concentrations in PBS pH 7.4 solution.  
There was clear distinction between the different glucose concentrations and 
absorbance produced; as the glucose concentration increased, the absorbance 
increased, but the protocol needs optimisation for use in the intended assay platform 
to standardise the absorbance values and to generate a calibration curve for on-device 
testing. When using H2O2 in lieu of glucose and GlOx, the reactions were complete 
within 5 minutes of incubation. However, when glucose and GlOx were used the 
reaction rate dropped, although not significantly, this being due to the incorporation of 
an additional reaction step. As discussed in section 3.3.8, the reaction rate can be 
increased or decreased by increasing or decreasing the GlOx concentration 
respectively, however, a GlOx concentration of 20 U/ml was sufficient at generating an 
absorbance trend line within 5 minutes incubation.  
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The testing showed that the absorbance curves can be shifted up or down 
according to incubation time, enzyme concentration and, to a lesser extent, CTA 
concentration. This allows the assay to be adjusted by increasing or decreasing the 
colour intensity.  
Due to the dimerization of AAP it was decided that a molar ratio of 2:1 CTA:AAP 
must be maintained, therefore a concentration of CTA (20 mM) and AAP (10 mM) was 
used. This concentration will be used for both cholesterol and glucose testing that 
takes place in future work so the assay solutions can be used to quantify both 
substrates without requiring a change in concentration; glucose has a higher clinically 
relevant quantification range and therefore requires a higher concentration of 
reagents relative to cholesterol. In addition, CTA, AAP and enzyme quantities in 
solution were not adjusted for whole blood relative to plasma as this provides 
flexibility in what samples can be tested without requiring a change in reagent 
quantities. 
Cholesterol and glucose colourimetric assays have been developed that 
produce distinct absorbance curves in the 650 nm region, the wavelength of the laser 
used in a DVD optical drive. Therefore, a standard unmodified DVD optical disc drive 
(ODD) could be used to quantify absorbance changes in these assays. The next stage of 
assay testing will involve the use of whole blood spiked with glucose solution, moving 
towards using 3D-printed devices, such as cuvettes and microfluidic channels, in which 
to quantify substrate. The testing will explore the problems and limitations of 
3D-printed objects for assay device development and how to minimise them.  
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 Introduction  4.1
The ability to manufacture detailed and complex prototypes in a fast and 
efficient way has led to rapid prototyping technology becoming a fundamental tool for 
many areas of research and development. Fused deposition modelling (FDM) based 3D 
printers are readily available for purchase, either as self-assembly kits or as 
pre-assembled units; they are already being used to develop components for research, 
as an on-site 3D printer allows for a rapid print, test and redesign sequence until an 
optimised product is achieved. Although design and manufacture takes time, the 
ability to make distinct items in the testing environment is highly advantageous 
regarding time and cost effectiveness when compared to external sourcing. The fact 
that a computer aided design CAD model is produced as part of the design process also 
means that it can be used with other computer aided manufacturing processes should 
the 3D printing technology not allow fabrication of devices with the required 
properties.  
The rapid advancement of low-end 3D-printing technology (< £2000) is largely 
due to the development of free and open source software and hardware (Zhang et al., 
2013). The large open community that surrounds the use of rapid prototyping 
technology is actively altering and improving the 3D printers, accelerating the advance 
of the technology. In addition, there is a large library of CAD models available freely, 
which provides shortcuts to product development.  
The aim of the work presented in this chapter is to design, create and test 3D-
printed objects with optical transparency such that colour change can be viewed and 
ultimately quantified within the object. Optical transparency is the physical property of 
allowing light to pass through the material without being scattered. The attenuation of 
light of all frequencies and wavelengths is due to the combined mechanisms of 
absorption and scattering (Fox, 2001). The results of the investigations could then be 
applied to the development of a lab-on-a-disc (LOAD) microfluidic platform for the 
colourimetric quantification of substrates in whole blood. The primary goals are to 
investigate manufacturing and post-production techniques to, (A) improve optical 
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transparency of low-cost 3D-printed objects and (B) form imbedded water-tight 
microfluidic channels within 3D-printed devices. The primary stages involved in making 
a 3D-printed product are creation of a CAD file, conversion and preparation of the file 
using a slicer program, then uploading the file to the printer and the physical creation 
of the object. The process from CAD model to completed printed object will be 
detailed and demonstrated. 
 Materials and Methods 4.2
The materials, equipment and software that were used are detailed in this 
section. Schematics of 3D-printed objects that were used as test samples are also 
included. 
4.2.1 3D-Printer 
All 3D printed models were fabricated using an Ultimaker 2+ 3D printer (cost: 
~£1500) using a 0.4 mm nozzle size (Ultimaking Ltd., Netherlands) Figure 4.1.  
 
 
Figure 4.1: Ultimaker 2+, (A) 3D-printer; (B) print head/extruder (Ultimaker Ltd., 
2014). 
(B) (A) 
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The Ultimaker 2+ printer uses a filament diameter of 2.85 mm and is equipped 
with a single print head/extruder. The build table moves vertically along the z-axis, 
while the print head moves horizontally in the x-y plane. The positional accuracy of the 
printer in the X, Y and Z dimension is 12.5, 12.5 and 5 µm respectively. The nozzle size 
of 400 µm allows for the design and constructions of features (such as channels) over a 
range of 20 µm to 200 µm layer resolution/layer height. The available build volume is 
230 mm x 225 mm x 205 mm. The print layer resolution/layer height (Z-axis) is up to 20 
µm for high quality/fine detail prints. The print speed can range up to 300 mm/s. The 
nozzle temperature during operation is variable from 180 – 260°C and the printer is 
equipped with a heated build table variable from 50 – 100°C. The heated build table 
reduces warping issues that can be severe for elongated, rectangular shaped objects 
and allows for printing using acrylonitrile butadiene styrene (ABS) (MakerGeeks.com, 
2014). The warping of the printed structure primarily occurs at the contact surface of 
the printed object and the build table due to the large temperature difference 
between the hot melt extrusion and the colder table; the first layers deposited cool 
down quicker and shrink, which causes the lower parts of the model to bend up at the 
edges. Heating up the build table reduces this temperature difference which reduces 
the shrinkage that occurs when the plastic cools quickly, therefore, warping issues are 
significantly reduced (Wang et al., 2007; Kantaros and Karalekas, 2013). In polylactic 
acid (PLA) models, less shrinkage occurs during cooling compared to ABS which is 
prone to shrinkage and warping; as a result PLA tends not to require a heated build 
table whereas it is required when printing in ABS (Grieser, 2016).   
When printing in PLA, the heated build table of the 3D-printer is set to 60 °C as PLA has 
a glass transition temperature of 60-65 °C (Grieser, 2016). The glass transition 
temperature is the range over which the mobility of polymer chains increases 
significantly compared to colder temperatures. By printing on to a surface which is at 
the glass transition temperature it is suspected that polymer chain mobility is 
maintained which may cause the deposited polymer strands to have increased 
merging which could result in improved layer homogeneity.  
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4.2.2 Software 
The software used in this work is as below: 
 Sketchup (Trimble Navigation Ltd., USA): 3D CAD modelling. 
 Cura (Ultimaker Ltd., Netherlands): CAD model slicer and printer control.  
 SpectraSuite (Ocean Optics, USA): Spectrum generation and analysis. 
 Image J (ImageJ.net): OCT image analysis. 
 
4.2.3 3D-Printing Process 
When using 3D-printing, several stages are required in order to progress from a 
conceptual idea to a physical model. The protocol followed in this thesis is as follows: 
 
Figure 4.2: 3D-printing protocol followed in this thesis. 
 
4.2.4 Print Material 
There are several different materials available for use with FDM 3D printers, 
each with their own strengths, weaknesses and distinct characteristics. For this project, 
(1) Concept/idea. (2) Create 3D CAD model in 
Sketchup and export .stl file. 
(3) Import 3D CAD model in 
Cura and set required 
printing parameters. Save to 
SD card. 
(4) Print 3D-model from 
SD card using 3D-printer.  
(5) Remove physical 
object from printer and 
perform required post-
print finishing. 
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the primary factor to be considered when choosing a print material is the transparency 
of the final item. Factors such as strength, extrusion temperatures and warping 
tendencies are also important. Currently the most commonly used materials for FDM 
3D printing are PLA and ABS; both are classed as thermoplastics, PLA is further classed 
as a polyester plastic, ABS is further classed as a styrenic plastic (Makeitfrom.com, 
2017). Table 4.1 contains a summary of quick reference, non-technical differences to 
be considered when working with ABS or PLA. Table 4.2 contains a comparison 
between the thermal properties of ABS and PLA. Table 4.3 contains a comparison of 
ABS and PLA material properties. Currently, there are several types of printing filament 
that are being marketed as natural, transparent or clear, but the actual optical 
transparency of the printed items tends to be poor for use in an optical device. The 
devices produced are not transparent but rather are translucent/ cloudy. Despite this, 
advances in 3D printing materials, like the printers themselves, have been and 
continue to be rapid and consistent, with new products becoming available daily. 
 
Table 4.1: Quick reference of differences between ABS and PLA (English, 2012). 
Acrylonitrile Butadiene Styrene 
 Extrude at ~225°C 
 Requires heated build table 
 Does not required cooling 
 Adheres best to polyimide tape 
 Filament tolerances are usually 
tighter 
 Prone to cracking, delamination, 
and warping 
 More flexible 
 Can be bonded using adhesives 
or solvents (Acetone or MEK) 
 Fumes are unpleasant in enclosed 
areas 
 Oil Based 
Polylactic Acid 
 Extrude at ~180-200°C 
 Benefits from heated build table 
 Requires cooling while printing 
 Adheres to a variety of surfaces 
 Finer feature detail possible on a 
well calibrated machine 
 Prone to curling of corners and 
overhangs 
 More brittle 
 Can be bonded using adhesives 
 More pleasant smell when 
extruded 
 Plant Based 
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Table 4.2: Reference of thermal properties of ABS and PLA (Grieser, 2016). 
Thermal Properties ABS PLA 
Melt volume index 9.7 cm3/10 min 10.3 cm3/10 min 
Glass transition temperature 105 °C 60-65 °C 
Slumping temperature 110-125 °C 70-80 °C 
Melting temperature 210-240 °C 160-190 °C 
Printing temperature 230-250 °C 190-220 °C 
Recommended build table 
temperature 
80-120 °C 
(heated build table 
required) 
50-70 °C 
(heated build table not 
required) 
 
 
Table 4.3: Reference of material properties of ABS and PLA (Makeitfrom.com, 2017).  
Material Properties ABS PLA 
Density 1.0 to 1.4 g/cm3 1.3 g/cm3 
Elastic (Young’s, Tensile) 
Modulus 
2.0 to 2.6 GPa (0.29 to 
0.38 x 106 psi) 
3.5 GPa (0.51 x 106 psi) 
Elongation at break 3.5 to 50 % 6.0 % 
Flexural Modulus 
2.1 to 7.6 GPa (0.3 to 1.1 x 
106 psi) 
4.0 GPa (0.58 x 106 psi) 
Flexural Strength 
72 to 97 MPa (10 to 14 x 
103 psi) 
80 MPa (12 x 103 psi) 
Strength to Weight 
Ratio 
37 to 79 kN-m/kg 38 kN-m/kg 
Tensile Strength: 
Ultimate 
37 to 110 MPa (5.4 to 16 x 
103 psi) 
50 MPa (7.3 x 103 psi) 
 
 
The quality of the final product largely depends on the printing parameters and 
post-print-finishing, so even if a particular material does not produce an acceptable 
optical transparency solely from the print, that does not mean it cannot be improved 
with post-print treatment. In this work experiments have been performed using a 
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variety of filaments and post-print finishing techniques to arrive at an acceptable 
material and manufacturing process.  
Due to the properties listed above, the primary printing material will be PLA; 
with the goal ultimately to produce a LOAD platform, PLA’s improved fine detail 
potential compared to ABS makes it a logical choice for initial designs, as precision is 
key when attempting to design and manufacture microfluidic channels; in addition, the 
use of PLA in biochemical devices is already established (Kadimisetty et al., 2016; 
Pioggia et al., 2007). While a number of materials can be used for 3D-printing, as the 
aim of the project is to investigate the capabilities of low-cost, commercially available 
3D-printing resources for the development of point-of-care (POC) diagnostic devices, 
all print materials will be 750 g filament spools purchased from Ultimaker.com 
(Ultimaking Ltd., Netherlands). A number of different batches and makes of 
transparent filaments were used. The filaments tested include: Ultimaker PLA 
Translucent, Ultimaker PLA Transparent, Innofil PLA Natural and InnoPET Natural. 
 
4.2.5 Other Materials 
Acetone and isopropyl alcohol were purchased from Sigma-Aldrich (Poole, UK). 
Microscope images were taken using an Olympus BX51 microscope (Olympus 
Corporation, Japan). 
 
4.2.6 Instrumentation Used to Measure Attenuation  
Instrumentation (Figure 4.3) was assembled to quantify the difference in 
optical attenuation between the 3D-printed plastic samples. Plastic samples were 
supported at a fixed distance in front of a Newport 1825-C Optical Power / Energy 
Meter (Newport, USA). The sample was then illuminated with a helium-neon gas laser 
(Uniphase, UK), operating at 633 nm with an output power of 0.8 mW fitted with a 
beam expander to create a spot diameter of 20 mm on the plastic sample. The 
110 Chapter 4: Lab-On-A-Disc Platform Design and Manufacture 
 
Alexander M. Tothill  Cranfield University 
attenuation of the sample was recorded as the difference between the transmitted 
power with and without the sample under test in the beam path. 
 
Figure 4.3: Instrumentation used to measure attenuation. 
 
4.2.7 Optical Coherence Tomography Instrumentation 
Fourier Domain Optical Coherence Tomography (OCT) is an interferometric, 
noninvasive tomographic imaging technique that is traditionally used to obtain 
subsurface cross-sectional images of a sample with micron-level resolution. A 930 nm 
Fourier Domain Thorlabs OCT system (Thorlabs Inc., New Jersey, USA) was used to 
generate surface trace images of channel samples (Figure 4.4). A broadband (i.e. a low 
temporal-coherence) light source illuminates a Michelson interferometer which splits 
the light into a reference path and sample path. The reference path terminates with a 
mirror, while the sample path contains an imaging lens that focuses the light onto the 
sample. The imaging lens collects light that is backscattered or reflected from the 
sample. The light returned from both paths is recombined and directed into a 
spectrometer, which forms the interference pattern that is then analyzed to yield the 
spectral OCT image. Interference fringes form when the optical path length difference 
between the reference and sample beams is less than the source coherence length. 
This technique provides precise axial positioning of an object in the direction of light 
propagation achieving precision on the order of microns. Typical scan depths for highly 
scattering biological samples range from 1 mm to several mm depending on the 
Helium-neon laser Power meter head Plastic sample 
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scattering properties of the sample (Thorlabs Inc., 2007; Drexler and Fujimoto, 2015). 
Samples with highly reflecting surfaces are usually tilted so surface reflections of high 
intensity are reduced in favour of reflections at inner structures (Berer et al., 2015). 
Therefore, samples were positioned at a 20 degree incline. 
 
Figure 4.4: Schematic of instrumentation used for optical coherence tomography 
(Thorlabs Inc., 2007). 
 
4.2.8 Plastic Samples 
A plastic sample (Figure 4.5) was designed as a means to quantify changes in 
optical transparency during experimentation. The sample was made using Ultimaker 
PLA Translucent with the back-side surface on to the heated build table; the square 
Channel sample 
OCT sample arm 
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region from which readings were taken was 400 mm2 with 400 µm thickness. An 
additional support structure borders the plastic sample for handling and identification, 
so that physical contact with the plastic sample was minimised and the risk of damage 
occurring when removing the plastic sample from the 3D-printer build plate was 
reduced. The back side was printed down onto the build table. 
 
Figure 4.5: Schematic of plastic sample.  
 
4.2.9 Open Face Plastic Channel Samples  
An open face channel sample, Figure 4.6, was designed as a means to quantify 
changes in channel surface roughness during experimentation. The test samples were 
made using Ultimaker PLA Translucent with the bottom surface on to the heated build 
table; the channel region from which readings were taken was 1 mm wide with 400 µm 
depth. All samples were printed at a print speed of 10 mm/s with 0.06 mm layer 
height. The top side was printed down onto the build table. 
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Figure 4.6: Schematic of the microfluidic channel. (A) Channel specifications; (B) 
cross-sectional specifications. 
 
4.2.10 Effect of Layer Height and Print Speed on Optical Transparency 
Plastic samples (section 4.2.9) were printed at different speeds (5 – 10 mm/s) 
and layer heights (0.06 – 0.25 mm), described fully in section 4.3.1. The distance 
between the print head and build table was < 0.05 mm. The optical transparency of 
each sample was measured using instrumentation described in section 4.2.6. 
 
4.2.11 Effect of 3D-Printer Print Head Position in Relation to Printer 
Build Table on Optical Transparency 
Plastic samples (section 0) were printed when the distance between the print 
head and build table was < 0.05 mm and then 0.25 mm. All samples were printed at 10 
mm/s with 0.06 mm layer height. The difference in attenuation was recorded using the 
plastic sample attenuation instrumentation (section 4.2.6). 
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4.2.12 Effect of Acetone Vapour Treatment on Optical Transparency 
Plastic samples (section 0) were exposed for differing times to acetone vapour 
and the difference in attenuation was recorded using the plastic sample attenuation 
instrumentation (section 4.2.6). Acetone liquid was added to a glass jar on a heat plate. 
The acetone was then boiled by setting the heat plate to 150 °C. An acetone vapour 
cloud was generated in the glass jar; the plastic samples were immersed in the acetone 
vapour cloud for varying times then allowed to dry. All samples were printed at 10 
mm/s with 0.06 mm layer height and the distance between the print head and build 
table was < 0.05 mm. 
 
4.2.13 Effect of Acetone Liquid Treatment on Optical Transparency 
Plastic samples (section 0) were exposed to liquid acetone (0-100%) and the 
difference in attenuation was recorded using the plastic sample attenuation 
instrumentation (section 4.2.6). Acetone liquid was diluted using isopropyl alcohol and 
the samples were immersed fully into the solutions then removed. Excess liquid was 
allowed to flow off the plastic sample and it was then allowed to dry. All samples were 
printed at 10 mm/s with 0.06 mm layer height and the distance between the print 
head and build table was < 0.05 mm. 
 
4.2.14 Effect of Acetone Liquid on Channel Surface Roughness 
Open face channel samples (section 4.2.9) were exposed to liquid acetone 
(0-100%). OCT instrumentation as described in section 4.2.7 was used to image the 
channel cross-sections before and after treatment so the change in surface roughness 
could be quantified. All samples were printed with plate 1 surface (top side) being 
printed onto the build table at 10 mm/s with 0.06 mm layer height and the distance 
between the print head and build table was < 0.05 mm. 
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 Results and Discussion 4.3
The investigation of the use of 3D printed plastics for microfluidic devices had 
two key aims. Firstly, the optimisation of the 3D printing methodology to produce 
plastic samples of sufficient optical quality to allow optical interrogation of internal 
cavities.  Secondly, the production of microfluidic channels imbedded in a 3D-printed 
device. The process of optimisation of the 3D printing methodology focussed initially 
on the layer height and the print speed. It then progressed to an investigation of post-
print treatments.  Error bars shown on graphs represent ± 1 standard deviation. 
 
4.3.1 Effect of Layer Height and Print Speed on Optical Transparency 
As previously discussed in section 2.4.1 and 4.2.4, many factors can influence a 
3D-printed object; it can take several print attempts and varying conditions to produce 
an object with the desired properties. The FDM printer used here deposits individual 
strands of polymer which merge together to form a layer; layers are built up on top of 
each other to form the object. Thinner layers result in better quality objects at the cost 
of increased print time. Therefore, an important parameter when printing an object is 
the height of the individual layers.  
The influence of the layer height on the attenuation of the transmitted light 
was investigated by characterising the 3D-printed solid plastic samples as described in 
section 0. The difference in attenuation was recorded using the plastic sample 
attenuation instrumentation (section 4.2.6).These samples were fabricated at a print 
speed of 10 mm/s, with varying layer height of the plastic.  Layer height and print 
speed is controlled using the Cura software. The results can be seen in Figure 4.7. 
An important factor observed during initial printing attempts was the 
difference in sample surface quality. From visual examination, the sample surface that 
was in contact with the heated build table was polished/smooth and had visibly 
improved form, structure and optical transparency; the top face is visibly rough and 
cloudy by comparison. It is possible that by ensuring that the most suitable surface is 
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printed face down on the build table, the object will have improved characteristics for 
its intended purpose. It was hypothesised that the rough surface may cause increased 
scattering relative to the smooth surface which could affect attenuation. Attenuation 
is the loss of flux intensity that occurs through a medium; attenuation is caused by 
absorbance, reflection and scattering. The attenuation in plastic samples was 
calculated by measuring the difference in beam intensity when the samples were 
placed in the laser beam path; (I0 – I) where I0 is the beam intensity detected without 
the sample and I is the beam intensity detected with the sample. Attenuation results 
were taken from the front-side of the plastic sample (rough surface away from heated 
build table) and then the back-side of the plastic sample (smooth surface on to the 
heated build table). This was done by placing the plastic sample with the relevant face 
towards the incident beam in the experimental setup so the difference could be 
investigated; ‘rough’ measurements had the rough face towards the incident beam as 
was the case with ‘smooth’ measurements. Results have been normalised. 
 
Figure 4.7: Attenuation measured at a wavelength of 633 nm in 400 µm thick plastic 
samples made from Ultimaker PLA Translucent using 6 different layer-heights (n=3). 
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As shown in Figure 4.7, an increase in the layer-height increases the 
attenuation of the transmitted light; as layer height increased from 0.06 – 0.25 mm, 
attenuation detected in samples increased by up to 252%.  However, at 0.04 mm and 
0.06 mm layer-heights the difference between the attenuation measurements was less 
than the experimental error. It is postulated that as layers are deposited, air can be 
trapped between the layers, reducing homogeneity. Such air pockets and the 
corresponding reduction in the merging of the polymer layers is thought to be 
responsible for the clouding observed in the printed samples  and the measured 
increase in attenuation. Where homogeneity between layers was improved, it was 
observed by eye that the optical transparency increased, even if intermittently and not 
across the entire object. It might be expected that by increasing the layer height the 
optical transparency would also increase, as there would be fewer layers and therefore 
less potential for air gaps. However, it is proposed that as the layer height increases 
the circular nature of the FDM extruded plastic causes the air pockets to become 
larger, increasing attenuation and decreasing optical transparency.   
A proposed solution to the formation of air gaps was to vary the print speed to 
allow the plastic time to flow into the gaps. However, as shown in Figure 4.8, the 
variation of the print speed had a mixed impact on the attenuation of the samples 
made using the PLA Translucent plastic. For 0.06 mm layer height, increased print 
speeds reduced the attenuation by up to 16%. Layer heights of 0.15 mm and 0.25 mm 
showed an increase in attenuation, up to 27% and 15% respectively, with speed. It was 
also seen that while there was a decrease in attenuation results taken from the 
smooth face compared to the rough face, there is little difference (<10%). All 
subsequent results were taken from the front (rough) surface.  
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Figure 4.8: Attenuation in Ultimaker PLA Translucent plastic samples made with 3 
different layer heights at 3 different speeds (n=3). 
Further experiments were undertaken at a range of higher print speeds, but 
this increased the failure rate of the prints. It has been documented that at higher 
print speeds the chance of print failure increases. This is due to the increased risk of 
the print not sticking to the build table, overheating, layer shifting and misalignment, 
grinding of the filament by the feed motor leading to interruption of feed, and 
increased vibrations impacting the quality of fine details (Simplify3D, 2016). This 
results in either incomplete, inadequate quality or aborted prints. All further prints 
were done at a layer height of 0.06 mm and at a print speed of 10 mm/s, as this 
appears to offer the best compromise between optical transparency, print success and 
print time. 
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4.3.2 Effect of 3D-Printer Print Head Position in Relation to Printer 
Build Table on Optical Transparency 
As it was postulated in section 4.3.1 that air pockets between filament strands 
and layers have a direct impact on attenuation and optical transparency, reducing this 
is paramount. Through preliminary testing using the 3D-printer it was discovered that 
the print build table position in relation to the printer nozzle can change the deposition 
of strands and change the homogeneity of layers, therefore affecting optical 
transparency. The manufacturer provides a ‘calibration card’ that is to be used to 
calibrate the position of the build table; the calibration protocol states that there 
should be slight friction when moving the calibration card between the printer nozzle 
and the build table (Ultimaker.com, 2016b). The thickness of the calibration card was 
0.15 mm (± 0.01 mm) when measured using a digital Vernier calliper. 
It was hypothesised that by reducing the space between the printers build 
table and print nozzle, the printer nozzle could physically smooth the previous layer as 
it moves over while depositing the next layer. This could improve strand merging and 
force the new layer into the previous, rather than just laying it on top. This process 
forces out air from the layers and improves homogeneity and decreases attenuation 
which improves optical transparency. This process of forcing or squashing the strands 
and layers together is how the recently introduced Dolomite Fluidic Factory seeks to 
improve optical transparency and water sealing of microfluidic chips (Dolomite, 2016) 
as illustrated in Figure 4.9. 
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Figure 4.9: Illustration of squashed filament strand (bead) compared to traditional 
circular strand (bead) (Dolomite, 2016). 
 
The difficulty encountered with calibrating the print head position was the 
difficulty in monitoring the build table position in relation to the print head. The 
position changed over time as the machine was in use, presumably due to vibrations 
and the action of the moving parts. As a result, the build table needed to be 
recalibrated before each printing session. This was performed by eye during printing 
by adjusting the positioning screws in the build table. There was a limited build table 
position range (approximately 0-0.25 mm), discovered during testing, in which the 
printer could produce objects; operation outside this range could result in damage to 
the machine (if too close) or unsuccessful prints (if too far).  
Experiments were performed to illustrate the difference in optical transparency 
of objects fabricated using a machine with calibrated build table positioning and that 
of objects fabricated with the machine in an uncalibrated configuration. Plastic 
samples were made on a calibrated build table position (distance between print head 
and build table < 0.05 mm) and an uncalibrated build table position (distance between 
print head and build table 0.25 mm). The distance between print head and build table 
was measured using steel feeler gauges, the thinnest being 0.05 mm thick, hence the 
calibrated build table position being stated as < 0.05 mm as this thickness of feeler 
gauge was unable to pass between the build table and print head after calibration.  
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Figure 4.10: Attenuation in Ultimaker PLA Translucent plastic samples made with 
two different print head to build table distances (n=3). 
 
As can be seen in Figure 4.10, the plastic samples printed on a machine with a 
calibrated build table have far greater optical transparency than those printed on a 
machine with an uncalibrated build table. The increase in attenuation was almost 
200% for the uncalibrated plastic samples compared to the calibrated plastic samples. 
Printing was not possible with a distance >0.25 mm as the print strands could not 
adhere to the build table. There is a visible difference between the plastic samples 
produced; the calibrated plastic samples are significantly clearer than the clouded 
uncalibrated plastic samples. Examples of the plastic samples can be seen in Figure 
4.11. 
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Figure 4.11: Plastic samples printed on a machine with calibrated and uncalibrated 
print head to build table distance. (A) Calibrated (< 0.05 mm); (B) Uncalibrated (0.25 
mm). 
 
Detailed images of the plastic sample surface taken using a microscope can be 
seen in Figure 4.12. With the calibrated plastic samples only the strands in the last 
deposited layer can be seen (the diagonal lines are the strand edges), due to the fusion 
of the preceding layers into a single homogenous layer. With the uncalibrated plastic 
samples, multiple layers in the sample can be seen as a lattice effect in the images. 
This is due to reduced fusion of the strands and layers in the sample, resulting in 
decreased homogeneity. 
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Figure 4.12: Microscope pictures taken of plastic samples printed on a machine with 
calibrated (< 0.05 mm) and uncalibrated (0.25 mm) print head to build table 
distance. (A) calibrated 5x magnification; (B) calibrated 10x magnification; (C) 
calibrated 20x magnification; (D) uncalibrated 5x magnification; (E) uncalibrated 10x 
magnification; (F) uncalibrated 20x magnification. 
This shows that a calibrated print build table position is of utmost importance 
when printing devices for optical detection as an uncalibrated position can impact the 
optical characteristics of the object produced. 
 
4.3.3 Effect of Acetone Vapour Treatment on Optical Transparency 
After improving the optical transparency of the printed objects by changing the 
printing parameters, the next stage was to explore the use of post-print treatments to 
further improve the transparency. The most common post-print technique for finishing 
3D-printed objects involves the use of acetone to treat the surface; acetone acts as a 
plasticiser and induces crystallisation (Naga et al., 2013), reducing imperfections and 
leaving a smooth finish. By removing imperfections from the exposed surfaces of the 
plastic sample it may be possible to improve optical transparency by reducing 
scattering.  
(A) (B) (C) 
(D) (E) (F) 
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An experiment was performed to investigate the effect of acetone vapour 
treatment on 3D-printed plastic samples. The results are displayed in Figure 4.13, 
negative attenuation change signifies an improvement in optical transparency. 
 
 
Figure 4.13: Changes in the attenuation of Ultimaker PLA Translucent plastic samples 
exposed to acetone vapour for a range of durations (n=3). 
 
The influence of the duration of the exposure to acetone vapour on the 
transparency of the printed samples is shown in Figure 4.13. At low exposure times, ≤ 
10 seconds, the transmission is improved by up to 30%. For exposure times > 10 s, the 
transparency decreases significantly, falling below the pre-treatment value, with the 
surface of the sample becoming cloudy and whitened. The change in surface structure 
is visible as the exposure time increases, as shown in Figure 4.14. The individual 
filament strands and demarcation become less apparent. This shows that brief 
exposure to acetone vapour (≤ 10 seconds) can be used to improve optical 
transparency. While this is a promising post-fabrication treatment, its use is limited by 
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the ability to control uniform exposure across the surface of the object. This approach 
would be difficult to deploy in imbedded microfluidic channels. 
Current methods involve simply immersing the entire object in a cloud of 
acetone vapour (Naga et al., 2013) and, while exposure time can be controlled, it is not 
possible to ensure that all surfaces experience uniform exposure and that the cloud 
itself is uniform in concentration. Condensation of the acetone vapour on surfaces also 
occurs; the acetone droplet then runs and leaves a white trail on the PLA that could be 
difficult to remove. If acetone vapour treatment was to be used for internal surface 
treatment, such as those of the microfluidic channels, it would be difficult to introduce 
the vapour into the channels and to remove it in a controlled fashion without 
condensation of the acetone occurring inside the channels. 
An unexpected consequence of the acetone vapour treatment was a change to 
the physical properties of the plastic samples. As exposure time increased, the plastic 
samples became increasingly pliable, taking on a more rubbery texture and becoming 
increasingly elastic, whereas the samples before treatment are hard and brittle. While 
the impact this could have on microfluidic devices is unknown, it is likely that making 
the surface more elastic could cause drooping or sagging, resulting in obstruction 
within channels. Another effect of the acetone vapour treatment was warping of the 
plastic samples, which increased as exposure time increased. This effect must be taken 
into account for devices that are thin, especially those with a large cross section such 
as LOAD platforms which are particularly prone to warping. 
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Figure 4.14: Images of plastic samples after acetone vapour treatment. As exposure 
time increases, warping and clouding increase. Exposure time: (A) 5 seconds; (B) 10 
seconds; (C) 20 seconds; (D) 30 seconds; (E) 40 seconds; (F) 50 seconds; (G) 60 
seconds. 
 
 
Figure 4.15: Microscope pictures taken of plastic samples after acetone vapour 
treatment (5 x magnification). Exposure time: (REF) 0 seconds; (A) 5 seconds; (B) 10 
seconds; (C) 20 seconds; (D) 30 seconds; (E) 40 seconds; (F) 50 seconds; (G) 60 
seconds. 
The microscope images, Figure 4.15, show in detail the changes in surface 
structure that occur as exposure time increases; the individual strands and 
demarcation become less apparent, the objects also get gradually darker as the 
cloudiness increases and optical transparency decreases.  
(A) (B) (C) (D) (E) (F) (G) 
Increasing acetone vapour exposure time. 
(REF) (A) (B) (C) 
(D) (E) (F) (G) 
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4.3.4 Effect of Acetone Liquid Treatment on Optical Transparency 
An alternative to acetone vapour treatment was tested to see if better results 
could be achieved. Liquid acetone of varying concentration (0-100%) was used to treat 
the plastic samples and the results can be seen in Figure 4.16.  
 
 
Figure 4.16: Change in attenuation in Ultimaker PLA Translucent plastic samples 
exposed to acetone solution of increasing concentration (n=3). 
In all cases, attenuation is increased and optical transparency is decreased. At 
20% and 40% acetone concentrations, the increases in attenuation are 13% and 10% 
respectively and there is little visible change to the transparency of plastic samples. 
However, at 60% and 80% acetone concentrations, the attenuation is increased by 
335% and 333%, respectively, and the surfaces of the plastic samples have become 
opaque, as can be seen in Figure 4.17. It was also observed that at 100% acetone 
concentration, the difference in attenuation following treatment was similar to those 
observed at low acetone concentrations (20-40%), with an increase in attenuation of 
12%. It is believed that the isopropyl alcohol affected the evaporation rates of the 
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solutions. The 100% acetone evaporated more quickly than the 60% and 80% solutions 
so that surface damage was limited. It is possible that the surface damage that 
occurred at 60% and 80% could have been reduced by including a rinsing step using 
isopropyl alcohol following immersion in the acetone solutions for all plastic samples 
however, this was not performed. The 0-40% concentration solutions did not have a 
significant effect on the surface before complete evaporation occurred.  
Whilst best efforts were made to drain all excess solution from the plastic samples 
after immersion, the effects of liquid that pooled can be seen, particularly along the 
bottom support of the plastic samples, as seen by the white plaque formation in Figure 
4.17(F). This emphasises a problem with the use of liquid acetone of any 
concentration: if it is allowed to remain on a PLA surface, damage will occur resulting 
in opaque white colouration. Thus control of surface exposure to acetone liquid is of 
utmost importance.  
 
 
Figure 4.17: Images of plastic samples after acetone liquid treatment and microscope 
pictures (5 x magnification). As acetone concentration increases clouding increases. 
Concentration: (A) 0%; (B) 20%; (C) 40%; (D) 60%; (E) 80%; (F) 100%. 
 
When liquid acetone was used there was no warping or change of the physical 
properties of the plastic samples. This was presumably due to the shorter exposure 
time to the acetone, as each plastic sample was immersed for approximately 1 second 
(A) (B) (C) (D) (E) (F) 
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during the dipping process and was then left to dry as the acetone solution 
evaporated, so the exposure rate was primarily controlled by rate of evaporation.   
Further investigations into the use of liquid acetone could be undertaken in an 
attempt at improving optical transparency.  It is possible that by using a low 
concentration of acetone (≤ 5%) and by flowing the solution over the surface, more 
controllable exposure could be achieved, particularly for treatment of internal surfaces 
such as those of the microfluidic channels, where it may be easier to control and 
manage liquid rather than vapour. In addition, the ability of acetone to ‘smooth’ 
surfaces of 3D-printed devices does present other possible uses; if controlled 
application of acetone liquid can minimise the destructive effect on optical 
transparency, there is potential to reduce imperfections of internal channel surfaces 
that acetone vapour would be unsuitable for.  
 
4.3.5 Development of a FDM 3D-Printed LOAD Platform 
The second area to be investigated regarding the use of 3D-printing for 
microfluidic diagnostic devices is the development and manufacture of a LOAD 
diagnostic device with imbedded microfluidic channels. An aim of the research 
presented in this thesis is that the LOAD device should be suitable for use in 
conjunction with an unmodified optical drive that will act as a centrifugal driver and 
reader platform. Referring back to the project aims and objectives, the LOAD device is 
intended to be a vessel in which centrifugal separation of whole blood and 
colourimetric quantitative assays for analytes in whole blood can be performed. The 
device must have sufficient optical transparency such that colourimetric assays can be 
quantified within the channels. The channels must have a volumetric capacity of ≤50 µl 
(a drop of blood) and be water tight to the point that centrifugally driven separation of 
blood plasma from whole blood can be performed within.  
Initial device design specifications were based on an optical disc, so the device 
could be spun using an unmodified ODD. According to the Guidelines on the 
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Production and Preservation of Digital Audio Objects (web edition), optical discs should 
adhere to the universal standards, listed within the publication, so that “discs are 
writable or playable on different manufacturers’ machines”. Therefore, it can be 
assumed that the specifications of optical disc drives adhere to the standardised 
specifications of optical discs, those being 80 mm or 120 mm in diameter, 1.2 mm thick 
with a 15 mm diameter spindle hole (IASA Technical Committee, 2009).  
When the internals of several ODDs were investigated, it was seen that the 
restrictions applied to the LOAD design would, in actuality, be primarily dictated by the 
specifications of the ODD being used to spin the device; specifically the drive spindle. 
While ODD drive spindle specifications are standard to fit the discs (15 mm diameter), 
two types of ODD spindle were encountered: one with locking clips and one without, 
as can be seen in Figure 4.18. The clips are intended to secure the disc onto the spindle 
to reduce vibration at high speeds, and have precise specifications to lock the 1.2 mm 
disc in place. Therefore, drive spindles with locking clips cannot accommodate a disc 
with a thickness > 1.2 mm. Due to the absence of locking clips on the alternative 
spindle design, it was assumed that a disc with thickness >1.2 mm could be spun, 
although, the maximum thickness of disc that could be spun was unknown. It was 
decided that initial LOAD specifications would be of an optical disc (diameter 120 mm, 
thickness 1.2 mm, spindle hole diameter 15 mm), however, should it be necessary, the 
disc diameter could be reduced and the thickness increased. 
  
Figure 4.18: Optical disc drive spindles. (A) with disc locking clips (Study.com, 2014); 
(B) without disc locking clips (Ausgamestore.com, 2008). 
(B) (A) 
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The initial channel design was based on a U-bend as this is a simple design that 
allows for two input/exits required to allow for pressure equalisation for capillary 
action to draw sample into the channel (Figure 4.20(B)). In addition, a U-bend design 
allows for centrifugal motion without requiring plugs to seal channel entry points as 
the force draws sample away from the openings. 
The LOAD device design process envisaged the disc as consisting of 3 distinct plates 
printed consecutively on top of each other to form one disc: 
 Plate 1 is the top plate; it is used to both seal the top of the internal channels 
and provide ‘windows’ into the internal channels, allowing visual interrogation 
of the channel interior. It also has openings/pores to allow for sample 
application and air release.  
 Plate 2 is the internal plate; it contains the channel space.  
 Plate 3 is the base plate; used to seal the internal chambers. 
The first LOAD design had a 120 mm diameter, 15 mm diameter central spindle 
hole and was 1.2 mm thick. Each plate was 400 µm thick, with 8 U-bend channels (2 
mm wide, 400 µm depth, approximately 52.5 mm long in total, 3 mm radius U-bend 
curvature of the inside wall) and 1 mm diameter pores. 8 channels were to be 
imbedded in order to maximise the space on the device that could be used for sample 
quantification, and to allow observation of any differences that may occur between 
channels printed within the same device. The channel volume was approximately 42 
µl. The schematics designed using Sketchup can be seen in Figure 4.19. 
The first print of the disc was completed using PLA Translucent with the aim of 
establishing that the disc would print and to assess the initial properties. The disc was 
printed using ‘normal print’ factory settings with the plate 3 surface being onto the 
build table. The settings to note are the print speed (50 mm/s) and layer height (0.1 
mm). The print time was approximately 5 hours and consumed approximately 18 g of 
plastic filament. When the disc was printed with settings determined from previous 
experimentation as detailed in section 4.3.1 (print speed: 10 mm/s, layer height 0.06 
mm), the print time per disc was approximately 10 hours. It should be noted that 
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decreasing the layer height of a print will increase print time, independently of the 
print speed setting. Figure 4.20 shows the disc immediately after printing and before 
post-print finishing. 
                   
Figure 4.19: Schematic of first LOAD device. (A) Disc specifications and channel 
layout; (B) channel specifications; (C) pore schematic; (D) cross-sectional 
specifications. 
 
The disc felt similar to an optical disc with no warping being visible; any 
warping could render the disc unusable due to instability that could arise when the 
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disc is spun. There were noticeable differences between the surface of plate 3, which 
was printed onto the heated build table, and the surface of plate 1 which was not. 
 
Figure 4.20: Angled view of printed disc faces to show different surface quality. (A) 
The surface of plate 1; (B) The surface of plate 3. 
The surface of plate 1, Figure 4.20(A), felt rough to touch and visible layers and 
strands could be seen and felt. There are visible integrity issues in the plate 1 windows  
over the channels with some bulging and sagging noticeable, in some cases the 
internal channel are exposed. In addition, the pores were not formed properly/circular 
as designed, but were visibly broken/misshapen. The surface of plate 3 which was 
printed onto the heated build table, Figure 4.20(B), displayed a superior finish and 
transparency, and is more glass like in appearance than the surface of plate 1. It would 
appear that direct contact of the face with the heated bed has maintained the strand 
melt temperature and allowed the printed strands to blend together, allowing for a 
homogenous layer. It is assumed that as subsequent layers were deposited, and 
distance from the bed increased, the strand/layer merging decreased and 
transparency was diminished.  
134 Chapter 4: Lab-On-A-Disc Platform Design and Manufacture 
 
Alexander M. Tothill  Cranfield University 
When using a FDM printer there will be visible print layers and strands to some 
degree regardless of the print quality and print resolution; obtaining a smooth finish, 
as seen in injection moulding, is unfeasible when using a FDM 3D printer unless post-
print finishing is performed (Benchoff, 2013). Printer calibration, print optimisation 
and post-print finishing offer the potential for significant improvement of final device 
quality.  
There were two fundamental issues that needed to be overcome. The first was 
the window surface integrity of the microfluidic channels, i.e. the plastic layer laid on 
top of the channel to seal it in plate 1; the visible gaps in the windows suggested that 
the channels were not being sealed properly during printing and therefore were not 
water tight. The second issue was the channels after printing; the channels were 
usually blocked and obstructed with plastic. These issues were linked directly, as the 
plate 1 windows, which should be sealing the channels, were sagging into the channel 
interior, blocking the channel and leaving gaps in the plate 1 windows. 
It was presumed that optimisation of the channel design may result in the 
formation of sealed imbedded microfluidic channels. The initial channel designed 
(Figure 4.19) was 2 mm wide, and it was the relatively large (2 mm) width of the over-
hang space on top of the channel that caused the problems; the plastic being laid on 
top would sag or drop between the channel walls. Different channel designs were 
investigated, examples of which are displayed below. All samples were printed at 10 
mm/s with 0.06 mm layer height. 
Channels with a circular cross-sectional geometry (Figure 4.21) were designed 
using Sketchup and printed with a range of diameters (0.5 mm, 0.75 mm, 1 mm, 1.1 
mm). Due to the 1.2 mm height constraint, sealed channel formation was not possible 
with a channel diameter >1 mm. A channel diameter of 1 mm could be formed, 
however as can be seen in Figure 4.21, the issue regarding plastic dropping and 
obstructing the channels was still present. A channel with a diameter of <1 mm would 
not form. A fundamental issue introduced by circular channels is that of shifting 
channel path length. As interrogation of the assay in the LOAD device is to be 
135 Chapter 4: Lab-On-A-Disc Platform Design and Manufacture 
 
Alexander M. Tothill  Cranfield University 
performed perpendicular to the channel, top down through the disc from plate 1 to 
plate 3, the circular channels have a different pathlength depending on the position 
the reading takes place over the channel. For example, if the reading takes place at the 
edge of the channel cross-section, the path length will be shorter than if the reading 
takes place in the centre of the channel cross-section; the path length of the sample 
must be maintained to reduce inaccuracy. 
  
Figure 4.21: (A) Schematic of circular channel. (B) Illustration of how strands are 
deposited to form the channel. (C) Microscope pictures taken of circular channel 
samples (5 x magnification). 
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Channels with a triangular cross-sectional geometry (Figure 4.22) were also 
investigated. Sealed channels with this geometry could be formed with a channel 
width up to 4 mm and height up to 0.8 mm; obstructions within the channels were also 
reduced. It is speculated that the way in which the layers are built up to form channels 
with triangular geometry, results in less plastic over-hang, and therefore improved 
channel formation, as illustrated in Figure 4.22 (B). 
Despite this success, the issue of shifting path length remains. The ultimate goal 
is to produce a diagnostic device that can be interpreted utilising optical absorbance 
quantification methods such as spectroscopy. Therefore the shifting path length 
introduced by a non-uniform design renders channel designs such as triangular or 
circular unusable.  
 
Figure 4.22: (A) Schematic of triangular channel; (B) Illustration of how strands are 
deposited to form the channel. (C) Microscope picture taken of triangular channel 
sample (5 x magnification). 
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It was decided that focus should be on printing sealed channels with a 
square/rectangular cross-sectional geometry as this geometry must be used to 
minimise shifting path length within the channel. The primary reason that the channels 
were not sealing was due to sagging and dropping of the plastic layers being laid on 
top of the open channel; it was speculated that this could be reduced by adjusting the 
plastic extrusion temperature. 
It was hypothesised that increasing the extrusion temperature would increase 
the fluidity of the plastic resulting in improved strand and layer merging. However, it 
could also introduce structural integrity issues when constructing the internal 
microfluidic channels, as increased fluidity of the plastic could cause increased sagging 
and dropping, and ultimately collapsing, of the channel. The converse would also be 
true; a lower extrusion temperature decreases plastic fluidity resulting in decreased 
strand and layer merging, however, channel formation is improved, as less fluidic 
plastic is being laid over open space. 
Samples were printed with up to 2 mm2 channels at a range of extrusion 
temperatures (180-210 °C) and the channels examined under a microscope. An 
extrusion temperature of 200 °C was found to be most successful for the formation of 
imbedded channels; the standard extrusion temperature of the printer is 210 °C. The 
reduction in extrusion temperature resulted in reducing the plastic sagging and 
dropping, allowing for increased freedom in channel specifications, as can be seen in 
Figure 4.23. Although there was still sagging, channels of cross sectional area up to 2 
mm2 could be formed without obstruction. At an extrusion temperature <200 °C, the 
prints were seen to delaminate due to inadequate strand and layer merging.  
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Figure 4.23: Microscope pictures taken of square channel samples printed with 
extrusion temperature at 200 °C (5 x magnification). (A) 2 mm2; (B) 1 mm2; (C) 0.5 
mm2. 
 
As was previously mentioned in this section (4.3.5), another area of concern 
was the pore formation required for channel access for sample application. Precise 
pore formation was unsuccessful when printing the LOAD devices. It was suspected 
that this was due to the pore being located above the channel, which made precise 
strand placement impossible due to it being over open space. This was solved by 
printing the LOAD disc with plate 1 (which contains the pores) down onto the build 
table. This means the pores are formed and built on the build table rather than in open 
space. This also results in improved transparency for the channel window, making it 
easier to view the assay in the channel.  
It was also observed that the plate printed onto the build table required fewer 
layers to seal the channels. It was assumed this was due to the heated build table 
improving strand and layer merging, therefore producing a better seal. This allowed for 
the plate being printed onto the build table, plate 1, to be made thinner as fewer 
layers were required to seal the channels. This meant plate 2 and plate 3 could be 
made thicker as required whilst maintaining a total LOAD thickness of 1.2 mm.  
Following the improvement of the print process and print parameters that have 
been discussed in this section 4.3.1 and 4.3.5, a LOAD device with embedded 
microfluidic channels was developed. Each ‘U’ channel is distinct from the other 
139 Chapter 4: Lab-On-A-Disc Platform Design and Manufacture 
 
Alexander M. Tothill  Cranfield University 
channels and must be filled individually; this facilites multiple individual assays to be 
performed on a single device without cross-contamination or reagents or samples. The 
schematics are shown in Figure 4.24.  The outer region of the disc was minimised to 
reduce print time and filament consumption. Channel volume was approximately 23 
µl. Plate 1 was 200 µm thick, plate 2 was 400 µm thick and plate 3 was 600 µm thick. 
The channels were 1 mm wide, 400 µm deep and the pore design remained unchanged 
from Figure 4.19 (C).  
 
 
Figure 4.24: Schematic of second LOAD device, channel capacity ~23 µl. (A) Device 
specifications and channel layout; (B) channel specifications; (C) cross-sectional 
specifications. 
 
The print time for the disc using optimum settings (10 mm/s speed, 0.06 mm 
layer height) was approximately 5.5 hours and consumed 9g of plastic filament; the 
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extrusion temperature was 200 °C. The disc size reduction decreased print time and 
material consumption by approximately 45%.  The disc was printed with the surface of 
plate 1 down on to the heated build table so pore formation could occur. The 
successful formation of imbedded microfluidic channels is illustrated in Figure 4.25, 
where the channels of a printed disc have been filled with red dye solution. This 
demonstrates that not only can embedded microfluidic channels be printed using a 
low-cost hobbyist FDM 3D-printer, but that optical transparency has been improved to 
the point that colour can be viewed within the channels. Samples were applied to the 
channels using a syringe and hypodermic needle; the needle is inserted through the 
pore (plate 1), into the channel (plate 2) and the sample forced into the channel via 
the syringe. The sample would not flow easily through the channel unless the needle 
was inserted into the channel and pressure was applied, this was presumed to be due 
to the surface roughness of the channel impeding the sample flow and preventing 
capillary action drawing the sample through the channel naturally. 
 
 
Figure 4.25: (A) 3D-printed LOAD device printed using PLA Translucent; (B) LOAD 
channels filled with red dye solution to illustrate improved optical transparency and 
successful formation of imbedded microfluidic channels. 
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Despite the successful formation of imbedded microfluidic channels in a LOAD 
device, the introduction of red dye solution into the channels revealed that the 
channels were not water tight. Within 30 seconds of the dye being introduced to the 
channels, there was visible permeation of the dye into the surrounding plastic. 
A time lapse observation was performed to quantify the approximate rate of 
passive liquid loss when no centrifugal force is being applied (Figure 4.26). Assuming 
that channel formation is ideal (ideal cross section = 1 mm x 400 µm) and fill at time 0 
is 100%, the volume is approximately 23 µl per channel and approximately 184 µl in 
total across all 8 channels. Images were taken at the specified times. The fluid loss in 
each channel was calculated by measuring the fluid loss in mm which was then 
converted into volume loss based on the channel dimensions. Although this would not 
be as accurate as directly quantifying the volume present in the channel, this method 
was the most practical for quantifying the fluid loss at multiple time points over an 
extended period. 
The following metric was used to calculate total percentage liquid loss across all 
channels (total % channel liquid loss): 
Equation 11: 100
𝑉𝑇−∑ (𝑉𝑥𝑖)
𝑁
𝑖=1
𝑉𝑇
 (11) 
Where VT is total approximate volume across all channels (184 µl), Vxi is the 
approximate volume difference per channel. 
It was expected that there may be liquid loss due to evaporation, however this was not 
factored in to calculations at this stage of investigation.  
 After 12 hours: mean liquid loss was calculated at approximately 48% across all 
channels. 
 After 24 hours: mean liquid loss was calculated at approximately 78% across all 
channels. 
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Figure 4.26: Time lapse series to quantify fluid loss from disc channels; (A) 0 hours; 
(B) 12 hours; (C) 24 hours. 
 
The results show that there is liquid loss from the channels, with 78% liquid lost 
over 24 hours, however, the platform will not be expected to remain accurate for 24 
hours after sample introduction. Assay results are intended to be generated and read 
within 5 minutes, a liquid loss of 3-4% per hour should allow for result generation 
without impacting the assay performance or accuracy; a liquid loss of 4% per hour 
translates to 0.33% (or 0.076 µl per 23 µl channel) in 5 minutes which is within the 
experimental error seen in section 3.3.9. However, the results display a weakness in 
(A) (B) 
(C) 
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the channel structure. The 3-4% liquid loss per hour is via passive diffusion, with no 
force being applied to the sample. While this degree of water-tightness would be 
acceptable for current POC microfluidic chips with a time-to-result of <10 seconds, the 
LOAD device is intended to perform centrifugally in an optical disc drive, being 
subjected to high RPM and g-force to separate blood plasma. For example, a 4x optical 
drive is intended to rotate at 800-2000 RPM while transferring data. This translates to 
an approximate g-force of 32-200 g being applied at the disc circumference with a 
radius of 45 mm. Any passive liquid loss recorded at this stage of device development 
is undesirable if the end goal of centrifugally separating blood plasma from whole 
blood within the device is to be realised, as the device is unlikely to remain water tight 
duration centrifugation. It is possible that a higher extrusion temperature (210°C) may 
improve strand and layer merging, therefore improving the water tight seal. However, 
as discussed in section 4.3.5, this would result in sagging and collapsing of the 
channels. There is potential that post-print heat treatment (section 2.4) could be used 
to improve strand and layer merging and seal the channels without causing structural 
deformation to the channels; this is investigated in section 5.3.4. 
 
4.3.6 Effect of Acetone Liquid on Channel Surface Roughness 
It has been shown in section 4.3.5 that it is possible to form imbedded 
microfluidic channels, however, the surface structure remains an area of concern. 
Obstructions and imperfections could introduce differences in sample-reagent mixing, 
sample volume, or influence the blood separation. This could lead to inaccurate assay 
results with poor reproducibility and therefore incorrect diagnostic evaluation. Due to 
the previous success of using acetone to reduce surface imperfections in 3D-printed 
samples as seen in section 4.3.3, acetone was investigated for its potential in reducing 
surface imperfections within channel formations. 
Surface roughness is traditionally used to compare manufacturing techniques 
(Hobson and Le, 2012), and is often quantified by the deviations in the direction of the 
normal vector of a real surface from its ‘ideal’ form. Surface roughness can have a 
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large impact on how an object interacts within its environment. For example, rough 
surfaces have higher friction coefficients, promote adhesion and are more prone to 
wear. Rough surfaces can also have reduced lifespan compared to smooth surfaces, as 
irregularities in the surface may create sites for cracks or corrosion (Photometrics Inc., 
2016). Manufacturing processes intended to control and reduce roughness can be 
expensive, therefore there is often a compromise between a components 
manufacturing cost and its performance. 
While there are several methods of quantifying and evaluating surface 
roughness, in general there are three different ways through which surface roughness 
can be represented. The arithmetic average (Ra) is the mean value of the deviation of 
the surface compared to the ‘ideal surface’ (Thorlabs Inc., 2016). This shows the 
location of the average surface position in relation to the ideal in the Y-axis. 
Equation 12: 𝑅𝑎 =
1
𝑁
∑ |𝑦𝑖|
𝑁
𝑖−1  (12) 
Where yi is the height difference from the ideal surface for each point of measurement 
and N is the number of measurements. The root mean squared (Rq) produces 
information about the mean value of the deviation of the surface compared to the 
ideal surface and statistical error (Thorlabs Inc., 2016). This is the most typically used 
method for quantifying surface roughness relative to the ideal surface. 
Equation 13: 𝑅𝑞 = √
1
𝑁
∑ 𝑦𝑖
2𝑁
𝑖=1  
(13) 
Where yi is the height difference from the ideal of each point and N is the number of 
measurements. The final method is the most basic, the peak-to-valley distance (PV). 
The PV is simply a measure of the distance between the highest and lowest points 
overall within a sample length; it provides no information on mean values or statistical 
variation (Thorlabs Inc., 2016). 
An experiment was performed in which channel samples were printed then 
treated using acetone liquid solution of a range of concentrations (0-100%). All 
samples tested in the following section were printed at 10 mm/s, 0.06 mm layer height 
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with plate 1 surface being printed onto the build table. OCT instrumentation as 
described in section 4.2.8 was used to image the channel cross-sections before and 
after treatment so the change in surface roughness could be quantified. OCT is a 
non-invasive imaging technique used to generate cross-sectional images of samples. 
The Images produced from OCT allows the surface trace, and therefore the surface 
roughness, to be analysed. 
Initial channel samples were of the same specifications as determined in the previous 
successful channel formation experiments, described in section 4.3.5, however it was 
found that plate 1, at 200 µm thick, was preventing OCT light transmission from 
imaging the base surface. As the surface of plate 1 has higher reflectivity relative to the 
channel surface due to being printed onto the heater build table, it is possible that the 
signal returned from the plate 1 surface is much larger than that of the channel, and 
thus, with the intensity scaling adopted for the image, the effective 
signal-to-noise-ratio of light reflected at the bottom of the channel was too low. This 
can be seen in Figure 4.27 from the horizontal white lines at the top of the image on 
the plate 1 surfaces indicating high reflectance. 
 
 
Figure 4.27: OCT image of 3D-printed channel sample (schematic: section 4.3.5). 
 
As a result, a new design with a thinner plate 1 was designed. The samples had 
channels of 1 mm wide and 400 µm depth (plate 2), positioned with plate 1 being 100 
Channel 
Channel base 
Plate 1 
400 µm 
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µm thick and plate 3 being 700 µm thick (Figure 4.28(A)). Inspection of the images 
(Figure 4.28(B)) revealed that the channel base surface was most prone to surface 
roughness and irregularities, having far greater peaks and troughs relative to the 
surface of plate 1 (channel ceiling). Although image quality was improved relative to 
the previous channel (Figure 4.27), this design still produced poor image quality of the 
bottom of the channel when using the OCT equipment.  
 
 
Figure 4.28 : (A) Schematic of channel sample. (B) OCT images of channel samples 
printed using schematic (A). 
 
In order to accurately image, and subsequently quantify any changes in surface 
roughness, improved image quality was required. It was determined after further trials 
of channel samples that the channels must be open-faced for the best possible imaging 
of the base channel surface, which is the surface most affected by surface roughness. 
By printing open face channels, reflection is reduced and better cross-sectional images 
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can be generated of the channel base. Also acetone treatment can be applied with 
greater control and any opaque white plaque that forms within the channel as a result 
of the acetone solution will not prevent imaging from being possible. Therefore, the 
optimised channel depth of 400 µm, as determined in section 4.3.5, was used and the 
open-faced channel schematic shown in section 4.2.10 used. Channel samples were 
printed open-face down to emphasise the roughness of the channel base surface, as 
would be the case in a LOAD device printed with plate 1 surface down onto the build 
table. Cross-sectional OCT images were taken at a fixed location marked by scoring the 
plate 1 surface using a scalpel. Acetone solutions of 0-100% concentration were 
prepared, applied to the channels and allowed to air dry. Then cross-sectional OCT 
images were taken and the surface trace of the channel base was then analysed. 
Figure 4.29 illustrates an OCT image with annotations highlighting the image features. 
 
 
Figure 4.29: OCT image of channel surface with surface roughness features 
highlighted.  
 
The first stage in image analysis was calculating the Ra of the channel surface 
relative to the ‘ideal surface’ as defined by the CAD model. The ‘ideal surface’ position 
of 400 µm depth was applied to the images so the mean deviation of the channel 
Location of 
ideal surface 
(400 µm depth)  
Location of 
average surface 
deviation (R
a
) 
Peak Max  
Peak to valley 
distance (PV) 
Surface Trace  
Valley Min 
100 µm 
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surface could be calculated using Equation 12 and the difference before and after 
acetone treatment quantified. The results can be seen in Table 4.4.  
 
Table 4.4: Mean deviation (Ra) of channel surface trace from the ideal surface (µm). 
Concentration 
of acetone in 
IPA 
Ra (µm) 
Pre-treatment Post-treatment Difference 
0% -79.3 -88.0 -8.8 
20% 134.4 130.7 -3.8 
40% -84.5 -95.7 -11.1 
50% -120.4 -123.8 -3.4 
60% -8.1 -9.8 -1.7 
80% 108.2 158.3 50.2 
100% 70.2 158.3 88.1 
 
 
The Ra data (Table 4.4 pre-treatment) revealed that the average channel 
surface position can fluctuate, with the position ranging from 120.4 µm below the 
ideal surface to 134.4 µm above the ideal surface in the Y-axis position. This 
emphasises how unpredictable/inaccurate 3D-printing can be and how large variations 
can be seen between models produced under identical conditions. In addition it 
revealed how the average surface position can shift in relation to the ideal surface 
following acetone treatment (Table 4.4 post-treatment); at 40% acetone 
concentration, the Ra shifted down by approximately 11 µm whereas at 80% 
concentration the Ra shifted up by approximately 50 µm. This was presumed to be due 
to the repositioning of polymer within the channels that takes place during the 
treatment.  
Due to the shifting average surface position, the definition of an ‘ideal surface’ from 
which surface roughness could be calculated became problematic and introduced 
potential variables not seen in other forms of manufacturing. As the position and 
structure of the channels within the samples varied, the application of an ideal surface 
from which surface roughness quantification could be performed was not relevant. 
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Therefore the Ra, as a method of quantifying surface roughness, is biased and 
inaccurate in this context.  
For example, a channel may be perfectly smooth but placed significantly above 
or below the ‘ideal’ channel location within the sample, as a result, the smooth surface 
would appear to have high surface roughness when average deviation (Ra) from the 
ideal is calculated. In addition, the apparent effectiveness of the acetone treatment on 
improving surface roughness would be diminished or inaccurate if the Ra had shifted 
away from the ideal despite actual roughness decreasing. The Rq, as calculated from 
the ideal using Equation 13, is displayed in Table 4.5 and OCT images shown in Figure 
4.30 to demonstrate the inaccuracy of using Ra as a method of quantifying surface 
roughness in this context. 
 
Table 4.5: Root mean squared deviation (Rq) of channel surface trace from the ideal 
surface (µm). 
Concentration 
of acetone in 
IPA 
Ra (µm) 
Difference 
(%) Pre-treatment Post-treatment Difference 
0% 141.6 146.5 4.8 3.4 
20% 187.3 182.1 -5.2 -2.8 
40% 105.7 113.1 7.5 7.1 
50% 135.5 134.9 -0.5 -0.4 
60% 58.2 40.6 -17.6 -30.3 
80% 167.2 182.1 14.9 8.9 
100% 148.2 181.5 33.4 22.5 
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Figure 4.30: OCT images focused on channel surface, pre and post acetone 
treatment.                                    
Acetone Pre-treatment Post-treatment 
40% 
50% 
60% 
80% 
100% 
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As can be seen from Figure 4.30, as acetone concentration increased, there was 
a visible decrease in the surface roughness. However, according to the Rq calculated 
from the ideal (Table 4.5), the roughness increased. This was due to the Ra shifting 
away from the ideal as seen in Table 4.4. For example, at an acetone concentration of 
100%, the Rq in relation to the ideal surface increased by approximately 22.5% despite 
the figure displaying a visible decrease in surface roughness following treatment Figure 
4.30 (100%). 
This bias, due to the shifting Ra relative to the ideal, was confirmed when the 
PV profile was investigated (Table 4.6). It was seen that the maximum peak to valley 
distance was reduced following treatment despite the roughness apparently 
increasing, according to Table 4.5. For 100% acetone, a PV decrease of approximately 
18% was observed, signifying a decrease in surface roughness. 
 
Table 4.6: Peak to valley distance (PV) (µm). 
Concentration 
of acetone in 
IPA 
Ra (µm) 
Difference 
(%) Pre-treatment Post-treatment Difference 
0% 427.0 427.0 0.0 0.0 
20% 535.5 549.5 14.0 2.6 
40% 252.0 227.5 -24.5 -9.7 
50% 220.5 213.5 -7.0 -3.2 
60% 280.0 150.5 -129.5 -46.3 
80% 448.0 259.0 -189.0 -42.2 
100% 395.5 325.5 -70.0 -17.7 
 
 
As this line of experimentation was investigating the potential use of acetone 
treatment for improving surface roughness, the Rq was not calculated relative to the 
‘ideal surface’ but rather as a deviation from the average surface (Ra). This would more 
accurately represent the difference in surface roughness following acetone treatment 
by removing any bias that would arise from the Ra shifting away from the ideal. The 
results can be seen in Table 4.7. 
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Table 4.7: Root mean squared deviation (Rq) of channel surface trace from the 
average surface (Ra) (µm). 
Concentration 
of acetone in 
IPA 
Ra (µm) 
Difference 
(%) Pre-treatment Post-treatment Difference 
0% 117.4 117.1 -0.3 -0.3 
20% 130.5 126.9 -3.6 -2.8 
40% 63.4 60.4 -3.0 -4.7 
50% 62.0 53.6 -8.4 -13.6 
60% 57.6 39.4 -18.3 -31.7 
80% 127.5 90.0 -37.5 -29.4 
100% 130.5 88.9 -41.6 -31.9 
 
 
As can be seen from the images in Figure 4.30 and Rq in Table 4.7, in all cases, 
liquid acetone treatment can be used to reduce surface roughness in PLA microfluidic 
channels. At a concentration of 100%, surface roughness was decreased by 
approximately 32%.  
However, Rq does not convey accurately the surface and structural changes 
that have occurred. White plaque formation becomes increasingly prevalent as 
concentration increases; as before, this is of concern as the white plaques are opaque 
and reduced optical transparency as discussed in section 4.3.4. As a primary point of 
investigation in this project is improving the optical transparency of 3D-printed 
devices, the white plaque formation is detrimental to this goal. In addition to the 
plaque formation, the destructive nature of acetone on PLA becomes apparent as the 
acetone concentration increases; there is visible damage and deformation to the 
fundamental channel structure, particularly evident in samples exposed to acetone 
concentrations ≥60 %. At concentrations of 80% and 100% the channel walls have 
been dissolved to the point where one would expect perforation of the channels. A 
point of interest however, is that despite channel destruction witnessed, plaque 
formation at 100% acetone solution is minimal compared to 60% and 80%. This mimics 
results seen from previous use of liquid acetone treatment (section 4.3.4).  
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The results presented in Table 4.7 show that, generally, as the acetone 
concentration is increased, the surface roughness decreased. 60% acetone solution 
provided the most improvement in PV with approximately 46% reduction and an 
improvement in surface roughness (Rq) of approximately 32% reduction; but, as stated 
previously, caused significant plaque formation. 80-100% acetone solutions, although 
successful in reducing PV and Rq, were destructive to the point of causing severe 
damage to integral channel structure; 80% acetone concentration reduced PV and Rq 
by approximately 42% and 29% respectively, 100% acetone concentration reduced PV 
and Rq by approximately 18% and 32% respectively. 50% acetone concentration 
decreased surface roughness by approximately 14% without causing significant 
structural damage or plaque formation. Therefore a concentration of 50% acetone 
provides the best compromise between smoothing effect and diminished optical 
transparency; whereas 60% acetone provides the best compromise between 
smoothing effect and structural damage to the channel. 
As stated at the beginning of this section, improving surface roughness is a key 
challenge in manufacturing. In the case of microfluidic channels for use within an 
optical LOAD platform, the channels serve as both vessel and window. Therefore, 
difficulties arising from surface roughness are compounded. In optical sensing it is 
usually desirable to have as little roughness as possible, so that light is scattered as 
little as possible (ZYGO, 2016). In a microfluidic channel, surface roughness can 
introduce variations in volumetric capacity, which is of particular concern in POC 
devices as control of sample volume is key to minimising variability in results (Gubala 
et al., 2012). In addition, roughness impacts on the capillary effect necessary for 
sample flow within POC microfluidic devices (Yuan and Lee, 2013) and introduces 
turbulence within the fluid sample, all of which can affect assay results and subsequent 
diagnostic evaluation. Reducing channel roughness will improve sample flow, however, 
turbulence may aid sample-reagent mixing should assay reagents be deposited in the 
channel to be dissolved and distributed within the sample. 
It has been demonstrated that significant improvement to surface roughness of 
PLA microfluidic channels using acetone solution is possible, and acetone remains a 
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potential low-cost post-print treatment method for sealed internal cavities where 
other methods are inapplicable. 
4.3.7 Problems 
As is the case with any emerging and evolving technology, one will naturally 
encounter problems. A significant problem involves filament feed. The filament is fed 
from a supply spool on the back of the printer, through a feed motor, up through rigid 
plastic tubing to the printer head. Often during printing the filament feed would stop 
which was inconvenient especially on prints with long print times (the average print 
time for a LOAD device was 5 hours). It was discovered that the filament would jam in 
the print head during the printing process, stopping all subsequent printing and 
requiring the filament to be forcibly removed, which would often require disassembly 
of the print head. Investigations were performed to try and reduce the occurrence of 
this. Initially it was thought that dust on the filament was being dragged into the print 
head, burning and building up an obstructive layer that blocked the nozzle. To prevent 
this, a dust filter was installed to try and clean the filament before it enters the feed 
mechanism; this did not improve the situation.  
After more investigation, swelling of the filament was identified as the most 
probable cause of blockage; when stored improperly, PLA filament absorbs water from 
the air and swells, exceeding the 2.85 mm diameter requirement of the printer 
(RepRage.com, 2015). As a result, the filament could not be fed into the printer head 
and filament flow stopped. Following this, all filaments were stored in air tight bags 
with desiccant when not in use which improved the situation. In addition, the 
3D-printer was upgraded to a geared feeder mechanism which also significantly 
reduced filament feed issues. Filament feed problems still occurred, primarily due to 
the filament randomly forming a plug when heated and obstructing flow, however this 
was less frequent. 
Another serious problem encountered during the project concerned the nozzle 
thermostat in the printer head. It malfunctioned, resulting in the 3D-printer being 
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unusable for approximately 6 months as several replacements had to ordered, fitted 
and tested until the repair was successful. 
Other problems encountered involved the unpredictable state of printed 
objects. There was a lot of variation in the quality and finish of printed objects, even 
between those made during the same print session. This could range from several 
missed/faulty layers in a model to the entire surface, internal and external, being 
extremely rough and covered in extrusions and nodules. When attempting to print 
objects that need to be water tight and optically transparent, any differences or 
imperfections could render them unusable. The occurrence of such imperfections 
appeared to be reduced when models were printed individually rather than in batches, 
however, this significantly increased labour and manufacturing time and reduced the 
number of objects that could be made.  
 
 Conclusions 4.4
A combination of print optimisation and post-print finishing techniques were 
used to improve optical transparency of 3D-printed objects significantly; the poor 
optical transparency of 3D-printed polymers is a fundamental obstacle that limits the 
potential for optical quantification and application of 3D-printing technology.  
Optimisation of the layer height, print speed and position of the build table in 
relation to the print nozzle all contributed to an improvement in optical transparency 
resulting in the ability to print objects in which colour change reactions can be viewed. 
It is believed that these parameters increased strand and layer merging in the prints 
which resulted in the increased optical transparency observed. Optimisation of the 
layer height and build table position displayed a decrease in attenuation in samples of 
up to 252% and 200% respectively. All further prints will be done at a layer height of 
0.06 mm and at 10 mm/s print speed as this appears to offer the best compromise 
between optical transparency, print success and print time.  
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When acetone vapour treatment was used, it was possible to improve 
transparency of plastic samples by up to a further 30%. Initial experimentation with 
acetone liquid treatments were unable to improve optical transparency, however, 
acetone liquid treatments was seen to reduce surface roughness in channel samples by 
up to 32%. In imbedded microfluidic channels it is not possible to directly access the 
channel surface in order to decrease surface roughness via cutting or sanding; a liquid 
treatment that could be pumped into the channels to decrease surface roughness 
without requiring the user having direct physical access, has the potential of being 
highly advantageous.  
A lab-on-a-disc device has been designed and developed with imbedded 
microfluidic channels with a volumetric capacity of approximately 23 µl, 54% better 
than target of ≤ 50 µl. Optimisation of print extrusion temperature (200 °C) has 
resulted in sealed channels that would be suitable vessels for performing assay 
reactions and optical transparency is such that colour is clearly visible within the 
channels. The LOAD devices were produced as a single manufacturing step and did not 
require post print treatments to successfully form the imbedded channels or improve 
optical transparency. However, the channels did not have a sufficient water seal to 
withstand the application of centrifugal force, which is necessary for the separation of 
plasma from whole blood. Experimentation with post-print heat treatment will be 
investigated as a potential means of adequately sealing the microfluidic channels in 
section 5.3.4. Testing will progress towards performing quantitative assays and whole 
blood separation within 3D-printed devices.  
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 Introduction 5.1
Experimentation and investigation thus far has resulted in an optimised assay for 
the quantification of cholesterol and glucose, significantly improved optical 
transparency of fused deposition modelling (FDM) 3D-printed devices and the 
formation of imbedded microfluidic channels in a lab-on-a-disc (LOAD) device. The 
final stages of device development involve proving and demonstrating the two final 
fundamental principles of the project:   
(1) That optical assays can be performed and quantified in a low-cost FDM 
3D-printed device, 
(2) That centrifugation based whole blood separation can be performed in a 
low-cost FDM 3D-printed device.  
Once these principles have been proven, they can be applied to the development of 
the 3D-printed LOAD device in an attempt to combine them and produce a LOAD 
device capable of centrifuging whole blood and performing optical quantitative assays 
in one step. 
The objectives of the work presented in this chapter were to progress assay 
development and to perform the glucose assay in a 3D-printed microfluidic device, 
with the goal of recording absorbance data and generating a glucose concentration 
calibration curve in a low-cost FDM 3D-printed microfluidic device. Glucose assay 
experimentation will progress towards using whole blood samples. Then 
experimentation will investigate the separation of blood plasma from whole blood 
samples in FDM 3D-printed devices. A serious obstacle to this is the inherent lack of 
adequate water-tightness in FDM 3D-printed devices due to the manufacturing 
method discussed previously. Finally, optimisation and development of the LOAD 
device will continue with the ultimate objective being the performance of the glucose 
assay in whole blood within the device, performing centrifugation based whole blood 
separation and the generation of coloured plasma visible in the LOAD microfluidic 
channels. 
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 Materials and Methods 5.2
Phosphate buffered saline (PBS, 10 mM phosphate buffer, 2.7 mM potassium 
chloride and 137 mM sodium chloride, pH 7.4) tablets, chromotropic acid disodium salt 
dihydrate (CTA), 4-aminoantipyrine (AAP), Horseradish peroxidase Type II essentially 
salt-free, lyophilized powder, 150-250 units/mg solid (using pyrogallol) (HRP), D-
glucose, glucose oxidase from Aspergillus Niger lyophilized, powder, ~200 units/mg 
protein (GlOx), were all purchased from Sigma-Aldrich (Poole, UK). Ultrapure water (18 
MΩcm) was produced using a Milli-Q water system (Millipore Corp., Tokyo, Japan). 
Defibrinated whole horse blood was purchased from TCS Biosciences (Buckingham, 
UK). The concentration of glucose in samples was tested and quantified independently 
using an Optium Exceed Blood Glucose Monitoring System (Abbott, UK). Mini Star 
Silverline microcentrifuge (VWR, USA) was used for sample preparation when 
necessary. Camlab Carbolite NR30 oven (Camlab, UK) was used for heat-treatment of 
samples.  
   
5.2.1 Buffers and Solutions 
 Phosphate Buffered Saline pH 7.4 was prepared by using PBS tablets with a 
final volume of 1 L using dH2O. 
 Horse blood was prepared by following the protocol detailed in section 3.3.6. 
 GlOx 1000 units / ml was prepared by adding 1 ml PBS, pH 7.4 to 5.88 mg GlOx 
solid and stored at -20°C until use. 
 CTA solution was prepared by dissolving the appropriate concentration of CTA 
in PBS pH 7.4. 
 AAP solution was prepared by dissolving the appropriate concentration of AAP 
in PBS pH 7.4. 
 HRP 1000 units / ml was prepared by adding 1 ml PBS, pH 7.4 to 6 mg HRP and 
stored at 4°C until use. 
 Glucose solution was used as a substrate for GlOx and prepared by dissolving 
the appropriate concentration of glucose in PBS pH 7.4. 
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5.2.2 Microfluidic Cuvette Devices 
Microfluidic cuvettes were designed as microfluidic vessels with decreased 
fluidic capacity and path length in which to perform the glucose assay and monitor the 
absorbance readings and how the assay performs in a 3D-printed microfluidic device. 
The microfluidic device was a 12 x 12 x 42 mm cuvette which had an internal 
microfluidic cavity with a thickness of 500 µm and volumetric capacity of ~ 190 µl. The 
cuvette design is shown in Figure 5.1. The chamber walls were 400 µm thick. The 
circular tube to one side allowed total filling of the cavity. All samples were printed at 
10 mm/s with 0.06 mm layer height. Devices took 1 hour to print and consumed 
approximately 2 g of plastic filament per device. The microfluidic cuvettes were also 
used as example fluidic vessels from which inter- and intra-variability of devices could 
be investigated. Cuvettes were made from Ultimaker PLA Transparent, Ultimaker PLA 
Translucent, Innofil PLA Natural and InnoPET Natural where stated. 
 
Figure 5.1: Schematic of the microfluidic device. 
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5.2.3 Spectral Analysis Instrumentation 
The absorbance of the substrate assay reaction in the 3D-printed microfluidic 
devices was quantified by analysing the transmission spectrum of the assay using a 
fibre coupled tungsten halogen light source (Ocean Optics ecoVis, Ocean Optics, USA) 
and a CCD spectrometer Ocean Optics ADC1000-USB spectrometer (Ocean Optics, 
USA). The light source has an integrated cuvette holder which was adapted to hold the 
microfluidic devices. The light source and the spectrophotometer were connected 
using a short length (10 cm) of multimode optical fibre. The instrumentation can be 
seen in Figure 5.2. 
 
Figure 5.2: Instrumentation used for spectral analysis. 
 
5.2.4 Centrifuge Pellet Device 
Pellets were designed to investigate blood separation in a 3D-printed device. 
They were designed to fit inside a standard 1.5 ml Eppendorf tube for use within the 
benchtop microcentrifuge. The pellets are 8.5 x 2.82 x 17 mm with 0.5 mm sample 
walls. The sample cavity was 4 x 2 x 14 mm with a volume of ~112 µl. The schematic 
can be seen in Figure 5.3. Pellets were made from PLA Translucent. All samples were 
printed at 10 mm/s with 0.06 layer mm height. Devices took 36 minutes to print and 
consumed approximately 1 g of plastic filament per device. 
 
Microfluidic 
device 
Spectrometer Optical fibre Light source 
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Figure 5.3: Schematic of the 3D-printed centrifuge pellet. 
 
5.2.5 Glucose Assay in 3D-Printed Microfluidic Cuvette Device 
Glucose assay reagent solution was made by dissolving CTA (20 mM), AAP (10 
mM), GlOx (20 U/ml) and HRP (6 U/ml) in PBS solution or CTA (40 mM), AAP (20 mM), 
GlOx (20 U/ml) and HRP (6 U/ml) in defibrinated whole horse blood. The reaction was 
started by adding glucose solution (0-10 mM). The assay was read after 2 minute 
incubation and the absorption spectrum recorded; blood samples were centrifuged for 
2 minutes at 6000 RPM and the liquid component isolated before analysis. The assay 
was performed in a microfluidic cuvette device (section 5.2.2) and the absorbance 
spectra assessed using the equipment described in section 5.2.3. 
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5.2.6 Blood Separation in a 3D-Printed Pellet Device 
Pellets (section 5.2.4) were printed and filled with defibrinated whole horse 
blood. Pellets were placed inside 1.5 ml Eppendorf tubes and centrifuged for 2 
minutes. A selection of pellets were also subjected to heat-treatment, consisting of 2 
hour incubation at 60 °C in an oven before centrifugation testing.  
 
5.2.7 Glucose assay in LOAD Platform 
A generic usb optical disc drive (ODD) (HL-DT-ST DVDRRW GSA-2164D USB) was 
used to perform centrifugation experiments involving LOAD devices. The drive was 
unmodified other than the removal of the outer case to give access to the spindle 
whilst the drive is operational. Attempts at using software to manually control the 
drive were unsuccessful and the drive firmware prevents the drive from operating or 
spinning without a signal detected from an optical disc, therefore, the simplest 
solution was to place the LOAD devices on top of a data disc which was spun by the 
drive, as can be seen in Figure 5.3. The same data disc was used to activate the drive in 
all testing. The average RPM of the drive whilst reading the data disc was 1270 – 3175 
(6.35x constant angular velocity) as determined using the software Nero Disc Speed 
(Nero AG, Karlsruhe, Germany). This translates to approximately 81 -  507 g-force 
being applied at the circumference of the LOAD device with a radius of 45 mm. 
Conventional protocols utilising centrifuges often apply 1000-2000 g-force for 10 
minutes. 
Glucose assay reagent solution was made by dissolving CTA (40 mM), AAP (20 
mM), GlOx (20 U/ml) and HRP (6 U/ml) in defibrinated whole horse blood. The reaction 
was started by adding glucose solution (10 mM). The assay was applied to the LOAD 
channels, incubated for 2-minutes and then centrifuged using the optical disc drive for 
approximately 10 seconds.  
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Figure 5.3: Generic optical disc drive with 3D-printed LOAD device placed on top of a 
data disc. 
 
 Results and Discussion 5.3
The following section describes the development process of two key aims. Firstly, the 
demonstration of filling and reading a biological assay within a 3D-printed microfluidic 
device. Secondly, the centrifugation and separation of plasma from whole blood within 
a 3D-printed microfluidic device. Finally, the development and optimisation of a 
microfluidic LOAD device is detailed, culminating in the performance of the whole 
blood glucose assay and plasma separation within a LOAD device. It should be noted 
that the blood washing protocol as discussed in section 3.3.6 has been implemented 
from section 5.3.1 onwards. 
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5.3.1 Glucose Assay Performed in a 3D-Printed Microfluidic Device. 
Following the optimisation of the 3D-printing methodology to produce plastic 
samples of sufficient optical quality to allow the optical interrogation of internal 
cavities and the formation of viable microfluidic channels, the next stage was to 
demonstrate the filling and reading of the glucose assay within a 3D printed 
microfluidic device.  
Cuvette design progressed from a 1 cm path length design, common in 
laboratories, to the microfluidic 500 µm path length cuvette demonstrated here. The 
microfluidic devices manufactured for use with the glucose assay were printed at a 
rate of 10 mm/second with a layer height of 0.06 mm using PLA Translucent. The 
glucose assay was performed in the 3D-printed microfluidic device as described in 
section 5.2.2. Samples were prepared using the chemical and enzyme concentrations 
described in section 5.2.5. The reaction was started by adding glucose solution of the 
desired concentration. Figure 5.5 shows a photograph of the microfluidic channel 
before and after the glucose assay reaction. The limits of the 3D-printers capabilities 
were tested through the design and manufacture of a 100 µm path length microfluidic 
cuvette and an S-shaped channel 2 mm wide with 500 µm path length, also shown in 
Figure 5.5. These are included to show the range of designs possible with the use of 
3D-printing. An important point to note is that the 3D-printed cuvette devices all 
appeared to be water-tight, no evidence of fluid dissemination was observed outside 
the microfluidic channels.  
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Figure 5.5: Microfluidic cuvette, (A) before glucose assay; (B) after glucose assay. 
Also shown are microfluidic cuvettes prepared with, (C) 100 µm thick chamber; (D) S 
shaped channel. 
 
The absorbance spectra of the 500 µm thick chamber cuvette, Figure 5.5(B), 
were recorded using the methodology described in section 5.2.3. The resulting spectra 
shown in Figure 5.5 are a mean of 3 separate samples intensity readings taken from 
the 500 µm pathlength cuvette. 
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Figure 5.5: Change in the quinoneimine dye absorbance spectra with glucose 
concentration. Glucose (0-10 mM), CTA (20 mM), AAP (10 mM), GlOx (20 U/ml) and 
HRP (6 U/ml) in PBS solution. The assay was read after 2 minute incubation. Assay 
performed in 500 µm pathlength cuvette. 
 
As the glucose concentration increases, the quinoneimine dye concentration 
also increases, resulting in an increase in absorbance centred around 590 nm.  The 
spectra produced illustrate the range over which absorbance can be quantified. In this 
work, the absorbance of quinoneimine dye has been quantified at 590 nm, the 
approximate peak absorbance of the quinoneimine dye, and at 650 nm, the 
wavelength that an optical DVD drive operates at. Both sets of absorbance data have 
been shown in Figure 5.7 to illustrate how shifting the detection wavelength from the 
peak of 590 nm shifts the trend line accordingly; linearity is unaffected, but sensitivity 
is decreased.  
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Figure 5.7: Difference in the absorbance of glucose concentration at 590 nm and 650 
nm, n=3. Glucose (0-10 mM), CTA (20 mM), AAP (10 mM), GlOx (20 U/ml) and HRP (6 
U/ml) in PBS solution. The assay was read after 2 minute incubation. 
 
The data displayed in Figure 5.7 shows a linear absorbance trend line at 650 nm 
for increasing glucose concentrations with an R-squared of 0.99. This establishes that it 
is feasible to measure glucose concentration using a colourimetric assay in a 3D-
printed microfluidic PLA device. The full range of glucose concentrations at 590 nm are 
shown in Figure 5.8, alongside the data from previous plate reader based experiments 
from section 3.3.9. 
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Figure 5.8: Absorbance comparison between 3D printed microfluidic device and well plate 
reader, n=3. Glucose (0-10 mM), CTA (20 mM), AAP (10 mM), GlOx (20 U/ml) and HRP (6 
U/ml) in PBS solution. The assay was read after 2 minute incubation.  
 
In Figure 5.8, the data produced shows a linear dilution curve for increasing 
glucose concentrations with an R2 of 0.99. When compared to results produced with a 
commercial plate reader assay, the 3D-printed microfluidic device performs well. 
There is around a 2-3 times difference in absorbance, which is consistent with the 
native attenuation of the 3D-printed plastic and reduced sample pathlength in the 
device compared to the well plate, which reduces the sensitivity as discussed in section 
5.3.2. However, neither the linearity nor the error of the assay were affected. 
The LoD is the lowest analyte concentration likely to be distinguished from the limit of 
blank at a 99% confidence level, as defined by Quansys Biosciences (Utah, USA). The 
LoD can be calculated from the slope of the absorbance curve, however, due to the 
observed nonlinearity in the curve between 0-2 mM in the well plate, the repeatability 
will be calculated from a 2-10 mM range as this data is approximately linear. While this 
is not a true LoD, it gives a good estimate of the repeatability of the assay in the 2-10 
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mM range. It is assumed that the nonlinearity in the curve between 0-2 mM is a 
repeatable feature of the assay as pathlength increases due to the strong colour 
produced at low substrate concentrations. The repeatability was calculated for the 
glucose assay performed in PBS pH 7.4 for the plate reading and microfluidic device 
reading. The repeatability was calculated in Excel from the slope of the absorbance 
curve between 2-10 mM. 
Equation 14: 𝐿𝑜𝐷 = 3.3 (
𝑆𝑦
𝑆
) (14) 
The standard deviation of the response of the curve (Sy) for 2-10 mM was calculated 
using the ‘=STEYX’ function in Excel. The slope of the calibration curve (S) for 2-10 mM 
was calculated using the ‘=SLOPE’ function in Excel. 
Repeatability of glucose assay in PBS pH 7.4 performed in a commercial plate reader: 
0.59 mM. 
Repeatability of glucose assay performed in PBS pH 7.4 and read using a low-cost FDM 
3D-printed microfluidic cuvette device: 0.60 mM. 
As can be seen, the assay repeatability is similar between the well plate and the 
3D-printed cuvette device with a difference of < 0.1 mM. As the most clinically 
important quantification range for glucose is 2-10 mM this gives a good estimate for 
the precision and repeatability of the assay within this range. While not a true LoD, it is 
sufficient for this stage of assay development, however, a true LoD would need to be 
calculated following further assay optimisation. 
The final stage of the glucose assay development was to test assay 
performance in whole blood samples. Glucose assay reagent solution was made by 
dissolving CTA (40 mM), AAP (20 mM), GlOx (20 U/ml) and HRP (6 U/ml) in 1 ml 
defibrinated whole horse blood. The reaction was started by adding glucose solution 
(0-10 mM). The assay was incubated for 2 minutes then centrifuged for 2 minutes at 
6000 RPM and the liquid component isolated for analysis in the 500 µm path length 
microfluidic cuvette device. The absorption spectrum recorded using the equipment 
described in section 5.2.3. Increasing colour generation in blood samples after 
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centrifugation as glucose concentration increases can be seen in Figure 5.9, and the 
absorbance at 590 nm in Figure 5.10. 
 
Figure 5.9: Glucose assay in whole blood samples, red cell mass is visible in the base 
of the tube. Glucose concentrations: (A) 0 mM; (B) 2 mM; (C) 4 mM; (D)  6 mM; (E) 8 
mM; (F) 10 mM. 
 
 
Figure 5.10: The glucose assay in whole blood read in a 500 µm path length 
microfluidic cuvette device, n=3. Glucose (0-10 mM), CTA (20 mM), AAP (10 mM), 
GlOx (20 U/ml) and HRP (6 U/ml) in defibrinated whole horse blood. The assay was 
read after 2 minute incubation. 
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The data shown in Figure 5.10 demonstrates that it is possible to measure 
glucose concentration in whole blood samples using a colourimetric assay in a 
3D-printed microfluidic PLA device. The data produced shows a dilution curve for 
increasing glucose concentrations with an R-squared of 0.96. The glucose assay 
performed in whole blood 0-10 mM LoD = 2.07 mM and was calculated using Equation 
14. The standard deviation of the response of the curve (Sy) was calculated using the 
‘=STEYX’ function in Excel. The slope of the calibration curve (S) was calculated using 
the ‘=SLOPE’ function in Excel. The LOD of 2.07 mM is satisfactory for the requirements 
of this assay at this stage, since blood glucose levels <2 mM could generally be classed 
as ‘LOW’ when using a POC electrochemical sensor.  By comparison, an Abcam 
enzymatic glucose assay kit (ab65333) (Abcam.com, 2017) for use with a well plate has 
an LoD of 1 µM, has a 40 minute incubation time, and costs £285 for 100 tests, 
whereas the assay described in this project is a fraction of the cost and offers the same 
real world detection range required for a POC glucose assay within 5 minutes. It should 
be noted that it takes 1 hour to print a single device which is not commercially viable 
for mass production, however, the devices are highly customisable and low-cost. 
 The price per 190 µl assay:  ~ 16.4 pence. 
 The price per microfluidic device: ~7.66 pence (2 g) (Ultimaker PLA 
Translucent). 
 Total cost per assay + disposable device: ~24 pence. 
 Total cost for 100 tests: £24 (<10% cost of the Abcam test) 
 (500 µm path length microfluidic cuvettes cost 6 – 9 pence depending on 
filament used) 
In comparison, Freestyle Optium blood glucose test strips cost £22.78 for 50 strips 
(at the time of writing) on Amazon.co.uk (Amazon.co.uk, 2017), however, it is stated 
that the test strips require a minimum of 0.6 µl blood sample to operate and have a 
detection range of 1.1 mM to 27.8 mM. This costing comparison is applicable should 
the user be printing their own devices; commercial purchasing of 3D-printed devices 
would be more expensive due to extra costs such as employee wages, marketing etc. 
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5.3.2 Device Variability 
To investigate the repeatability of the optical properties of the 3D printed devices, 
3D-printed microfluidic cuvette devices, section 5.2.2, were manufactured from a 
selection of transparent PLA filaments: Ultimaker PLA Transparent, Ultimaker PLA 
Translucent, Innofil PLA Natural and InnoPET Natural. Three devices were produced 
from each filament and 5 spectral readings taken from each device, so the inter- and 
intra-filament variability could be observed. Devices were empty and repositioned 
between spectral measurements. The spectra were standardised and the difference 
was compared using the spectral analysis instrumentation described in section 5.2.3 
and the resulting spectra are presented in Figure 5.11. In this data the spectra of a 
polymethylmethacrylate (PMMA) cuvette was standardised and used as 100% intensity 
in order to highlight the spectral difference from the commercial PMMA material and 
the 3D printed samples. All samples were printed at 10 mm/s with 0.06 mm layer 
height. 
 
Figure 5.11: Difference as a percentage of intensity in the spectra of 3D printed 
cuvette devices compared to a PMMA cuvette. 
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All of the plastic filaments show around a 15% increase in the 390 to 700 nm 
region and approximately a 10% decrease from 700 to 1000 nm. The Innofil Natural 
and Ultimaker Translucent plastics have less absorbance in the 390 to 700 nm range 
and appear to have decreased in the 700 to 1000 nm wavelength range. 
Coefficient of variation (CV) is a standardised measure of dispersion of a 
probability distribution; it is widely used to express precision and repeatability. At the 
590 nm absorbance peak of the quinoneimine dye, the inter-filament CV was less than 
1 % and there was a maximum CV of 2.6 % between 390–700 nm. The intra-filament 
CVs are shown in Table 5.1 where the transmission spectrum of each device was 
recorded a total of five times and averaged. Devices were empty and repositioned 
between measurements. CV values were not being compared to a PMMA cuvette. 
Table 5.1: Intra-filament (%) CV 
Filament type CV between devices (n=3) (%) 
Ultimaker translucent 
Ultimaker transparent 
Innofil 
InnoPET 
4 
7 
4 
3 
 
 
For a device to be used as an assay platform, reproducibility is imperative (a CV 
of < 5 % is generally seen as acceptable); any optical differences between 3D-printed 
devices could have an impact on the quantified data leading to inaccurate conclusions. 
While the spectral data showed good reproducibility between absorbance profiles of 
devices made from the same filament batch, the large differences observed between 
filament batches require that a filament specific calibration curve is used for each 
batch of filament to maximise the accuracy of quantitative data produced in each 
device.  
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5.3.3 Blood separation in 3D-Printed Device 
The final principle required to be established, was whether centrifugation 
based whole blood separation could be performed in a low-cost FDM 3D-printed 
microfluidic device. Previous experimentation with liquids in 3D-printed devices 
(section 4.3.5) had mixed results regarding the water-tightness of printed channels. 
The first LOAD device to have its channels filled with red dye, section 4.3.5, showed 
dye permeation from the channels into the surrounding plastic, particularly during 
sample application when the sample was under pressure from the syringe. The 
microfluidic cuvettes, however, showed no evidence of fluid leakage into surrounding 
plastic. As a primary project aim was to perform whole blood separation in a 
3D-printed microfluidic device utilizing centrifugal force, the unpredictable nature of 
the water-tight seal of 3D-printed devices was concerning. The evidence suggested 
fluid would not remain within a 3D-printed device when subjected to the extreme 
forces experienced during centrifugation, in addition, plastic samples had not been 
subjected to centrifugal force, so how they would behave was unknown; the devices 
themselves may not be able to withstand the force. 
A microfluidic pellet device was designed to investigate whole blood separation 
within a 3D-printed microfluidic device. The pellets are described in section 5.2.4 and 
were printed at a rate of 10 mm/second with a layer height of 0.06 mm using PLA 
Transparent. 10 pellet devices were printed per batch. The pellets were filled with 
defibrinated whole horse blood, placed inside 1.5 ml Eppendorf tubes and centrifuged 
using a microcentrifuge at 6000 RPM for 2 minutes. The pellets were designed to be 
centrifuged inside 1.5 ml Eppendorf tubes for two reasons, (1) to contain any blood 
sample that leaked from the devices during centrifugation, and (2) to minimise the risk 
of injury should a device shatter. Examples from the first batch of pellets tested can be 
seen in Figure 5.12 and results in Table 5.2.  
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Figure 5.12: Batch 1 Pellet containing whole horse blood, (A) before centrifugation; 
(B) after centrifugation, (left) partial success with 25% of the blood sample remaining 
and separated, (right) 100% of blood sample leaked out of the pellet. 
 
In every case the pellet remained structurally intact after centrifugation, with 
no evidence of compromise to the structural integrity even after prolonged (30 
minute) centrifugation using a microcentrifuge at 6000 RPM.  
Results were based on 25% thresholds of liquid remaining in the pellet channel 
following centrifugation. It should be noted that blood samples that collected in the 
bottom of the Eppendorf tube had undergone separation, indicating that sufficient 
time and force had been applied for successful plasma separation to occur in all cases. 
7 pellets were unsuccessful, with 0% of the blood sample remaining in the pellet 
channel, having leaked through the base of the pellet and collected in the bottom of 
the Eppendorf tubes. The remaining 3 pellets had 25% of the blood sample remaining 
in pellet channel; despite the majority of blood leaking through the base of the pellets, 
there was clear evidence of blood separation having occurred within the three devices. 
This confirmed two important objectives for the project, firstly that low-cost FDM 
3D-printed microfluidic devices can withstand the forces applied during centrifugation 
without any structural compromise, and secondly that it is possible to separate plasma 
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from whole blood in low-cost FDM 3D-printed microfluidic devices using 
centrifugation.  
Due to the unpredictable results seen, testing continued. A second batch of 
pellets were printed under identical conditions to the first batch. Examples from the 
second batch of pellets tested can be seen in Figure 5.13 and results in Table 5.2. 
                    
Figure 5.13: Batch 2 Pellet containing whole horse blood, (A) before centrifugation; 
(B) after centrifugation. 
 
In contrast to the first batch of pellets tested, the 5 pellets had 50-100% of 
blood sample remained after centrifugation. Of the remaining 5 pellets, 3 had 25% of 
the blood sample remaining in pellet channel and 2 were unsuccessful, with 0% of the 
blood sample remaining in the pellet channel. In all cases, plasma had been separated 
from whole blood with no loss of structural integrity, further confirming and 
reinforcing the principles of whole blood separation in a 3D-printed device. It would 
appear that the water-tightness of 3D-printed devices was primarily based on the 
merging of the strands and layers forming the channel which is dependent on the 
accuracy of the 3D-printer. Variances in the accuracy of strand deposition during 
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printing, as seen in section 4.3.6, would result in inconsistencies in the integrity of the 
channel walls leading to weak points through which liquid can pass through when 
subjected to sufficient force. It is suspected that this is the reason for pellets printed 
under identical conditions within the same batch, displayed large variances in water-
tightness. A better quality 3D-printer may demonstrate more reliable and reproducible 
water-tightness between batches of devices. 
 
Table 5.2: Blood sample (%) remaining in 3D-printed PLA microfluidic pellet after 
centrifugation for 2 minutes at 6000 RPM. 
Pellet 
Blood sample 
(%) remaining: 
Batch 1 
Blood sample 
(%) remaining: 
Batch 2 
1 0 25 
2 0 100 
3 0 100 
4 25 50 
5 0 0 
6 0 75 
7 0 50 
8 25 25 
9 0 25 
10 25 0 
 
 
Following the observed variability in device water-tightness, post-print 
treatments were employed in an attempt to improve the water-seal of devices. First 
efforts utilised acetone liquid treatment to see if treating the surface of the channel 
would reduce imperfections and potentially seal any micro channels/cavities present in 
the channel walls. Pellets were filled with 100% acetone solution, incubated for 30 
seconds, then the acetone liquid was emptied and the pellets flushed with dH2O 
before being left to dry. All attempts were unsuccessful with no improvement 
observed in water-tightness following acetone liquid treatment; the observed 
water-tightness results were similar to those observed in batch 1.  
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Post-print heat treatment was employed to see if incubating the devices at an 
elevated temperature would improve layer and strand merging, increasing 
homogeneity and subsequently improving the water-tightness (3ders.org, 2017). 60 °C 
incubation temperature was chosen for the heat-treatment process as this is the glass 
transition temperature of PLA. Due to the improved properties observed that the 
heated build table (set to 60 °C) imparts on the surface and structure quality it is in 
direct contact with, it was anticipated that incubation at 60 °C may provide similar 
improvements throughout the entire device. 3D-printed pellets were filled with whole 
blood samples and centrifuged for 2 minutes. The remaining blood in the device was 
subsequently quantified. Pellets were flushed with dH2O and allowed to dry before 
being incubated in an oven at 60°C for 2 hours before centrifugation testing again. It 
was decided to use a 2 hour incubation time as it has been recommended that 
heat-treatment performed at < 110 °C should have the incubation time increased from 
≤ 60 minutes (Proto-Pasta.com, 2017).  
Results were based on 25% thresholds of liquid remaining in the pellet channel 
following centrifugation. Examples from the batch of heat-treated pellets that were 
tested can be seen in Figure 5.14 and results in Table 5.3. 
 
 
Figure 5.14: Heat-treated pellets containing whole horse blood after centrifugation. 
Warping to structure and clouding of the plastic is visible.  
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10 pellet devices were subjected to heat-treatment. 3 devices were rendered 
unusable by the process due to severe warping of the pellet devices; the 3 devices 
could not be put inside the Eppendorf tube and therefore were inadmissible. The 7 
remaining samples also suffered warping, however, not to the same degree. All devices 
also showed signs of clouding in the plastic, with a decrease in optical transparency. 
However, blood samples could still be seen through the devices.  
 
Table 5.3: Blood sample (%) remaining in 3D-printed PLA microfluidic pellet after 
centrifugation for 2 minutes at 6000 RPM following heat-treatment at 60 °C for 2 
hours. 
Pellet 
Blood sample 
(%) remaining: 
Before treatment 
Blood sample 
(%) remaining: 
After treatment 
1 25 50 
2 50 100 
3 75 50 
4 75 100 
5 50 50 
6 25 75 
7 50 25 
8 0 x 
9 25 x 
10 75 x 
 
 
4 out of 7 pellet devices showed an increase in water-tightness, with up to 50% 
improvement observed in blood sample remaining after the second centrifugation 
process. 2 out of 7 pellet devices showed a decrease in water-tightness, with up to 
25% reduction observed in blood sample remaining after the second centrifugation 
process. It is possible that the warping to the pellets increased the inter-layer 
weaknesses present rather than improving the layer merging. Across the 4 pellets that 
displayed increased water-tightness, a mean improvement of 37.5% was observed. 
The use of heat-treatment on 3D-printed PLA pellets revealed 2 factors that 
must be considered should the treatment be utilised on devices, (1) heat-treatment of 
PLA devices can cause warping of the structure, which can be extreme in cases 
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rendering the device unusable; (2) heat-treatment causes visible clouding and 
subsequent loss of optical transparency in PLA devices. However, both of these factors 
were not unexpected as certain PLA filaments that are marketed as having ‘improved 
high-temperature performance’ following heat-treatment, are described as changing 
from translucent to opaque in colour and can suffer from deformation following 
heat-treatment (Proto-Pasta.com, 2017). 
Preliminary data suggests that heat-treatment can be used to increase 
water-tightness in 3D-printed FDM PLA microfluidic devices but large statistical 
variation between devices means it is not possible to be unequivocal. The most 
influential factor in a devices water-tightness remains the print process and print 
quality. The use of heat-treatment to improve water-tightness in LOAD devices will be 
explored in future work. 
 
5.3.4 Blood separation in a Low-Cost 3D-Printed FDM Microfluidic 
LOAD Device. 
The work presented in this chapter has so far demonstrated that it is possible 
to perform and quantify blood based optical assays in a low-cost FDM 3D-printed 
microfluidic device (section 5.3.1) and that it is possible to perform whole blood 
separation via centrifugation in a low-cost FDM 3D-printed microfluidic device (section 
5.3.3). This section will detail the changes in the designs of the LOAD made in order to 
perform whole blood separation using centrifugation within a low-cost FDM 
3D-printed microfluidic LOAD device.  
The first stage of development was to observe the existing state of 
water-tightness in initial LOAD platform design to establish if whole blood separation 
can be performed without need for changes to the design. A LOAD device (Figure 4.24) 
was printed from PLA Transparent at 10 mm/s with 0.06 mm layer height and shell 
thickness 0.41 mm, disc plates thickness were: plate 1 (top plate) 200 µm, plate 2 
(channel plate) 400 µm, plate 3 (base plate) 600 µm. The channels were 1 mm wide 
182 Chapter 5: The Performance of a Whole Blood Colourimetric Assay in a 3D-
Printed LOAD Device 
 
Alexander M. Tothill  Cranfield University 
and 400 µm deep with ~ 23 µl volumetric capacity. The channels were filled with whole 
horse blood and the disc placed on the optical drive centrifugation instrumentation as 
described in section 5.2.7. The disc was spun for ~ 5 seconds and the images shown in 
Figure 5.15.  Assuming that channel formation is ideal (ideal cross section = 1 mm x 
400 µm) and that the fill at time 0 is 100%, the volume is approximately 23 µl per 
channel, with approximately 184 µl in total across all 8 channels. The total percentage 
liquid loss across all channels was calculated using Equation 11. 
 
 
Figure 5.15: PLA LOAD microfluidic device with channels filled with whole horse 
blood, (A) before centrifugation; (B) after centrifugation for ~ 5 seconds. 
 
The fluid loss in the channels occurred within 5 seconds, with approximate 70% 
of the total blood volume leaving the channels and permeating into the surrounding 
plastic; there was no evidence of blood separation occurring within the channels. This 
first centrifugation test involving a LOAD device illustrated how porous the devices 
were, as the blood flowed through pre-existing channels within the disc structure. 
Heat-treatment was then applied to a LOAD platform printed under identical 
conditions to investigate if channel water-tightness could be improved. The disc was 
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incubated at 60 °C for 2 hours, after which the device was allowed to cool naturally; 
Figure 5.16 displays a LOAD disc before and after the heat-treatment.  
 
 
Figure 5.16: (A) PLA LOAD microfluidic device before heat-treatment; (B) PLA LOAD 
device after heat-treatment at 60 °C for 2 hours. 
 
First observations gathered from the heat-treated disc was the difference in optical 
transparency; the heat-treated plastic became cloudy (Figure 5.16(B)), however, 
despite a decrease in optical transparency, blood was still visible in the channels. 
Warping was also observed, but not enough to affect device centrifugation capability. 
A time lapse experiment was performed to quantify the passive liquid loss over time 
for a heat-treated LOAD device under these conditions. The total percentage liquid loss 
across all channels was calculated using Equation 11. 
 After 12 hours: liquid loss was calculated at approximately 55% across all 
channels. 
 After 24 hours: liquid loss was calculated at approximately 73% across all 
channels. 
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This demonstrates no improvement in water-tightness over time compared to the 
previous time-lapse performed on an untreated disc in section 4.3.5. Another disc 
printed under identical conditions and subject to the same heat-treatment had its 
channels filled with whole horse blood and the disc was spun for approximately 5 
seconds; the images are shown in Figure 5.17. 
 
   
Figure 5.17: PLA LOAD microfluidic device containing whole blood following 
heat-treatment at 60 °C for 2 hours. (A) before centrifugation; (B) after ~ 5 seconds 
centrifugation. 
 
After the first centrifugation of approximately 5 seconds, the fluid loss from the 
channels was approximately 55% of the total blood volume. Following a further 5 
seconds centrifugation, fluidic loss was 100%. Despite an initial 15% improvement to 
water-tightness compared to the untreated device, (55% vs 70% fluid loss after 
approximately 5 seconds centrifugation), there was no evidence of blood separation 
occurring within the channels.  
Upon inspection of the discs, it was suspected that the method of sample 
introduction using a syringe and hypodermic needle was applying leverage force to 
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plate 1 (top plate) of the disc, potentially causing delamination of the disc layers 
between plate 1 and plate 2, introducing additional weaknesses in the channel walls. 
Therefore, a new pore was designed with an approximate 17° pore angle vs the 
previous 90° angle (Figure 4.19) to allow easier insertion of the needle into the channel 
for sample introduction and to reduce this issue, potentially improving 
water-tightness. The new pore schematics can be seen in Figure 5.29 (P.203). 
It was decided to subject a disc to a longer heat-treatment to investigate the 
effects of excess duration (> 24 hours) heat-treatment on the disks physical properties. 
A LOAD device was printed under the same conditions as before: from PLA 
Transparent at 10 mm/s with 0.06 mm layer height and shell thickness 0.41 mm. The 
disc’s plates thicknesses were: plate 1 (top plate) 200 µm, plate 2 (channel plate) 400 
µm, plate 3 (base plate) 600 µm. Channels were 1 mm wide and 400 µm deep with ~ 
23 µl volumetric capacity. The device was incubated at 60 °C over a weekend for 
convenience. Images can be seen in Figure 5.18. 
 
   
Figure 5.18: PLA LOAD microfluidic device after excess duration (>24 hours) 
heat-treatment at 60 °C, (A) without red dye; (B) with red dye. 
 The disc after heat-treatment is shown in Figure 5.18(B). It was observed that 
the heat-treatment process caused the disc to warp so much so that centrifugation 
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experimentation could not be performed as the disc was not flat enough to come into 
contact with the optical drive spindle motor. The change in optical transparency was 
visually similar to that of the previous heat-treatment of 2 hours, with dye clearly 
visible within the channel; this implies that duration of heat-treatment above 2 hours 
does not increase clouding of the plastic, but further quantitative experimentation will 
need to be performed regarding heat-treatment and decreasing optical transparency 
of PLA. The quantification and description of PLA warping following heat-treatment 
would also be of value.  
 A time lapse experiment was performed to quantify the liquid loss over time for 
a heat-treated LOAD device under these conditions. The total percentage liquid loss 
across all channels was calculated using Equation 11. 
 After 12 hours: liquid loss was calculated at approximately 45% across all 
channels. 
 After 24 hours: liquid loss was calculated at approximately 67% across all 
channels. 
 An improvement in water-tightness of channels was observed following the 
excess duration (> 24 hours) heat-treatment. A summary of the passive fluid loss over 
time experiments is displayed in Table 5.4.   
 
Table 5.4: Summary of passive fluid loss over time following heat-at 60 °C. 
Heat treatment duration Fluid loss after 12 hours Fluid loss after 24 hours 
none 48% 78% 
2 hours 55% 73% 
Excess (>24 hours) 45% 67% 
 
 
Despite the improvement to passive fluid loss, the LOAD device could not be subjected 
to centrifugation testing due to the warping so the practical water-tightness could not 
be compared.  
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To prevent warping of LOAD devices induced by heat-treatment, subsequent LOAD 
devices would be covered with a sheet of tin foil and two 40g desiccant tins placed on 
top during heat-treatment. It had also been observed that disc diameter would shrink 
during heat-treatment on average 5.6%; the diameter of 10 discs was measured before 
and after being subjected to excess duration (> 24 hours) heat-treatment at 60 °C. 
Therefore 15 mm outer diameter washers would be placed into the spindle hole during 
heat-treatment to maintain spindle accessibility should the discs shrink; this prevented 
the requirement for physical enlargement of the spindle hole following excess duration 
(> 24 hours) heat-treatment. 
So far, experimentation with heat-treatment alone had not been successful in 
creating a microfluidic LOAD device capable of performing centrifugation based whole 
blood separation. It was decided at this point that the fundamental disc parameters, 
specifically the 1.2 mm total disc thickness, be relaxed. It was believed that, despite 
appearances, the channels were not being adequately sealed above or below the 
channel. Therefore, additional layers were added to the CAD model to plate 1 (top 
plate) and plate 3 (base plate); the parameters of plate 2 (channel plate) remained the 
same.  
Plate 1 and plate 3 were increased in thickness, in 100 µm increments, and 
tested with and without heat-treatment at 60 °C for 2 hours; LOAD device dimensions 
progressed up to: plate 1 (top plate) 800 µm and plate 3 (base plate) 800 µm. Plate 2 
(channel plate) was not changed and remained 400 µm, with the channels remaining 1 
mm wide and 400 µm deep with ~ 23 µl volumetric capacity. Total device thickness 
increased from 1.2 mm to 2 mm; the increase in device thickness increased print time 
from 5.5 hours to 9.3 hours and filament consumption from 9g to 15g compared to a 
1.2 mm thick disc. All devices were capable of being spun using the ODD 
instrumentation, despite being up to 800 µm thicker than a regular optical disc. 
However, experiments failed to produce evidence of whole blood separation, with the 
fluid sample leaking into surrounding plastic in every device. Despite increasing the 
thickness of plate 1 by 100% (from 400 to 800 µm) and plate 3 by approximately 33.3% 
(from 600 to 800 µm), the blood samples continued to leak out of the channel and into 
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the surround plastic as soon as centrifugal force was applied. It was suspected that 
rather than the fluid leaking above and below the walls as was previously thought, the 
fluid was passing through the walls themselves via weak points that exist between the 
layers.  
Samples printed for experiments have demonstrated varying levels of 
water-tightness; pellet devices (section 5.2.3) demonstrated superior water-tightness 
compared to LOAD devices when subjected to centrifugal force. It was suspected that 
the construction process, specifically the print orientation relative to the build table, 
had a large impact on the inherent water-tightness of a device. Pellet device channels 
were orientated orthogonal to the build table, whereas the LOAD device channels 
were parallel to the build table. The result of this was orthogonal channels did not 
have layers, and the subsequent interlayer weaknesses, located where fluid would be 
forced against it, whereas parallel channels did. Orthogonal channels had less 
inter-layer weak points relative to parallel channels, which must withstand and contain 
the fluid when centrifugal force was applied. This is illustrated in Figure 5.19.  
 
Figure 5.19: Illustration of channels printed (A) orthogonal to the build table; (B) 
parallel to the build table. The arrow indicates motion of fluid when centrifugal force 
is applied.  
As the LOAD devices could not be printed in another orientation whilst 
maintaining channel structure, optical transparency, device quality and surface finish, 
it was decided that wall structure must be improved without changing the print 
orientation. It was suspected that increasing the shell thickness, a print parameter in 
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Cura that defines ‘walls’ within a print, would increase the number of PLA strands 
deposited to define the channels. When a CAD file is uploaded to the Cura software, 
the ‘shell’ or ‘walls’ are used to define the physical edges of the object relative to open 
space. The solid space within the shell is defined as ‘fill’. When printing an object, shell 
strands are deposited first in the layer to construct the edges, and then fill strands are 
deposited to fill the solid space. Fill percentage can be adjusted depending on how 
solid the object is required. For a completely solid object, a fill percentage of 100% is 
used. Fill strands are deposited in a way that minimises the tool path of the nozzle, and 
as a result, the fill strand orientation in the X Y plane is independent of the shell strand 
orientation. This can result in weaknesses in the shell strand integrity if the fill strands 
are deposited in such a way that they interrupt the shell strands (due to inaccurate fill 
deposition by the printer). By increasing the shell thickness, the number of strands 
used to define the edges within a layer can be increased, which can increase the 
strength/integrity of the walls and reduce weakness introduced by the fill strands 
overlapping the wall strands. This is illustrated in Figure 5.20.  
 
Figure 5.20: LOAD device as seen in Cura software. (A) 0.41 mm shell thickness; (B) 2 
mm shell thickness.  
In Figure 5.20, the red lines are the outer shell wall (bordering open space), the 
green lines are the inner shell wall, the yellow region is fill and blue lines are 
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movements the print head will make without extruding (not relevant to this 
discussion).  
As can be seen in Figure 5.20, when the shell thickness is 0.41 mm there is a 
single strand defining the outer edges (red lines). Any inaccuracy when the fill strands 
(yellow region) are being deposited could compromise the integrity of the shell. When 
the shell thickness is 2 mm, the shell definition is reinforced with additional strands 
(green lines) that are deposited in line/parallel with the edges, reducing any impact on 
surface structure from inaccuracies when fill strands are being deposited. 
Previously all prints had been performed using a shell thickness of 0.41 mm for 
print accuracy, as this was the closest value to the nozzle head extrusion diameter that 
could be successfully interpreted by the Cura software. The investigation proceeded by 
observing the effect of increased shell thickness on water-tightness; shell thickness 
specified was increased from 0.41 mm to 1 mm in the Cura software. Disc dimensions 
would remain: plate 1 800 µm, plate 2 400 µm, plate 3 800 µm, print speed 10 mm/s, 
layer height 0.06 mm. The increased shell thickness resulted in the need to remove 
four of the channels. 10 LOAD devices were printed, with a selection being subjected 
to excess duration (> 24 hours) heat-treatment at 60 °C then being allowed to cool 
naturally. Whole blood was introduced to the channels and devices were spun for 
approximately 5 seconds; images can be seen in Figure 5.21.  
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Figure 5.21: PLA LOAD device containing whole blood. (A) before centrifugation; (B) 
after ~ 5 second centrifugation; (C) after excess duration (> 24 hours) heat-treatment 
at 60 °C before centrifugation; (D) after excess duration (> 24 hours) heat-treatment 
at 60 °C after ~ 5 second centrifugation. 
As can be seen in Figure 5.21, the increased wall thickness of 0.41 mm to 1 mm 
was not successful in sealing the channels; fluid continues to leak into surrounding 
plastic, therefore shell thickness was increased further. The shell thickness was 
increased from 1 mm to 2 mm.  
It has been suggested that putting thermal stress relief holes through 
3D-printed objects could promote even cooling throughout the parts and reduce 
warping due to thermal stress (Herrmann et al., 2014). Due to the loss of 4 channels, 
free space became available in the model in which holes could be introduced to 
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explore this and potentially remove the requirement for weights being used to prevent 
warping during the heat-treatment process. The introduction of thermal stress relief 
holes did not reduce warping induced by the heat-treatments so the prints continued 
to be weighed down during heat-treatments. However, a positive consequence of this 
was a reduction in disc print time and filament consumption. The inclusion of holes 
decreased print time from 9.3 hours to 8.5 hours and filament consumption from 15g 
to 14g compared to a 2 mm thick disc without holes, however, this is still ~34% longer 
than a 1.2 mm thick disc with 8 channels.  
10 devices were printed with the following dimensions: plate 1 800 µm, plate 2 
400 µm, plate 3 800 µm, print speed 10 mm/s, layer height 0.06 mm, shell thickness 2 
mm, channels remain 1 mm wide and 400 µm deep with ~ 23 µl volumetric capacity. 3 
devices were subjected to heat-treatment at 60 °C for 2 hours, and 3 were subjected 
to excess duration (> 24 hours) heat-treatment at 60 °C. Devices were allowed to cool 
naturally, then whole blood was introduced to the channels and devices were 
centrifuged for ~ 5 seconds. Devices that were not subjected to heat-treatment and 
those subjected to 2 hour heat-treatment were unsuccessful in separating whole 
blood; as before, the blood leaked into the surrounding plastic. Devices subjected to 
excess duration (> 24 hours) heat-treatment can be seen in Figure 5.22. 
The devices were centrifuged for ~ 5 seconds, and then the results observed. As 
seen in Figure 5.22(B), one channel lost 100% of sample into surrounding plastic, 
however the other channel showed no signs of sample loss and evidence of blood 
separation occurring. As can be seen in Figure 5.22(C), there is clear and significant 
separation of blood plasma from whole blood (~10 µl plasma from 23 µl of whole 
blood), with red cell solids collecting at the bottom of the channel and clear blood 
plasma towards the top half of the channel. The unsuccessful channel, Figure 5.22(D), 
has been included for a direct comparison of colour difference between the empty 
channel and successful plasma separation. It is unknown exactly why one channel 
failed and one was sealed, however, it was suspected that there was an inter-layer 
weakness that could not rectified by heat-treatment. This again displays the variation 
193 Chapter 5: The Performance of a Whole Blood Colourimetric Assay in a 3D-
Printed LOAD Device 
 
Alexander M. Tothill  Cranfield University 
in strand deposition accuracy and the subsequent shell integrity that can occur within 
samples. 
   
Figure 5.22: 2 mm shell thickness PLA LOAD device containing whole blood after 
excess duration (> 24 hours) heat-treatment at 60 °C, (A) before centrifugation; (B) 
after ~ 5 seconds centrifugation; (C) successful blood separation in microfluidic LOAD 
channel; (D) unsuccessful channel. 
 
Following a further centrifugation period of ~ 10 seconds one of the channels 
showed no signs of fluid loss into surrounding plastic and a fluid decrease of < 5% after 
a total centrifugation period of ~ 20 seconds. As assay performance displays 
observable colour generation within 5 seconds, an incubation period of < 20 seconds is 
achievable with further enzyme optimisation; this would provide potential for a total 
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assay and centrifugation time of < 20 seconds. The combination of increased shell/wall 
thickness and heat-treatment resulted in the successful water-sealing of a low-cost 
3D-printed FDM PLA microfluidic channel in a LOAD device, so that whole blood 
separation can be performed in ~ 23 µl of whole blood and blood plasma can be 
viewed inside the channels; a key objective and obstacle in developing a 3D-printed 
POC LOAD device. 
Further alterations to devices were performed in an attempt to improve the 
water-tightness across all channels. As it was observed that increasing shell thickness 
improved water-tightness by reinforcing the channel walls with additional strands, it 
was possible that increasing layer height, and subsequently decreasing the number of 
layers and inter-layer weak points/ imperfections in channel walls, would also improve 
the water-tightness. So far all LOAD devices have been printed with 0.06 mm layer 
height, as this demonstrated the best optical transparency in devices. However, as has 
been demonstrated, colour change can be seen in devices with relatively poor optical 
transparency. Therefore, layer heights of 0.1 mm and 0.2 mm were investigated in an 
attempt at reducing the number of layers used to construct the disc, therefore, 
reducing the number of potential inter-layer weak points; illustrated in Figure 5.23. 
 
Figure 5.23: Illustration of channels printed with varying layer heights: (A) 0.06 mm; 
(B) 0.1 mm; (C) 0.2 mm. 
10 devices were printed with the following dimensions: plate 1 800 µm, plate 2 
400 µm, plate 3 800 µm, print speed 10 mm/s, layer height 0.1 mm and 0.2 mm, shell 
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thickness 2 mm, channels were 1 mm wide and 400 µm deep with ~ 23 µl volumetric 
capacity. 4 devices were subjected to heat-treatment at 60 °C for 2 hours. Devices 
were allowed to cool naturally, then whole blood was introduced to the channels and 
devices were centrifuged for ~ 5 seconds. Devices with 0.2 mm layer height, both 
untreated and heat-treated, were unable to separate whole blood; as before, the 
blood leaked into the surrounding plastic. It is suspected that the poor layer 
homogeneity and strand merging that introduced poor optical transparency in 
previous experiments, was responsible for weaknesses in the channel walls.  
Untreated devices printed with 0.1 mm layer height were capable of separating 
whole blood, as can be seen in Figure 5.24, however, ~30% fluid was lost during the ~ 5 
second centrifugation, which is inferior to the previous successful result of < 5% fluid 
loss after ~20 seconds centrifugation and significantly less plasma was separated (~3 µl 
plasma from ~23 µl whole blood). Despite this, this demonstrates that low-cost FDM 
3D-printed microfluidic LOAD devices are capable of being used for the centrifugation 
of ~ 23 µl whole blood without any post-print treatments being applied. The potential 
exists for optimisation to further improve the water-tightness of the LOAD channels to 
improve fluid retention and plasma yield, and to negate the requirement for any 
post-print treatments. 
     
Figure 5.24: 0.1 mm layer height PLA LOAD device containing whole blood, (A) before 
centrifugation; (B) after ~ 5 seconds centrifugation; (C) blood separation in 
microfluidic LOAD channel. 
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Devices printed with 0.1 mm layer height that were subjected to 
heat-treatment of 60 °C for 2 hours were also capable of separating whole blood, as 
can be seen in Figure 5.25, however, ~85% fluid was lost during the ~ 5 second 
centrifugation which is inferior to the untreated device results (Figure 5.24) of ~ 30% 
fluid loss after ~5 seconds centrifugation and only ~1.5 µl plasma was produced from 
~23 µl whole blood. 
     
Figure 5.25: 0.1 mm layer height PLA LOAD device containing whole blood after 60 °C 
heat-treatment for 2 hours, (A) before centrifugation; (B) after ~ 5 seconds 
centrifugation; (C) blood separation in microfluidic LOAD channel.  
 
The results presented in this section have demonstrated that it is possible to 
centrifuge whole blood and to produce plasma within a 3D-printed microfluidic LOAD 
device. Post-print excess duration (>24 hours) heat-treatment at 60 °C was used in 
combination with print and device optimisation to create a water-tight channel in a 
device that could withstand ~20 seconds of centrifugation, which was sufficient time to 
produce ~10 µl plasma from ~23 µl whole blood. 
It was suspected that the inconsistency of the effectiveness of heat-treatment 
on water-tightness could be attributed to the inaccuracy and inconsistency of the 
3D-printer strand deposition, as varying degrees of channel water-tightness were 
observed between channels on the same device. This reemphasises the importance of 
printer quality and the role it plays determining whether a device will be viable. It was 
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suspected that post-print treatments could be used to improve the water-tightness of 
channels, but the channels must already have acceptable channel wall integrity and 
therefore a high degree of water-tightness. Further experimentation and optimisation 
improving water-tightness is necessary to produce consistent results. It is likely that a 
3D-printer with improved accuracy of strand deposition would have better print 
consistency and therefore more consistent water-tightness across devices for 
optimisation to be truly effective. 
 
5.3.5 Performing the Glucose Assay in Whole Blood and Centrifugation 
in a Low-Cost FDM 3D-Printed Microfluidic LOAD Device. 
The final stage of LOAD device development was to perform the glucose assay 
in whole blood and separate quinoneimine dye coloured plasma within a LOAD device. 
The 3 LOAD devices in which plasma separation was performed, described in 
section 5.3.4, were used to perform the assay experimentation. Only 2 channels were 
utilized during the whole blood centrifugation experiments, leaving 2 channels per 
device available for assay testing. As every channel on each device had different 
properties, it was uncertain whether the remaining channels would be capable of 
separating whole blood and producing coloured plasma, however, as the other 
channels on each device demonstrated some degree of capability it was anticipated 
that at least 1 of the remaining channels would be viable. Assay experimentation was 
performed within 2 hours of the initial centrifugation experiments. 
Glucose assay reagent solution was made by dissolving CTA (20 mM), AAP (10 
mM), GlOx (20 U/ml) and HRP (6 U/ml) in defibrinated whole horse blood. The reaction 
was started by adding glucose solution (10 mM). The assay was applied to the LOAD 
channels, incubated for 2-minutes, and then centrifuged using the ODD for ~5 seconds. 
The first LOAD device tested using the assay in whole blood was the only device 
to separate whole blood without having being subjected to heat-treatment (Figure 
5.23). To recap: the LOAD device was printed with the following dimensions: plate 1 
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800 µm, plate 2 400 µm, plate 3 800 µm, print speed 10 mm/s, layer height 0.1 mm, 
shell thickness 2 mm, channels 1 mm wide and 400 µm deep with ~ 23 µl volumetric 
capacity. The disc was not subjected to heat-treatment before testing. The assay-blood 
sample was prepared, applied to the disc and centrifuged as described above and in 
section 5.2.7. The results can be seen in Figure 5.26. 
     
Figure 5.26: 0.1 mm layer height PLA LOAD device containing whole blood, (A) before 
centrifugation; (B) after ~ 10 seconds centrifugation; (C) blood separation and colour 
generation in microfluidic LOAD channel.  
 
It can be seen from Figure 5.25(C) that, despite ~10.4 µl fluid loss during 
centrifugation (~45%), the whole blood was successfully separated and ~3.2 µl of 
coloured plasma is clearly visible in the channel. While the channel water-tightness 
was inferior to the whole blood separation previously performed in this device (~30% 
fluid loss), plasma generation performance remained the same.   
The second LOAD device to be tested using the assay in whole blood had 0.1 
mm layer height wand was subjected to heat-treatment (Figure 5.24). To recap: the 
LOAD device was printed with the following dimensions: plate 1 800 µm, plate 2 400 
µm, plate 3 800 µm, print speed 10 mm/s, layer height 0.1 mm, shell thickness 2 mm, 
channels 1 mm wide and 400 µm deep with ~ 23 µl volumetric capacity. The disc was 
subjected to heat-treatment at 60 °C for 2 hours, and was allowed to cool naturally 
before testing with whole blood. The assay-blood sample was prepared, introduced to 
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the channels and centrifuged as described above and in section 5.2.6. The results can 
be seen in Figure 5.27. 
 
     
Figure 5.27: 0.1 mm layer height PLA LOAD device containing whole blood after 60 °C 
heat-treatment for 2 hours, (A) before centrifugation; (B) after ~ 5 seconds 
centrifugation; (C) blood separation and colour generation in microfluidic LOAD 
channel. 
 
As can be seen in Figure 5.27(C), the channel had superior water-tightness (~8 
µl, ~35% fluid loss) and plasma production (~2.4 µl) compared with the initial blood 
separation performed in this device (~85% fluid loss and ~1.5 µl plasma produced). 
Despite the low volume of plasma produced in the channel, the remaining plasma is 
visibly coloured by the glucose assay reaction.  
The third and final LOAD device to be tested using the assay in whole blood was 
the first and most successful device in which whole blood separation was 
demonstrated (Figure 5.22). To recap: the LOAD device was printed with the following 
dimensions: plate 1 800 µm, plate 2 400 µm, plate 3 800 µm, print speed 10 mm/s, 
layer height 0.06 mm, shell thickness 2 mm, channels 1 mm wide and 400 µm deep 
with ~ 23 µl volumetric capacity. The disc was subjected to excess duration (>24 hours) 
heat-treatment at 60 °C, and was allowed to cool naturally before testing with whole 
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blood. The assay-blood sample was prepared, applied to the disc and centrifuged as 
described above and in section 5.2.6. The results can be seen in Figure 5.28. 
 
 
Figure 5.28: 0.06 mm layer height PLA LOAD device containing whole blood after 
excess duration (>24 hours) heat-treatment at 60 °C, (A) before centrifugation; (B) 
after ~ 5 seconds centrifugation; (C) blood separation and colour generation in 
microfluidic LOAD channel; (D) comparison of whole blood separation without assay 
reagents (left) and with assay reagents (right). 
 
Following the assay-blood centrifugation, it is clear that this device contains 
channels of superior water-tightness when compared to the others tested. After ~ 10 
second centrifugation the fluid loss from the channel was ~3.6 µl (~15%) and with ~8.8 
µl of coloured plasma remaining in the channel as can be seen in Figure 5.28(C). Figure 
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5.28(D) shows two successful channels on the same device displaying the distinct 
colour difference between the basic unreacted plasma (left) and the plasma containing 
quinoneimine dye from the glucose assay that was performed in the whole blood 
sample (right). 
The final specifications for the LOAD device developed are as follows, the most 
successful options are underlined, schematics can be seen in Figure 5.29: 
 90 mm diameter with 15 mm diameter spindle hole at the centre, 2 mm total 
thickness, 
 Plate 1 (top plate) 800 µm thickness,  
 Plate 2 (channel plate) 400 µm thickness,  
 Plate 3 (base plate) 800 µm thickness, 
 4 U-bend channels with 1 mm width and 400 µm depth with approximately 23 
µl volumetric capacity positioned in plate 2. Pores have ~17° angle for sample 
introduction. 
 Print speed: 10 mm/s, layer height 0.06 mm or 0.1 mm, shell thickness 2 mm. 
 Heat-treatment: None / 60 °C for 2 hours / 60 °C for excess duration (>24 
hours). 
 Print time per device:  8.5 hours (0.06 mm layer height); 5 hours (0.1 mm layer 
height). 
 Extrusion temperature 200 °C 
 Cost per device using Ultimaker PLA Transparent:  57 pence, ~14g filament.  
 Cost per device: 43-71 pence depending on filament used. 
 
The final assay specifications for glucose or cholesterol quantification range of 0-10 
mM are: 
 20 mM chromotropic acid (CTA),  
 10 mM 4-aminoantipyrine (AAP),  
 6 U/ml horseradish peroxidase (HRP),  
 20 U/ml glucose oxidase (GlOx) or cholesterol oxidase (ChOx), 
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 Glucose assay price per 23 µl channel: ~ 2 pence, 
 Cholesterol assay price per 23 µl channel: ~ 58 pence, 
 
  
Figure 5.29: Schematics of final LOAD design, channel capacity ~23 µl. (A) Device 
specifications and channel layout; (B) channel specifications; (C) pore specifications; 
(E) cross-sectional specifications.  
 
It has been demonstrated that whole blood optical assays and centrifugation 
based whole-blood separation can be performed within a low-cost 3D-printed FDM 
microfluidic LOAD device. All successful devices were capable of being spun using an 
unmodified optical disc drive and coloured blood plasma produced and clearly visible 
within the channels ≤ 10 seconds centrifugation time.  
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 Conclusions 5.4
A colourimetric glucose assay capable of distinguishing between a range of glucose 
concentrations (0-10 mM) in whole blood has been used to demonstrate the capability 
and functionality of FDM 3D-printed microfluidic devices. The glucose assay was 
performed in an FDM 3D-printed microfluidic cuvette device with 500 µm sample path 
length. Absorbance data was gathered during testing that shows that it is possible to 
quantify colourimetric assay data in a low-cost FDM 3D-printed device.  
Each device cost ~7.6 pence (2g filament), which is comparable to purchasing standard 
disposable PMMA cuvettes which cost approximately 7 pence each (Sigma-Aldrich, 
2016b), resulting in an economical device that can be custom designed and built to the 
users’ requirements without having to wait for purchasing or delivery. This provides 
the potential for the user to print their own highly customisable devices in the 
laboratory. 
The cuvette devices demonstrated water-tightness, with no sample leakage. The use of 
an enzymatic cascade demonstrated that a multistage assay process can be performed 
within the device as a single user step. It has been previously thought that the poor 
optical transparency of low-cost FDM 3D-printed polymers is a fundamental obstacle 
that considerably limits their potential to fabricate optically interrogated devices 
(Willis et al., 2012). Furthermore, the variability and error in low-cost FDM printers was 
thought to limit their use in fabricating microfluidic structures, however, it has been 
demonstrated that accurate quantification of absorbance data can be performed in 
devices printed using a low-cost FDM 3D-printer. Further investigation is required into 
secondary adsorption phenomena that may influence the analytical spectroscopy and 
reproducibility of data involving 3D-printed PLA devices however the use of PLA in 
biochemical devices is already established (Pioggia et al., 2007; Kadimisetty et al., 
2016). 
Microfluidic cuvette devices with a channel width of 100 µm were also manufactured 
which are 66% narrower than the minimum channel width possible using the closest 
comparable commercial device currently on the market, the Dolomite Fluidic Factory 
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(Dolomite, Royston, UK). The Fluidic Factory FDM 3D-printer has a minimum channel 
width limitation of 300 µm, costs £14,000 and requires print material only available 
from their website for £350 per 60 m reel. The price per metre for the Dolomite cyclic 
olefin copolymer is approximately £5.83 compared to the Ultimaker PLA Transparent 
price per metre of approximately 33 pence. The Dolomite Fluidic Factory is unable to 
print the LOAD microfluidic devices developed and demonstrated in this project due to 
the limited print volume of 80mm x 50mm x 25mm. However if it could, the price per 
500 µm microfluidic cuvette would be £1.34 and per LOAD device it would be £10.08; 
this is compared to 7.6 pence and 57 pence respectively for the same devices printed 
using the Ultimaker 2+ and Ultimaker PLA Transparent filament. This demonstrates the 
significant potential reduction in manufacturing costs possible when low-cost (< 
£2000) FDM 3D-printing technology and low-cost (< £50 per reel) print filament is 
optimised for the production of microfluidic devices; this is the difference between 
producing low-cost disposable devices that are suitable for a point-of-care setting and 
expensive devices that would need to be cleaned and reused to maintain financial 
viability. 
Whole blood separation was performed in 3D-printed microfluidic pellets with a 
volumetric capacity of ~112 µl to demonstrate the capability of low-cost FDM devices 
in performing centrifugation using significantly less volume of blood than traditional 
methods that typically require >1 ml. The optimised pellet devices displayed sufficient 
water-tightness to withstand the centrifugal forces required to separate whole blood, 
a significant obstacle in FDM 3D-printed devices. 
The progression of investigation culminated in the design and manufacture of a 
low-cost FDM 3D-printed microfluidic lab-on-a-disc device that was capable of 
performing centrifugation based whole blood separation within 10 seconds and 
viewing optical quantitative assays within. Despite the LOAD devices being thicker than 
anticipated, at 2 mm vs 1.2 mm of a normal optical disc, this was not shown to be an 
issue as all discs were capable of being spun using the unmodified optical disc drive. In 
addition, discs can be designed so that region around the central spindle hole is 1.2 
mm thick should it be required for spindles with locking clips. Further optimisation is 
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required to reliably and consistently produce LOAD devices with sufficient 
water-tightness for centrifugation purposes. Due to difficulties in water-sealing the 
LOAD devices and inconsistent load performance at this stage, time constraints meant 
that quantification of glucose in whole blood using a LOAD device was not performed. 
However, the accurate quantification of absorbance within a FDM 3D-printed 
microfluidic device has already been demonstrated using the cuvette devices, which 
have a similar sample path length (500 µm) to that of the LOAD devices (400 µm). 
Further investigation will be necessary into secondary adsorption phenomena that 
may influence the analytical spectroscopy and reproducibility of data involving 3D-
printed PLA devices. 
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 General Conclusions  6.1
 Health care establishments globally are overworked, underfunded and 
understaffed. With an increasing aging population and the exponential increase in 
people developing cardiovascular disease and diabetes, the dependence and pressure 
on healthcare services could potentially rise to unsustainable and dangerous levels. A 
consequence of this is the increasing reliance on point-of-care (POC) diagnostic and 
quantitative devices as an attempt at relieving the burden being placed on healthcare 
professionals and pathology departments in hospitals.  
Whilst many industrial microfluidics are produced using injection moulding, this is a 
costly production method for research labs (Fiorini and Chiu, 2005) as each design 
change can cost as much as £2750 to have the moulds made. The use of low-cost FDM 
3D-printing in device fabrication would allow researchers to prototype various 
microfluidic systems quickly and cheaply, both reducing the cost and time for 
development of a microfluidic platform. 3D-printing also allows for structures and 
shapes that are not possible in injection moulding and could open up new three 
dimensional designs in microfluidics. 
The aim of this project was to investigate the use of 3D-printing in the development 
and manufacture of a low-cost lab-on-a-disc (LOAD) device with multiple imbedded 
microfluidic channels. The device needed to have sufficient optical transparency that 
optical assays can be performed within. The existence of multiple separate channels 
would mean the quantification of multiple analytes could be performed 
simultaneously on a single device, reducing operator workload, providing a panel of 
diagnostic and quantitative data and mitigating previous concerns regarding accuracy 
of POC testing. The device was intended to be capable of separating plasma from 
whole blood via centrifugation ≤ 2 minutes and to be used with an unmodified optical 
disc drive (ODD). It was hoped, that if successful, the combination of low-cost (< 
£2000) fused deposition modelling (FDM) 3D-printing technology with a microfluidic 
LOAD could provide POC functionality, portability and affordability with the diagnostic 
capability of laboratory tests. 
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Three fundamental principles had to be demonstrated to establish the feasibility of 
using low-cost FDM 3D-printing technology as a means of developing and 
manufacturing microfluidic LOAD assay devices for use with whole blood samples. 
1. Imbedded microfluidic channels can be formed using a low-cost FDM 
3D-printer. 
2. Quantitative whole blood optical assays can be performed in a low-cost FDM 
3D-printed microfluidic device. 
3. Separation of plasma from whole blood via centrifugation can be performed in 
a low-cost FDM 3D-printed microfluidic device. 
The work performed over the course of this thesis demonstrated all three of the 
principles and culminated in the development of a LOAD device with imbedded 
microfluidic channels and centrifugation based plasma separation from whole blood 
utilising an unmodified optical disc drive (ODD). Improvements made to the optical 
transparency of 3D-printed devices provide the potential of performing quantitative 
colourimetric whole blood assays within. The development process of the LOAD device 
involved many minor but cumulative and necessary changes; all iterations were 
manufactured and physically examined, which would not have been possible if being 
developed using traditional manufacturing techniques. 
This demonstrates that despite more expensive 3D-printing technology existing, 
low-cost consumer grade FDM 3D-printing technology and print materials have the 
potential for developing and manufacturing low-cost POC diagnostic devices that are 
highly customisable and capable of performing multiple whole blood centrifugations 
and quantitative assays simultaneously using existing unmodified ODDs as reader 
devices. It should be noted that the more expensive 3D-printing technologies have 
higher resolution and better accuracy, which can improve the optical properties and 
performance of the devices. However, these systems can cost as much as £150,000 
which is beyond the budget of many research laboratories and render the cost per 
consumable device prohibitive in many applications. 
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 Development of an Optical Cholesterol and Glucose Assay 6.2
The experiments presented demonstrate a quantification method for cholesterol 
in whole blood and glucose in whole blood. It was shown that cholesterol oxidase or 
glucose oxidase, horseradish peroxidase, chromotropic acid and 4-aminoantipyrine 
when mixed together produce an enzymatic cascade and optical reaction that can 
distinguish between a range of analyte concentrations in various solution mediums 
including whole blood. Testing showed that the absorbance curves can be shifted up or 
down according to incubation time, enzyme concentration and to a lesser extent 
chromotropic acid concentration. This allows the assay to be calibrated to the 
requirements of the optical device recording absorbance and the assay platform and 
allow accurate quantification of cholesterol and glucose by increasing or decreasing 
colour intensity. The final assay reagent concentrations were as follows: chromotropic 
acid (20 mM), 4-aminoantipyrine (10 mM), horseradish peroxidase (6 U/ml), 
cholesterol oxidase or glucose oxidase (20 U/ml). The current study has been 
attempting to quantify free cholesterol in whole blood. The reaction can be expanded 
to quantify total cholesterol in blood through the addition of cholesterol esterase into 
the enzyme mixture. However, this has yet to be implemented at this stage. 
Cholesterol and glucose colourimetric assays have been developed in this work 
successfully that produce distinct absorbance curves in the 650 nm region, the 
wavelength of a DVD optical drive laser, therefore a standard unmodified DVD ODD 
laser diode has the capability of quantifying absorbance changes in these assays. 
 
 LOAD Device Design, Manufacture and Optimisation 6.3
It has been previously thought that the poor optical transparency of low-cost 
FDM 3D-printed polymers is a fundamental obstacle that considerably limits their 
potential to fabricate optically interrogated devices (Willis et al., 2012). Furthermore, 
the variability and error in low cost (< £2000) FDM printers was thought to limit their 
use in fabricating microfluidic structures. In this work it has been demonstrated that 
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through printer calibration and print optimisation, it is possible to improve optical 
transparency of FDM 3D-printed devices such that colourimetric optical assays can be 
viewed within. In addition, visible imbedded microfluidic channels with a volumetric 
capacity of approximately 23 µl have been successfully manufactured in a LOAD device 
as a single manufacturing step without the need for any post-print treatment 
techniques. The LOAD devices developed at this stage of the project would be suitable 
vessels for performing multiple parallel colourimetric assays simultaneously for optical 
quantification, despite not being suitable for centrifugation purposes at the time. 
When acetone vapour treatment (Naga et al., 2013) was used, it was possible to 
improve the transparency of plastic samples by up to a further 30%. While not 
applicable to microfluidics this highlights that for some applications it is possible to 
further improve sensitivity and surface quality of devices manufactured using low-cost 
3D-printers with simple post-processing techniques. Acetone liquid treatment 
displayed significant potential for reducing the surface roughness of microfluidic 
channels by up to 32%, which provides a low-cost method of further improving 
inaccessible microfluidic surfaces. In this work, a key fundamental principle was 
demonstrated, that imbedded microfluidic channels can be formed using a low-cost 
FDM 3D-printer. 
 
 The Performance of a Whole Blood Colourimetric Assay in a 6.4
Low-Cost FDM 3D-Printed LOAD Microfluidic Device  
 Microfluidic cuvette devices with channels ranging from 100 - 500 µm wide 
were designed and manufactured in this work. Each device cost approximately 7.6 
pence (2 g filament) rivalling commercially available PMMA cuvettes which cost 
approximately 7 pence each. The optimised colourimetric whole blood glucose assay 
was performed in a 500 µm path length microfluidic cuvette and was capable of 
distinguishing between a range of glucose concentrations (0-10 mM) which has been 
used to demonstrate the capability and functionality of the printed devices. The 
absorbance data gathered during testing shows that it is possible to quantify 
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colourimetric assay data in a low-cost FDM 3D-printed microfluidic device. The use of 
an enzymatic cascade demonstrates how a multistage assay process can be performed 
within the device as a single user step. The microfluidic cuvette devices were produced 
in a single manufacturing step and required no post-print treatment techniques for the 
generation of calibration curves. This demonstrates the second key fundamental 
principle required as set out in the aims and objectives for the project. 
Whole blood centrifugation was performed in 3D-printed pellet devices to investigate 
and demonstrate if plasma can be separated from whole blood via centrifugation using 
a FDM 3D-printed device. Clear plasma was separated from whole blood in 3D-printed 
pellet devices which demonstrated the third and final key fundamental principle.  
The final stage of the project attempted to combine the whole blood colourimetric 
assays previously developed, with a FDM 3D-printed microfluidic LOAD device in order 
to demonstrate the three key principles in a single FDM 3D-printed microfluidic POC 
device. The aim was to investigate the performance of whole blood separation in a 
LOAD device and produce coloured plasma from which absorbance data could 
potentially be gathered. Through further print and design optimisation, the 
centrifugation based separation of coloured plasma from the whole blood glucose 
assay was performed in a LOAD device using an unmodified ODD. LOAD devices were 
designed and produced in a single manufacturing step and untreated devices displayed 
evidence of successful coloured plasma generation following centrifugation; however, 
the devices subjected to post-print heat-treatment demonstrated superior evidence 
compared to the untreated devices. Each load device contained 4 embedded 
microfluidic channels with a volumetric capacity of approximately 23 µl and cost pence 
57 pence each (14 g filament). Due to time constraints, the generation of a calibration 
curve in a LOAD device was not possible; however, the fundamental principle has 
already been demonstrated in the microfluidic cuvette devices. This demonstrates that 
it is possible to use low-cost readily available FDM 3D-printing technology and print 
materials to design, develop and manufacture viable POC LOAD device capable of 
utilising existing unmodified ODDs to perform centrifugation based whole blood 
separation within 10 seconds and quantitative assays.  
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 Limitations 6.5
 The primary advantages and disadvantages of the low-cost FDM 3D-printing 
technology and 3D-printed devices are summarised below.   
Advantages 
 Low relative upfront costs, < £1500 for the 3D-printer.  
 Low relative print material and maintenance costs, £29.99 per 90 metre 
filament reel, freely accessible software and no subscription fees. 
 Device flexibility and freedom of design. Devices can be designed to the users’ 
specifications at little to no additional cost. For example parameters such as 
sample size can be adjusted by altering channel specifications and the low-cost 
per device renders trial-and-error viable with low financial restrictions. 
 Whole blood separation using centrifugation. There is no risk of interaction 
with membranes or requirement of coagulation factors as blood separation is 
performed via centrifugation. 
 Small sample size ~23 µl. 
 Ability to perform multiple different assays on a single device simultaneously 
provides the flexibility of POC testing with the capability of laboratory testing. 
 Low cost of devices renders them disposable. 
 Ability to improve device properties further using low-cost post-print treatment 
techniques. 
 LOAD devices can be centrifuged using an unmodified ODD, with the potential 
for assay quantification using existing 650 nm DVD laser diodes present in DVD 
drives should device development continue, providing cheap diagnostic reader 
devices from existing technology. 
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Disadvantages 
 Requirement for substantial calibration and optimisation of the 3D-printer and 
print parameters. 
 Inherent inaccuracy, inconsistency and relative low-quality of devices produced 
using low-cost 3D-printer technology. 
It should be noted that all disadvantages witnessed could potentially be overcome 
with higher quality 3D-printers with improved strand deposition accuracy and 
consistency, however, this can substantially increases costs, both upfront and running 
which will impact price per device. But over time such improvements often trickle 
down into lower cost kits. 
 
 Proposed Future Work 6.6
 The overall results achieved in this project include the development and 
demonstration of a low cost FDM 3D printed microfluidic LOAD device that is highly 
customisable, capable of performing whole blood centrifugation and optical assays 
with a sample volume of approximately 23 µl. In addition to this, a colourimetric whole 
blood cholesterol assay, and colourimetric whole blood glucose assay were optimised 
for use in a low cost FDM 3D printed microfluidic cuvette device. The assays produce 
absorbance in the 650 nm region and have the potential of being quantified by an 
unmodified ODD; a DVD ODD utilises a 650 nm laser diode. The assay involves a single 
aqueous reagent, requires no sample pre-treatment, is reproducible, simple, specific, 
and uses no corrosive reagents. Due to the multifaceted nature of the project, and the 
requirement of first overcoming and demonstrating previously unachievable and 
undocumented fundamental principles, there are areas which due to time constraints 
were not fully developed and suggestions for possible future work for both the assay 
and device development.   
 
    
214 Chapter 6: General Conclusions and Future Work 
 
Alexander M. Tothill  Cranfield University 
1. Colourimetric Assay Development 
 Implement cholesterol esterase into cholesterol assay for the 
quantification of total cholesterol in samples.  
 Investigate assay reaction < 2 minutes incubation and optimise assay for 
time-to-result ≤ 10 seconds by increasing enzyme concentration. 
 Investigate long term stability of assay reagents in solution and as solid 
mixture. 
 Progress to human blood samples. 
 Investigation of matrix effect and potential interactions with assay. 
 
 
2. Low-Cost FDM 3D-Printed Microfluidic LOAD Device Development 
 Water-tight and perform blood separation in 1.2 mm thick LOAD device 
to ensure device dimensions are compatible with all ODDs. 
 Reduce dimensions of microfluidic channels, and therefore sample 
volume, to volumetric capacity of <15 µl to rival existing POC devices. 
 Further explore heat-treatment. Avenues of investigation include:  a 
range of temperatures, duration vs optical transparency, warping of 
devices, quantification of changes to water-tightness in printed devices, 
method of heating and their effects (e.g. direct contact, baking, etc.). 
 Investigate alternative liquid-solvent treatments suitable for the 
internals of microfluidic channels. 
 Investigate additional post-print finishing techniques for improving 
transparency and build quality suitable for application within sealed 
microfluidic channels. 
 Use computational fluid modelling to aid in channel design optimisation 
for sample flow and reagent mixing in microfluidic channels. 
 Perform accurate measurement of microfluidic channels to gauge 
deviation from the ‘ideal’ model. 
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 Investigate other low-cost 3D-printing technology for device 
manufacture and compare advantages and disadvantages of devices 
produced to FDM technology. 
 
3. Performing The Colourimetric Assays In 3D-Printed Microfluidic Devices 
 Generate a calibration curve for the whole blood glucose assay 
performed in the LOAD device. 
 Investigate the performance of the assay during centrifugation in load 
device. The effect of the centrifugation process on the assay 
performance will determine how the LOAD device usage protocol is 
developed. 
 Investigate the performance of assay reagent and sample mixing within 
the LOAD microfluidic channels; the assay reagents should be deposited 
in the channels either in liquid or solid form, then the blood sample is 
applied and the assay performed. 
 Investigate deposition of dry assay reagents into channels, potentially 
through developing liquid reagent mix which is introduced to channels, 
then the solution allowed to evaporate, leaving a dry reagent mix in the 
channels to then be dissolved by the sample. 
 Perform a cross-reactivity study of the assay reagents with print 
materials and investigate secondary adsorption phenomena. 
 
4. Progress Towards the use of an Optical Disc Drive as a Reader Device 
 Investigate and develop software necessary for directly controlling 
spindle motor for centrifuging whole blood in the LOAD device. 
 Investigate implementation of reflective surface into LOAD device as 
ODDs utilise reflection not transmission. 
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 Final Conclusions 6.7
 As discussed in section 2.1, the global healthcare systems are already stretched 
beyond capacity so the development of affordable multi-analyte diagnostic 
development technology is of utmost importance. The capability of developing and 
manufacturing POC diagnostic devices tailored to specific requirements for a fraction 
of current costs will provide establishments, especially those with restricted resources, 
essential diagnostic data cheaply and quickly that would otherwise be unavailable. This 
may significantly improve prognostic and therapeutic patient outcomes and reduce 
financial strain on healthcare services. In addition, low-cost POC devices that are 
capable of quantifying multiple biomarkers in biological fluids have the potential of 
combining existing home testing devices into a single platform, reducing costs to the 
customer as well as reducing waste from used devices. 
The overall outputs achieved from this study include the development of two 
highly customisable low-cost FDM 3D-printed microfluidic devices; a microfluidic 
cuvette which has been used to quantify glucose concentration and a LOAD device 
with multiple microfluidic channels (~23 µl) capable of performing centrifugation 
based whole blood separation and generation of coloured plasma that has the 
potential for analyte quantification. In addition to this, two whole blood optical assays 
suitable for use within low-cost 3D-printed devices were developed and optimised that 
demonstrate the quantitative potential of assays read in microfluidic FDM 3D-printed 
devices. All device development and manufacture was performed using an Ultimaker 
2+ FDM 3D-Printer costing ~£1600 at the time of writing; with the closest commercial 
competitor capable of producing similar products being the Dolomite Fluidic Factory 
which costs £14,000 at the time of writing. It is hoped that the results produced in this 
work will, as a consequence, aid in reducing the price of high-end 3D-printing 
technology to more affordable levels rendering it accessible to a much larger 
proportion of research and development groups who currently cannot afford it. This 
will drive diagnostic device research forward to the benefit of all.  
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